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ABSTRACT 
Ergothioneine, a histidine-derived thiol, protects cells against reactive oxygen 
species and is emerging as a longevity vitamin. Ovothiol, another histidine-derived thiol, 
is also a potent antioxidant with therapeutic potential due to its anti-inflammatory and anti-
proliferative activities. Despite these promising health benefits, the production of 
ergothioneine is limited by the underlying challenges of its only industrial synthetic 
method, while ovothiol is not commercially available. Due to these issues, the production 
of these thiols through metabolic engineering/synthetic biology approaches is appealing. 
The central steps in the ergothioneine and ovothiol biosynthetic pathways are the oxidative 
coupling C-S bond formation reaction mediated by non-heme iron sulfoxide synthases, and 
the pyridoxal-5'-phosphate (PLP)-dependent C-S lyases. This sulfur transfer strategy 
differs from all other pathways reported. Therefore, these trans-sulfuration reactions in 
ergothioneine and ovothiol biosyntheses are significant from both basic and translational 
research perspectives, hence, they were selected as my thesis project. 
This thesis comprises of five chapters. Sulfur metabolism and the biosynthesis of 
sulfur-containing natural products are presented in Chapter 1. The computational-guided 
 
 viii 
protein engineering of a thermophilic sulfoxide synthase (EgtB) from 
Chloracidobacterium thermophiluim is covered in Chapter 2. Chapter 3 describes the 
mechanistic studies of the reductive C-S lyase (Egt2 from the Neurospora crassa’s 
ergothioneine biosynthesis), which revealed the involvement of a sulfenic acid 
intermediate in this reaction. In addition to reconstituting the ergothioneine biosynthetic 
pathway in vitro presented in Chapter 3, I fully reconstituted the in vitro ovothiol A 
biosynthetic pathway from Erwinia tasmaniensis, which is described in Chapter 4. In 
Chapter 5, the mechanistic studies of the ovothiol sulfoxide synthase OvoA using unnatural 
amino acid incorporation via amber-codon suppression are discussed. The success of this 
thesis work paves the way for the industrial production of ergothioneine and ovothiol 
through metabolic engineering/synthetic biology approaches. This study has also laid the 
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Chapter 1 Sulfur Metabolism and Incorporation in Natural Product Biosyntheses 
Reproduced with permission from Biochemistry 2018, 57, 24, 3309-3325 
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Sulfur, the tenth most abundant element on Earth, is found in a wide range of 
bioactive molecules including amino acids, nucleotides, coenzymes, proteins and 
antibiotics.1,2 Organosulfur compounds possess unique chemical properties, particularly 
the wide range of the oxidation states from +4 (sulfonic acid) to -2 (thiol, thio-ether, and 
sulfonium ion). Sulfur biomolecules exhibit crucial functions in all living organisms 
including maintaining cellular homeostasis, enzyme functionality, regulation of gene 
expression, DNA methylation and repair, lipid metabolism, and metal ion transportation.3-
5 Due to its central importance, this chapter presents the discussion of sulfur metabolisms 
across different domains of life. The links between sulfur metabolism, human health and 
diseases are discussed with an emphasis on the emerging role of hydrogen sulfide as a 
signaling molecule. Finally, the second half of this chapter focuses on the sulfur 
incorporation strategies in natural product biosyntheses. 
 
1.1 Microbial sulfur-based respiration 
Microbial inorganic sulfur metabolism plays an important role in the sulfur cycling, 
one of Earth’s major biogeochemical processes. The ability to use inorganic sulfur 
compounds for growth may be an early microbial metabolism that evolved approximately 
3.5 billion years ago, as suggested by sulfur isotope analysis.6 Sulfur metabolism in several 






2-), or elemental sulfur (S0) as shown in Figure 1-1. On the other hand, 
some chemophotolithotrophic archaea use electrons from sulfide (S2-) oxidation in their 
energy metabolisms. Despite the diverse metabolic processes, the biological functions of 
inorganic sulfur compounds could be roughly divided into two primary categories: they 
function as either electron acceptors or donors of energy-producing sulfur dissimilatory, or 
they serve as sources for sulfur assimilation pathways, respectively (Figure 1-1). This 
section provides an overview of the sulfur-reducing and sulfur-oxidizing metabolism in 
bacteria and archaea. 
 
 
Figure 1-1 Sulfur cycling and relevant sulfur metabolisms in microorganisms. Dashed lines represent 
anaerobic reactions, solid lines show aerobic reactions, and dotted lines show both aerobic and 





1.1.1 Oxidative sulfur metabolism in photolithotrophic bacteria 
The oxidative sulfur metabolism is present in both bacterial and archaeal 
organisms. Photolithotrophic bacteria perform a light-driven CO2 reduction process under 
anoxic environments by oxidizing reduced sulfur compounds.8,9 The preferred electron 
donor for these photolithotrophs is sulfide, however, other inorganic sulfur compounds are 
also widely used, including elemental sulfur, polysulfide, and thiosulfate. Among these 
photolithotrophs, Chlorobium ferrooxidans is an exception because they make use of 
ferrous ions instead of inorganic sulfur compounds as the reductants.10 Unlike 
photolithotrophic bacteria, chemolithoautotrophic archaea harness the sulfur compound 
oxidation processes for both the purposes of extraction both electrons and energies.11 These 
two domains of life serve as good systems for comparative studies for oxidative sulfur 
metabolism.  
The photolithotrophic bacteria are categorized in two major groups: green sulfur 
bacteria (GSB) and purple sulfur bacteria (PSB). GSB belong to Chlorobiacae family and 
as the name suggested, they contain green pigments from bacteriochlorophyll c, d, and e. 
On the contrary, PSB belong to the families Chromatiaceae and Ectothiorhodospiraceae 
and contain pigments from bacteriochlorophyll a, and b, and other carotenoids.12 Although 
these two groups inhabit similar anoxic aquatic environments, GSB do not have the 
chemotrophic ability to use oxygen as the terminal electron acceptor.13 On the other hand, 
in the absence of light, some PSB, such as Allochromatium vinosum, could switch between 




makes the discussion on the oxidative sulfur metabolism of photolithotrophs difficult. 
Hence, the focus of this section is on the sulfur metabolism in GSB.  
  
 
Figure 1-2 Proposed pathways of sulfur oxidation metabolism in GSB. The oxidative enzymes are 
localized in the periplasm including SQR, SOX, and FCSD. The deposited sulfur globules are found 





In GSB, several pathways for inorganic sulfur oxidation have been reported and a 
number of the electron carrier proteins have been characterized.11,16 The majority of GSB 
and PSB could utilize hydrogen sulfide, and approximately half the species could use 
thiosulfate as the inorganic sulfur source. There are four major inorganic sulfur-oxidizing 
pathways in GSB: the sulfide-quinone reductase (SQR), the flavocytochrome c-sulfide 
dehydrogenase (FCSD), the monomeric flavoprotein (SoxF), and the thiosulfate-oxidizing 
multi-enzyme system (TOMES, Figure 1-2). Notably, none of the GSBs has all four 
pathways depicted in Figure 1-2.The sulfide oxidizing activity of SQR was first discovered 
in Chlorobium limicola f. thiosulfatophilum.17 The resulting reduced menaquinone (MK) 
is further oxidized by a membrane-bound menaquinol:cytochrome c oxidoreductase (ISP) 
coupled with a cytochrome (cyt) c556 (Figure 1-2).
18 Alternatively, sulfide can be oxidized 
by a cytochrome flavoprotein, FCSD, located in the periplasmic space between the inner 
and outer membrane of bacteria. FCSD is a heterodimeric protein containing a glutathione 
reductase-like flavin-binding subunit and a diheme cytochrome subunit. In vitro 
characterization of FCSD from GSB suggests that a small molecule cyt c is the electron 
acceptor of this sulfide dehydrogenase (Figure 1-2).19 Genomic analysis and genetic studies 
of GSB Paracoccus pantotrophus illuminated that the sulfide dehydrogenase activity is 
mediated by TOMES, which is also known as a sulfur oxidizing system (Sox). However, 
the sulfide dehydrogenase activity of TOMES is significantly lower than that of FCSD.20 
In addition to sulfide oxidation, the Sox system also mediates the thiosulfate oxidation, in 
which, at minimum, requires three components: SoxAXK, SoxB, and SoxYZ (Figure 




recognizes the oxidized product of the thiosulfate and forms a cysteinyl S-thiosulfonate, 
which is further hydrolyzed to cysteinyl persulfide by SoxB (Figure 1-2).21 Intriguingly, 
among the genes in sox cluster, soxF shares 29-67% identity with the flavoprotein subunit 
of FCSD of photolithotrophic sulfur-oxidizing bacteria.22 Biochemical characterization of 
the monomeric SoxF revealed the sulfide dehydrogenase activity with cyt c as the electron 
acceptor.20 The addition of SoxF to the Sox system in the cell lysate significantly increases 
the rate of thiosulfate oxidation. However, adding SoxF to the purified Sox core does not 
change the level of thiosulfate oxidation. This is attributed to the lack of some other key 
components for fully reconstituting the SoxF activity.23  The SoxF catalysis in thiosulfate 
oxidation remains to be explored.  
Two electrons from the sulfide oxidation processes are transferred to the 
photosynthetic machinery through either a cyt c554 or an oxidoreductase ISP (Figure 1-2). 
In contrast, the electrons from thiosulfate oxidation are only transferred through cyt c554.
24 
These sulfur oxidation reactions also results in the production of persulfides, which 
ultimately forms the sulfur globules (Figure 1-2). The mechanism for the formation of these 
elemental sulfur globules is not clear. The exact molecular structure of sulfur globules is 
also an ongoing debate, while it is generally believed that the key components are long-
chain, zero-valent polysulfanes. These sulfur globules are stored in the extracellular surface 
of the outer membrane of GSB. When sulfide is depleted and reducing equivalents are 
required, the sulfur globules are oxidized completely to form sulfate to provide electrons. 
This process is linked to the dissimilatory sulfite reduction (DSR) system.25 The DSR 




sulfur transferase (DsrEFH), an electron transport complex (DsrTMKJOP), and a 
flavoprotein with oxidoreductase activity (DsrL, Figure 1-2). In a recent study on A. 
vinosum, recombinant DsrL strongly prefers NADH over NADPH as an electron acceptor 
for the oxidoreductase activity.26 Notably, the DSR system is not only involved in the 
formation of elemental sulfur globules, but also in the reverse direction, the oxidation of 
sulfide to sulfite, which will be discussed in the section on sulfate-reducing bacteria.15 
The formation of sulfite as a product from the DSR system raises a question as to 
what enzymes are responsible for the next step, the oxidation of sulfite to sulfate. Genomic 
analysis and biochemical characterizations revealed that one-third of GSB encode 
adenosine-5’-phosphosulfate reductase (APR), a protein that is proposed to couple sulfite 
oxidation with ATP sulfurylase (Sat) and the membrane-bound quinone oxidoreductase 
(QmoABC) as shown in Figure 1-2. Intriguingly, the knockout of the apr-sat-qmoABC 
gene did not prevent Cba. tepidum from growing on sulfide and from producing sulfate.27 
This result suggested that this pathway is not the only mechanism for sulfite oxidation. 
Subsequent genomic analysis revealed a putative sulfite dehydrogenase, polysulfide 
reductase-like complex 3 (PSRLC3), found in some GSB. This gene is located upstream of 
the dsr gene cluster, suggesting that they might be functionally related.15 The biochemical 
function of PSRLC3 remains to be characterized.  
Besides investigating the inorganic sulfur oxidation reactions in GSB, several 
studies were performed to map the electron transfer paths related to the energy 
production.24,28-30 The electron gained from oxidizing an inorganic sulfur compound can 




carriers, the electrons are shuttled to the cyt c551 (PscC), which is bound to the homodimeric 
PscA core of the photosynthetic machinery referred as the reaction center (RC) complex. 
The electrons from PscC are transported to a special bacteriochlorophyll a (BChl a) dimer, 
P840 bound to the PscA core, and then, to the electron acceptors ferredoxin and 
flavodoxin.28 The interaction between PscA and PscC facilitates the electron transfer from 
PscC to P840.31 Besides the PscA core and PscC, the RC complex also contains the iron-
sulfur cluster containing PscB protein, the PscD protein, and the Fenna-Matthews-Olsen 
antenna protein (FMO). Structural studies on the FMO-RC complex reveals that PscD 
stabilizes interactions between FMO and the RC complex and facilitates the electron 
transfer to PscB and to the terminal electron acceptors ferredoxin and flavodoxin.16,31  
For their energy production, the photolithotrophic GSBs use light as the energy 
source and inorganic sulfur compounds (e.g., sulfide and thiosulfate) as the electron doors. 
Several enzymes and multi-enzyme complexes involved in the sulfur metabolism in GSB 
have been isolated and characterized, including SQR, FCSD, and TOMES. However, very 
little is known about how these sulfur-oxidizing pathways are linked to the formation of 
extracellular sulfur globules. Understanding the mechanism of sulfur globule formation 
will fill the knowledge gap and paint a complete picture of sulfur metabolism in GSB, 
which plays an important role in the biogeochemical process of Earth’s sulfur cycle.    
1.1.2 Dissimilatory sulfate-reducing bacteria 
The sulfur oxidation metabolism in GSB represents only a fraction of the diverse 
energy metabolism found in bacteria. In addition to sulfide and thiosulfate oxidation, some 




different inorganic sulfur compounds (e.g., elemental sulfur, thiosulfate, and sulfate) as the 
electron acceptors, and they are generally referred to as sulfate-reducing bacteria (SRB). 
SRB were once believed to only grow on organic substrates such as lactate, pyruvate, and 
acetate obtaining energy mainly through substrate-level phosphorylation. However, the 
discovery of sulfate as the electron acceptor and H2 as the electron donor suggested the 
presence of electron-transport phosphorylation in SRB. The H+ gradient generated from 
this process then drives ATP formation (Figure 1-3). This biological activity of SRB was 
present at least 3.5 billion years ago, but has become an impactful biogeochemical process 
approximately 2.5 billion years ago.32 This change is due to the increasing sulfate 
concentration in the ocean due to the Great Oxidation Event, which was the introduction 
of free oxygen in Earth’s atmosphere. As a result, SRB is one of the major players in 
Earth’s sulfur cycling.  
The dissimilatory sulfate reduction pathway (DSR) is found in the Gram-positive 
bacteria Desulfotomaculum, the mesophilic-proteobacteria Desulfovibrio, and the 
thermophilic Gram-negative bacteria Thermodesulfovibrio.33,34 Notably, the sulfate-
reducing biological activity is also found in archaea, in which the DSR pathway is highly 
similar to that of SRB. In DSR, the reduction of sulfate to sulfite is mediated by an ATP 
sulfurylase (Sat), which activates sulfate at the expense of an ATP to afford adenosine 
phosphosulfate (APS, Figure 1-3). Subsequent reduction of APS by APS reductase yields 
sulfite and AMP. The subsequent step is the reduction of sulfite to sulfide, which is not yet 
well understood. Using Desulfovibrio vulgaris as a model organism has shed some light 




showed that sulfite and DsrC are the co-substrates for sulfite-reduction activity. In this 
process, DsrAB reduces sulfite to a protein-based trisulfide on DsrC, and this sulfite-
derived sulfur bridges the two conserved cysteines in DsrC (Figure 1-3). Additionally, a 
recent study showed that DsrL of A. vinosum can facilitate the electron transfer from 
NADH to DsrAB in the sulfite reduction process.26 The trisulfide DsrC is further reduced 
by a trithionate reductase complex (DsrMKJOP) to sulfide as the final product (Figure 
1-3).36 The trisulfide DsrC not only plays crucial role in DSR pathway, but also in other 
cellular processes. The discovery of the trisulfide DsrC highlights the importance of zero-
valent sulfur in the form of protein polysulfides, which have been proposed as the activated 
sulfur currency in H2S signaling, redox homeostasis, enzymatic modulation, and 
protein/tRNA sulfuraiton.36  
 
Figure 1-3 Sulfate respiratory pathway in SRB. This figure was adapted from Liu et al, 2012.37 
  
A diverse range of inorganic sulfur compounds participate in bacterial metabolism 
through oxidation and reduction processes and these pathways are linked to energy 
metabolism, too. For instance, oxidizing sulfur bacteria like GSB, use the SQR, FCSD, or 




system for their sulfur metabolism. These different energy metabolic pathways are 
evolutionary results for these microorganisms to adapt to their environments. There is still 
a wide range of understudied habitats on Earth, which implies that more microorganisms 
with intriguing energy metabolisms await to be discovered.  
1.1.3 Sulfur oxidation and reduction in archaea  
In bacteria, the energy metabolism undergoes either oxidation or reduction of 
inorganic sulfur compounds. Bacterial photolithotrophs use inorganic sulfur compounds as 
the electron donor, while sulfate-reducing bacteria use oxidized inorganic sulfur 
compounds as the electron acceptors. Likewise, archaeal species possess a diverse range 
of energy metabolisms using inorganic sulfur compounds. Many archaeal 
chemolithoautotrophs use sulfur compounds as electron donors or acceptors in respiratory 
processes.38  Archaea can perform sulfur oxidation and reduction under various 
environments such as sediment of hot spring, geysers, acid-mine drainage site, and 
hydrothermal vents. Aerobic sulfur oxidation is commonly found among 
thermoacidophilic archaea, while the anaerobic sulfur reduction is found across diverse 
members of the archaeal domain.  
Aerobic oxidation of elemental sulfur by chemolithoautotrophic archaea is 
commonly found in the order Sulfolobales. Most of these archaea have been isolated from 
hydrothermal systems, hot springs, and heated sediments. These organisms have an optimal 
growth temperature between 60 to 90 °C and under a pH range of 2-4.5.39 The oxidation 
of S0 in Acidianus ambivalens has been characterized,38,40 demonstrating that  a 




S0 to sulfide, sulfite, and thiosulfate (Figure 1-4).41  In this reaction, the production of 
thiosulfate has also been proposed as a product of a non-enzymatic process in the presence 
of excess amount of S0. Whether thiosulfate is produced as the product of an enzymatic, 
non-enzymatic pathway, or both is not yet known.40,41 The SOR contains 24 identical 
monomers that form a hollow sphere. Each monomer of the SOR contains a non-heme iron 
binding site and a catalytic Cys31, which is persulfurated, potentially by using linear sulfur 
chains such as polysulfide as the substrate. Additionally, this SOR-mediated sulfur 
disproportionation affords a 1:1 stoichiometry sulfite and sulfide. This finding led 
researchers to propose that the non-heme iron center is responsible for both sulfur oxidation 
and reduction.42 The sulfide, sulfite, and thiosulfate resulted from S0 oxidation are further 
oxidized to sulfate through the thiosulfate: quinone oxidoreductase (TQO).40 TQO 
catalyzes thiosulfate oxidation to tetrathionate (S4O6
2-) and reduced caldariella quinone 
(CQ) is another product (Figure 1-4). Subsequently, electrons from CQ are transported to 
the quinol oxidase to reduce oxygen to water.  
 
 
Figure 1-4 Aerobic oxidation of elemental sulfur in archaea. SOR mediates the oxidation of S0 and the 
electrons from this reaction are transported for reduction of oxygen. This figure was adapted from Liu 




 Although aerobic sulfur-oxidation is common among these archaea, they can 
also perform anaerobic sulfur reduction. This biochemical activity is found in the orders 
Sulfolobales, Thermoproteales, and Desulfurococcales. Two major mechanisms of S0 
reduction are: the reduction of S0 with H2 as the electron donor and the fermentation of 
organic compounds with S0 as the electron acceptor. Using A. ambivalens as a model 
organism, extensive studies on the sulfur reduction reactions have been performed.37,38,41 
The respiratory reduction of S0 involves two membrane-bound multi-enzyme complexes: 
the sulfur/polysulfide reductase (SR/PSR) and the NiFe hydrogenase (Figure 1-5).37,40 In 
A. ambivalens, the SR/PSR complex is encoded by a core subunit (SreA), an iron-sulfur 
cluster containing subunit (SreB), the membrane anchor protein (SreC), and two proteins 
with unknown functions (SreD and SreE). The SR/PSR complex reduces S0 to H2S using 
H2 as the electron donor produced by the NiFe hydrogenase. The NiFe hydrogenase 
consists of the core subunit (HynL), the hydrogenase small subunit (HynS), the membrane 
anchor protein (Isp1), two maturation proteins (HypCDE and HoxM), and three proteins 
with no known functions (Isp2, HynYZ, and HypYZ).43 In this process, the electron flow 
has been proposed to be mediated by a sulfolobous quinone (SQ), whose 
oxidation/reduction reactions lead to the transfer of protons to the outside of the membrane, 






Figure 1-5 Anaerobic sulfur reduction in archaea. The SR and NiFe hydrogenase play key roles in this 
process using SQ as the electron carrier, whose oxidation/reduction reactions lead to the production 
of a proton gradient across the membrane. The enzyme subunits with unknown roles are not represent 
here. This figure was adapted from Liu et al, 2012.37  
 
The ability to reduce sulfur in hyperthermophilic archaeal groups is not only limited 
to reducing S0 by using H2 as the electron donor. Some archaeon such as the Pyrococcus 
and Thermococcus species can perform fermentation-based reactions of organic 
compounds using S0 as the electron acceptor. These microorganisms can thrive when 
peptides are used as the carbon source, while requiring S0 for optimal growth. Using 
Pyrococcus furiosus as the model organism, studies have shown that the fermentation-
based reduction of S0 involves two components: a cytoplasmic coenzyme A (CoA)-
dependent NAD(P)H sulfur oxidoreductase (NSR), and a membrane bound oxidoreductase 
complex (MBX, Figure 1-6).44,45 The NSR reduces S0 to intracellular sulfide (Figure 1-6). 
The MBX was suggested to be a respiratory ferredoxin NADP oxidoreductase, which 
supplies NADPH for the NSR. This process in turn generates an electrochemical gradient 
to drive ATP synthesis. Notably, the activity of the MBX in vitro has not been 
characterized, but bioinformatic and genetic results suggested that the MBK might link 
NADPH-dependent sulfur reduction to glycolysis through ferredoxin as a mediator.45 The 





Figure 1-6 Proposed pathway for fermentation-based S0 reduction in P. furiosus. This figure was 
adapted from Liu et al, 2012.37 
  
In summary, archaeal microorganisms employ both oxidation and reduction of 
sulfur for their metabolisms. Some chemolithoautotrophs use inorganic sulfur compounds 
as electron donors through the SOR system and oxygen is the oxidant. On the other hand, 
most archaeon species can perform anaerobic S0 reduction with H2 the as electron donor, 
involving the SR/PSR and the NiFe hydrogenase. Alternatively, some members of this 
domain can undergo fermentation based S0 reduction using peptides as the carbon source. 
Although the genes involved in these processes were identified, many of them have not 
been characterized biochemically. Hence, there are still many unanswered questions in 




1.1.4 Sulfur assimilation in bacteria 
In addition to dissimilatory sulfate reduction, sulfur assimilation is of central 
importance in the biological sulfur cycle. Most microorganisms and plants can assimilate 
inorganic sulfur compounds namely sulfate, thiosulfate, sulfite, and sulfide for the 
biosynthesis of L-Met and L-Cys. On the contrary, mammals, have to uptake L-Met from 
their diet and metabolize it to produce L-Cys and other important sulfur-containing 
biomolecules such as coenzyme A, reductant glutathione, and cofactor biotin. Due to the 
emerging role of microbial sulfur metabolism in human health and diseases, this section 
focuses on the sulfur assimilation in bacteria and the biosynthesis of L-Cys and L-Met. 
The assimilatory sulfate reduction in Escherichia coli is well characterized. This 
pathway begins with the uptake of sulfate from the environment through an ATP-
dependent transporter complex (CysUWA).46,47 Extracellular sulfate is recruited to the 
transporter complex by a periplasmic sulfate-binding protein, Sbp. Sulfate then crosses the 
membrane through a channel formed by subunits of CysU and CysW. This process is 
proposed to be driven by an ATPase, CysA.48 Upon entering the cell, sulfate is assimilated 
into L-Cys through a series of enzymatic reactions (Figure 1-7). First, sulfate is activated 
by an ATP-dependent sulfate adenyltransferase (CysDN) to adenosine 5’-phosphosulfate 
(APS). Subsequent phosphorylation of APS by an adenylsulfate kinase (CysC) produces 
3’-phosphoadenosine 5’-phosphosulfate (PAPS).49 Then, PAPS undergoes a reduction 
catalyzed by a 3’-phosphoadenylsulfate reductase (CysH) mediated by a thioredoxin and 
thioredoxin reductase. This reaction affords adenosine 3’,5’-bisphosphate (PAP) and 




complex (CysIJ) at the expense of three molecules of NADPH.50 Finally, sulfide reacts 
with O-acetyl-L-serine (OAS) catalyzed by an O-acetyl-L-serine sulfhydrylase A (CysK) 
to produce L-Cys as the final product. In this pathway, OAS is a product from L-Ser and 
acetyl-CoA catalyzed by L-serine-O-acetyltransferase (CysE).51,52 
 
 
Figure 1-7 Sulfur assimilation pathways in bacteria. This figure was adapted from Kawano et al, 
2018.52 
 
L-Cys resulted from the assimilatory sulfate reduction pathway can then serve as a 




pathway. One known exception being the endosymbiont Wolbachia, which contains a 
degraded genome reflecting the loss of L-Met biosynthesis genes to avoid the insect host 
defense systems.53 The biosynthesis of L-Met is initiated by the activation of homoserine, 
a derivative of L-Asp from the TCA cycle (Figure 1-7). The homoserine activation is 
mediated by a homoserine O-succinyltransferase (MetA) resulting in O-
succinylhomoserine as the product. Then, the thiol group on L-Cys is transferred to 
homoserine to generate homocysteine by a two-step process (Figure 1-7). This reaction is 
catalyzed by a cystathionine -synthase (MetB) to produce cystathionine and succinate. 
Subsequent cystathionine cleavage mediated by a cystathionine -lyase (MetC) results in 
homocysteine. In Figure 1-7, the last step of L-Met biosynthesis is catalyzed by one of the 
two enzymes: cobalamin-dependent methionine synthase (MetH) or cobalamin-
independent methionine synthase (MetE). 
In addition to sulfate assimilation, some microorganisms have been reported to 
have the ability to assimilate thiosulfate. Similar to sulfate, thiosulfate is transported into 
the cell through the CysUWA transporter (Figure 1-7).46 However, in this case, CysP is the 
periplasmic thiosulfate-binding protein, instead of Sbp in the sulfate case . Thiosulfate is 
then assimilated into L-Cys via a two-step reaction. The first reaction is mediated by O-
acetyl-L-serine sulfhydrylase B (CysM), which incorporates thiosulfate into OAS.54 The 
resulting S-sulfo- L-Cys (SSC) then undergoes reductive cleavage of its disulfide bond 
catalyzed by a glutaredoxin (Grx1) or a glutaredoxin-like protein (NrdH) at the expense of 




Microorganisms use different sulfur assimilatory pathways to harness the inorganic 
sulfur sources present in their habitat. Two common bacterial pathways include sulfur 
reduction and thiosulfate assimilation. Due to their emerging role in human health and 
diseases, a better understanding of microbial sulfur assimilatory pathways can serve as a 
potential target for therapeutic development against diseases caused by virulent 
microorganisms.  
 
1.2 Emerging role of sulfide in human health  
Reducing-sulfur assimilatory pathways in microorganisms produce sulfide, the 
sulfur source for L-Met and L-Cys biosynthesis. These pathways are well understood, 
however, much less is known about the sulfur metabolism in gastrointestinal microbes and 
how they affect the intestinal health of the host. Although there is no direct evidence of 
microbial sulfur cycling in the digestive system, increasing evidence points to a greater 
impact of microbial sulfur metabolism in human colonic health than previously 
recognized.54,56,59-61 Mammals uptake L-Met and L-Cys from their diets. In mammalian 
systems, L-Cys serves as a building block for the biosynthesis of other sulfur biomolecules 
such as proteins, the cellular antioxidant glutathione, and the vitamin thiamine. 
Alternatively, L-Cys can undergo degradation to produce sulfide, which is then 
metabolized via various pathways (Figure 1-8). Initially, H2S studies mainly focused on its 
toxicity. H2S has been known as a poisonous foul-smelling gas emitted from sewers and 
septic tanks. This gas was related to eye diseases observed in sewer workers. The 




the roles of H2S in many physiological processes including neurodegeneration, regulation 
of inflammation, and colonic diseases. Increasing evidence has pointed out that H2S 
produced from endogenous enzymes and colonic SRB is involved in inflammatory bowel 
disease (IBD) and colorectal cancer (CRC). However, the exact pathways and the 
mechanisms of actions regulated by H2S is not well understood. This section presents the 
discussion of the production of H2S, and its emerging biological roles in IBD and CRC. 
 
 
Figure 1-8 Mammalian metabolism of H2S. This figure was adapted from Lin et al, 2015.57 
 
1.2.1 Metabolism of H2S in the mammalian system  
The metabolism of H2S in mammalian cells is regulated by three principle enzymes: 
a cystathionine -synthase (CBS), a cystathionine -lyase (CSE), and a 3-
mercaptopyruvate transferase (3-MST). Under regular physiological condition, 70% of 
H2S is produced from L-Cys and the remaining 30% from homocysteine.




concentration of L-Cys and homocysteine are regulated through a trans-sulfuration 
pathway involving CBS and CSE, which is the major source of H2S in mammalian cells 
(Figure 1-8). In this pathway, CBS mediates the condensation of L-Cys and homocysteine, 
while CSE catalyzes an ,-elimination of L-Cys to afford H2S.
59 Alternatively, H2S can 
be produced through a two-step enzymatic reaction involving cysteine aminotransferase 
(CAT) and 3-MST (Figure 1-8). The cellular concentration of H2S is measured by trapping 
H2S with a metal, which is then acidified and followed by a reaction with the dye, N,N-
dimethyl-p-phenylenediamine (DMPD) to produce a product that is blue in color and this 
reaction is monitored spectrophotometrically to determine the level of H2S. According to 
the results from this measurement, the concentration of H2S was reported to be in the 
micromolar ranges in mouse liver and brain. This assay does have its limitations, however. 
This assay could not differentiate HS- and S2- from H2S, which results in an inflated H2S 
concentration.60 A more specific biosensor, amperometric, has been used, and the 
concentrations of H2S in mouse liver and brain were found to be in the sub-micromolar 
range instead.61  
Despite the discrepancy in the concentration measurements, the levels of H2S were 
found to be tissue- and age-specific. For instance, the H2S concentration in peripheral blood 
is within a range of 30-300 µM, however, levels of H2S in the brain are up to 3-fold greater 
than that of the blood.62,63 Higher levels of H2S in the brain has been linked to higher 
expression of CBS in brain tissues. At certain concentrations, H2S becomes acutely toxic, 
binding to hemeprotein such as cyt c oxidase resulting in the inhibition of cellular 




of H2S is strictly regulated through multiple pathways. For instance, H2S can directly 
scavenge reactive oxygen and nitrogen species (ROS/RNS) resulting in the formation of 
inorganic sulfur compounds such as S0, Sn
2-, S2O3
2-, etc. Cellular levels of H2S are also 
regulated through enzymatic reactions (Figure 1-8). Specifically, H2S can undergo 
oxidation to S2O3
2- mediated by the SQR and a rhodanese (RHOD). Alternatively, a sulfur 
dioxygenase (SDO) can oxidize sulfide to sulfite, which is further converted to sulfate via 
a sulfite oxidase (SO). These sulfide oxidation reactions are mediated by the SQR, which 
is coupled with the mitochondrial electron transport chain, regulating cellular metabolism. 
Another sulfide regulatory pathway is the methylation reaction catalyzed by a thiol S-
methyltransferase (TMT), resulting in methanethiol as the product (Figure 1-8).  
1.2.2 Emerging role of H2S as a signaling molecule 
The first glimpses of the biological role of H2S emerged from the studies on the 
levels of endogenous H2S in the brain tissues of humans and animals. Subsequent studies 
have revealed crucial roles of H2S in many physiological processes, including cellular 
bioenergetics, neuromodulation, and cytoprotection; now it is considered as a signaling 
molecule.56,64-66 In the central nervous system, H2S facilitates the induction of hippocampal 
long-term potentiation (LTP) by enhancing the activity of the N-methyl D-aspartate 
(NMDA) receptors and stimulating the release of Ca2+ in cells. Altered activity in the 
NMDA receptor has been linked to neurological disorders and overstimulation causes 
excitotoxicity and neurodegeneration. The activation of the NMDA receptors and increased 
intracellular Ca2+ level stimulate nerve excitation. Through this mechanism of action, H2S 




In addition to its effect on neurons, a study has demonstrated the effect of H2S on 
relaxing vascular smooth muscles through the activation of ATP-sensitive K+ (KATP) 
channels.65,69 The activation of these KATP channels by H2S was confirmed through 
electrophysiological studies in which NaHS stimulates the KATP current in rat aortic and 
smooth muscle cells. The increased flow of KATP also resulted in the relaxation of some 
smooth muscles such as mouse gastric fundus.70 However, the mechanism of action of H2S 
in the activating KATP channels is not yet known. These channels were recently found to be 
sulfhydrated by H2S, however, the link between this post-translational modification and 
the activation of  KATP channels remains to be verified.
66,71 The physiological functions of 
H2S is also involved in modulation of cellular oxidative stress. H2S can function as a 
cytoprotectant against oxidative stress by directly scavenging mitochondrial ROS/RNO 
and restoring the level of glutathione (GSH).72 Increased level of GSH was proposed to be 
the result of increased activity of the -glutamyl-cysteine synthetase and upregulation of 
cystine transport.  
Despite its important role in modulating cellular oxidative stress, how H2S exhibits 
this function—whether through repressing or activating its targets—remains to be further 
investigated. Under physiological pH, approximately two-third of H2S exists as the 
hydrosulfide anion (HS-), which can function as a potent nucleophile. This chemical 
property allows H2S to exhibit its signaling function through persulfidation (oxidative post-
translational modification of L-Cys residues).65,71,73 In persulfidation, HS- nucleophilically 
attacks the post-translationally modified L-Cys residue on a protein (Figure 1-9). Proteins 




when compared to their unmodified ones. This increased chemical reactivity might result 
in enhanced biological activity of these proteins. For instance, persulfidated GAPDH 
exhibits greater enzymatic activity than that of the non-persulfidated enzyme.71 For kinases 
whose activity is regulated by L-Cys modification, persulfication of these enzymes via H2S 
might be an alternative pathway for their activity regulation.  
In summary, H2S has been found as an integral part of many cellular processes,
56,60-
62 however, how this gaseous molecule exhibits its function it not well understood. H2S 
may play a role in persulfidation, which might be one of the mechanisms of actions of this 
molecule. More research is required to fully understand the physiological roles and the 
functional mechanisms of H2S. 
 
Figure 1-9 Proposed persulfidation reactions mediated by hydrogen sulfide. 
 
1.2.3 Role of sulfide in host-pathogen interactions  
The roles of H2S as a signaling molecule in regulating ion channels, protecting cells 
from oxidative stress, and protein persulfidation modifications are well recognized.56,61-66 




interactions between hosts and pathogens. Host-derived H2S has a significant impact on 
the outcome of bacterial infections. For instance, inhibiting the trans-sulfuration pathway 
of the host with propargyglycine results in increased viability of Mycobacterium 
smegmatis. The reduced capacity in pathogenic mycobacteria clearance could be due to the 
defects in phagolysosomal fusion during the infection. Intriguingly, increasing the L-Cys 
flux through H2S production with N-acetylcysteine (NAC) enhanced phagolysosomal 
fusion and improved levels of pathogenic mycobacteria clearance.74 The crucial roles of 
H2S between host and pathogen are not only limited to bacterial infection, but also colonic 
diseases such as inflammatory bowel diseases (IBD) and colorectal cancer (CRC). Most 
gut bacteria are sulfur-reducing bacteria (SRB) from the genera Desulfovibrio, 
Desulfobacter, Desulfolobus, and Desulfotomaculum. These SRB are the main contributors 
for H2S production in the gastrointestinal tract (GI tract).
65 The first glimpse of the 
significance of gut microbiota-derived H2S were obtained from the studies on germ-free 
animals. Fecal samples of germ-free mice exhibited half of the H2S compared to that of 
control mice. Additionally, the level of H2S in gastrointestinal tissues and blood plasma 
was lower in germ-free mice compared to that of the controls.65,75 This result implies that 
the host H2S level is related to the amount of H2S produced from gut microbiota. 
 
1.2.4 Production of sulfide from organosulfur in colorectal bacteria 
Unlike the mammalian system, the bacteria derived H2S is produced mainly from 
the DSR system. Characterization of the anaerobic bacterial metabolism of the colorectal 




converting the host-derived organosulfur such as taurine 1-1 to H2S (Figure 1-10A).
76 
Taurine is an abundant substrate in the human intestinal microbiota. In colonic microbiota 
of healthy human, B. wadsworthia is typically present in low abundance. However, this 
microorganism has been implicated in several pathological conditions such as CRC, 
ulcerative colitis, and appendicitis.76 In B. wadsworthia, the deamination of taurine is 
catalyzed by a taurine:pyruvate aminotransferase (Tpa). The resulting sulfoacetaldehyde 
1-2 is reduced to isethionate 1-3 by an NADH-dependent sulfoacetaldehyde reductase 
(SarD). Subsequently, an isethionate sulfite-lyase (IsIA) mediates a radical-based C-S bond 
cleavage reaction converting isethionate to sulfite and acetaldehyde 1-4. The resulting 
acetaldehyde is then oxidized to acetyl-CoA by a dehydrogenase (Figure 1-10).76 In 
addition to taurine, a study using another colorectal and opportunistic pathogen, 
Alcaligenes faecalis, also revealed the production of H2S from the host-derived 
organosulfur, ergothioneine. Ergothioneine 1-5 is a histidine-derived thiol found in many 
mycobacteria and fungi (Figure 1-10).77-79 Using A. faecalis cell extract, ergothioneine was 
degraded into thiourocanic acid 1-6 and trimethylamine.80 Subsequent characterization 
demonstrated the production of L-Glu and H2S from this reaction corresponded to the 
amount of thiourocanic acid produced. However, the identity of the enzymes involved in 
this pathway have not been characterized.   
Thus far, ergothioneine has been primarily recognized as a potent antioxidant, 
protecting cell from oxidative stress.77-79 However, the discovery of ergothioneine 
degradation pathway in A. faecalis suggests that ergothioneine might play some role as a 




and ergothioneine might exert their function through H2S. This highlights the potential role 
of ergothioneine in human health and diseases and warrants further examination of its 
biosynthetic pathways.    
 
Figure 1-10 Colorectal bacterial production of H2S derived from host-organosulfur. 
 
1.2.5 Role of sulfide in colonic health and diseases 
Although the link between H2S and pathogen-host interactions has been 
established, it is not clear how gut bacteria-derived H2S affects host’s colonic health. H2S 
produced by gut bacteria has been shown to exhibit both protective and detrimental effects 
on the host’s colonic health. For instance, H2S has been proposed as a potential pathogenic 
cause of ulcerative colitis (UC), which afflicts 0.1-0.5% of individuals in Western 
countries.81 Colonic epithelial cells rely on short-chain fatty acids such as butyrate, 
produced by microbiota as a nutritional source. Colonocytes then oxidize butyrate via 
acetyl-CoA dehydrogenase to form CO2
 and a ketone body. In a patient with UC, this 





UC patients have been reported to consume more protein, and thus, they ingest more sulfur 
amino acids than that of control cases. The numbers of SBR, specifically Desulfovibrio 
piger and H2S level in feces were also found to be greater in patients with UC compared to 
that of control subjects. 65,83 However, recent studies suggested that high levels of H2S may 
not be due to a greater number of SBR since qPCR did not show that UC patients contained 
more SRB in rectal mucosa or stool than control subjects.65,84 Patients with UC are 
generally prescribed an anti-inflammatory 5-aminosalicylic acid (5-ASA), which inhibits 
the growth and H2S production of SBR.
85 
In addition to inhibiting butyrate oxidation, H2S might be linked to UC via a mucin 
desulfating sulfatase, an enzyme which belongs to the glycosulfatase family. This enzyme 
is presented in gut bacteria allowing them to thrive via glycan metabolism. The mucous 
layer of colon consists of two layers: the outer loose mucous layer where microbiota resides 
and the inner dense mucous layer that serves as a barrier between colonic microbiota and 
colonocytes. Mucins are glycosylated proteins which serve as the major components for 
mucus layer in gastro-intestinal tract. Individual with high sulfur diet i.e. high in animal 
protein and fat, and low in fiber, results in diminishing nutrients for the microbiota. To 
survive, the colonic bacteria then initiate mucin degradation by increasing the mucin 
sulfatase activity, which ultimately leads to the increasing H2S production. Increased level 
of H2S might become toxic to colonocytes. Notably, the activity of mucin sulfatase is 
enhanced in patients with UC. Generally, the fluctuations in activity of fecal sulfatase is 
linked to the severity of UC, suggesting that the increased fecal sulfatase activity results in 




experience enhanced sulfatase activity, which might result in increased risk of UC due to 
the increasing sulfide production by SRB. 
Despite the evidence suggesting the negative impacts of H2S on UC, some studies 
suggest that H2S can positively affect the prognosis of IBD such as colitis. A study on 
colitis using animal models showed that scavenging bacteria that produce H2S did not 
improve the condition of colitis. After induction of colitis, the level of H2S spiked up and 
decreased back towards control levels as the symptoms of colitis were resolved. Inhibition 
of H2S production by gut bacteria resulted in mortality among animals with colitis. Most 
importantly, the administration of exogenous H2S ameliorated the symptoms of colitis.
87 
These conflicting results on the effects of endogenously and exogenously produced H2S on 
colonic diseases requires further research to understand. 
H2S has been found to play some roles in CRC—the second leading cause of 
mortality from cancer worldwide.65,88 Studies have demonstrated a selective upregulation 
of CBS in colon cancer tissue compared to that of control human colonic tissue. Subsequent 
studies showed that endogenous H2S produced by CSE and CBS promoted cancer cell 
proliferation by stimulating the phosphorylation of the extracellular signal-regulated kinase 
(ERK) and the p38 mitogen-activated protein kinase (MAPK). These kinases are involved 
in regulation of cell proliferation. On the contrary, exogenous H2S reduced cell viability in 
a dose-dependent manner.89 Another study demonstrated that H2S can inhibit cell 
proliferation and promote protective autophagy in colon epithelial cells via the activation 




In summary, studies have demonstrated the roles of H2S in many physiological 
processes ranging from cellular bioenergetics, neuromodulation, cytoprotection, and cell 
signaling. However, the mechanism of action of this gaseous compound in these pathways 
are poorly understood. H2S has been proposed to exhibit its function through protein 
persulfidation, its reactivity as a molecule, or both. More in-depth studies are required to 
unravel the biological functions and mechanisms of action of this compound. In addition 
to its crucial physiological role, H2S also serves as a bridge between host and pathogen 
interaction. More in-depth characterization on the host and microbial pathways involved 
in colonic sulfur metabolism is required for a better understanding of its impact on colonic 






1.3 Sulfur incorporation mechanisms in natural product biosyntheses  
Microorganisms utilize inorganic sulfur as either electron acceptors or donors as 
part of their energy metabolism or sulfur dissimilation pathways. In addition, inorganic 
sulfur compounds are widely used by microorganisms for sulfur assimilation, in which 
inorganic sulfur is incorporated into L-Cys, serving as the sulfur source for the biosynthesis 
of many sulfur-containing metabolites including biotin,91-95 lipoic acid,96 molybdopterin,97 
coenzyme B,98 and coenzyme M99,100. The metabolism of these sulfur-containing natural 
products might play some roles the host-pathogen interactions, possibly via the H2S 
signaling as discussed in the case of taurine and ergothioneine. Besides these molecules 
covered in previous sections, the biosynthesis of sulfur-containing natural products has 
received considerable attention in recent years. The explosion of genetic information from 
genome sequencing in recent years has provided a wealth of knowledge on the sulfur 
incorporation mechanisms of these sulfur-containing compounds. Currently known 
enzymatic C-S bond formation reactions can be roughly divided into two categories: ionic 
and radical mechanisms. 
1.3.1 Ionic types of C-S bond formation 
The pKa of the cysteine thiol is  8.3—under physiological conditions e.g., pH 
7.4—a portion of the cysteine side chain is present as a thiolate, which can function as a 
nucleophile. In nisin 1-8 biosynthesis (Figure 1-11A),101  an example of lantibiotics 
biosyntheses,102 the thioether bond formation involves several steps. First, the serine and 




(Dha) or 2,3-didehydrobutyrine (Dhb) moiety (Figure 1-11A). Then, a Zn2+-containing 
cyclase, NisC, catalyzes the nucleophilic attacks on the β-carbon position of Dhb or Dha 
by cysteine residues, producing thioether linkages. In the NisC reaction, the coordination 
of a cysteine residue with Zn2+ decreases its pKa, facilitating the thioether bond formation 
(Figure 1-11B).101 In the last step, NisP protease cleaves off the leader peptide from the 





Figure 1-11 Nisin biosynthesis employs ionic type of C-S bond formation. (A) Overall biosynthetic 
pathway of Nisin. (B) NisC activates the cysteine thiol by coordination to a Zn2+ ion, allowing 
nucleophilic attacks of the Dhb or Dha-β-carbon position to give a thioether linkage. 
 
In some cases, electrophiles for the thiolate-involving nucleophilic reactions are 
generated by oxidative activation mechanisms. Several types of oxidases have been 




non-heme iron enzymes, flavin-dependent enzymes, and copper containing oxidases.103 
This strategy is present in the biosynthesis of gliotoxin (1-19, Figure 1-12),104,105 
leukotriene D4,
106,107 and glucosinolate.108 In gliotoxin 1-19 biosynthesis, a non-ribosomal 
peptide synthetase, GliP, catalyzes the condensation between L-Ser 1-9 and L-Phe 1-10 to 
cyclo-phenylalanyl-Ser 1-11 (Figure 1-12). Hydroxyl groups are incorporated into the α-
positions of 1-11 by a P450-catalyzed hydroxylation mediated by GliC. The subsequent 
dehydration reaction of 1-12 produces an electrophilic acyliminium intermediate 1-12a, 
which then reacts with glutathione (GSH) to form the C-S bonds in bis-glutathionylated 
intermediate 1-13 (GliG-catalysis). Then, a γ-glutamyl-transferase, GliK, cleaves the 
isopeptide bond and the resulting Cys-Gly dipeptide bond in compound 1-14 is hydrolyzed 
by a metal-dependent dipeptidase, GliJ. A PLP-dependent C-S lyase, GliI, finishes the 
sulfur transfer process to produce the epidithiol 1-16. The disulfide bridge in gliotoxin 1-






Figure 1-12 Gliotoxin biosynthesis involves the ionic-type C-S bond formation reaction. 
 
In other ionic sulfur transfer reactions, sulfur atoms are first activated by the 
generation of a persulfide (R-S-SH)111 or a thiocarboxylate intermediate (R-CO-SH).112-114 




tRNAs,95,116 provide mechanistic details on these types of reactions. These two 
intermediates have also been proposed in several secondary metabolite biosynthetic 
pathways, including BE-7585A,117 thioquinolobactin,118,119 and thiolactomycin.120-122 The 
recently reported biosynthetic details for a thiosugar BE-7585A (1-22, Figure 1-13) are 
consistent with the findings of studies on sulfur-containing cofactors, although some 
unique features were also uncovered.117 In the BE-7585A biosynthetic gene cluster, the 
BexX gene is homologous to the thiazole synthase, thiG gene, in thiamine 
biosynthesis.95,115,123 The covalent adduct between BexX and the glucose-6-phosphate 
derived 2-ketosugar has been confirmed biochemically123 (1-20a, Figure 1-13) and the 
crystal structure of the BexX-substrate complex has also been reported.117 Results from 
biochemical and structural studies support the mechanistic similarities between BexX in 
BE-7585A biosynthesis and ThiG in thiamine biosynthesis.117,123 
Interestingly, the BE-7585A biosynthetic gene cluster does not contain any cysteine 
desulfurases, sulfur-carrier proteins, nor rhodanese-like proteins, which are required for the 
transfer of cysteine sulfur to the BexX-substrate complex 1-20a. This observation raises 
the question about what sulfur-delivery machinery is employed by BexX. The genome of 
the BE-7585A-producing strain, Amycolatopsis orientalis, contains five cysteine 
desulfurase homologs, four sulfur-carrier protein homologs (ThiS, MoaD, CysO, and 
MoaD2), and five rhodanese homologs. The thiS, moaD, and cysO genes are part of the 
thiamine, molybdopterin and cysteine biosynthetic gene clusters while moaD2 is a stand-
alone gene lacking a clear association with any biosynthetic pathways. Moreover, the 




responsible for activating the sulfur-carrier proteins (SCP). In the genome of A. orientalis, 
there is a MoeZ gene whose N-terminal is homologous to ThiF, an activating enzyme in 
thiamine biosynthesis. While the C-terminal of MoeZ has a rhodanese domain. MoeZ can 
catalyze the activation of both MoaD2 and CysO to produce the thiocarboxylate 
intermediate at the C-terminal of these SCPs (Figure 1-13). The C-terminal rhodanese 
domain of MoeZ mobilizes the sulfur atom into the activated SCP (e.g., CysO or MoaD2), 
from which sulfur is transferred to the BexX-substrate complex (1-20a → 1-21 conversion, 
Figure 1-13).117 This study demonstrated that the sulfur-delivery system (e.g., desulfurases, 
sulfur-carrier proteins, and their activating enzymes) may not be located in the biosynthetic 
gene cluster of a particular secondary metabolite. Instead, the system can be shared 
between primary and secondary metabolic pathways. 
 
 
Figure 1-13 Sulfur-delivery machinery in BE-7585A biosynthesis. MoeZ not only activates the C-
terminal of a sulfur-carrier protein (SCP) using ATP, but also mediates the sulfur transfer to the 






1.3.2 Radical types of C-S bond formation 
In addition to the ionic mechanism, many C-S bonds in natural products are 
constructed through a radical-type mechanism. The radical-types C-S bond formation 
mechanisms include two major sub-categories:99 aerobic and anaerobic reactions. The 
anaerobic reactions include the biotin synthase and lipoate synthase. The aerobic reactions 
include the biosynthesis of the first modern antibiotic penicillin, in which isopenicillin N 
synthase mediates the C-S bond formation reaction. In the biotin biosynthesis, biotin 
synthase (BioB) is a Radical SAM enzyme, which mediates the reduction of S-
adenosylmethionine (SAM, 1-23) by an [4Fe-4S] cluster.124 The resulting 5ˊ-
deoxyadenosyl radical (1-25, 5’-dAdo•) then abstracts a hydrogen from the substrate to 
produce a substrate-based radical (1-26a, Figure 1-14); this reaction is followed by sulfur 
insertion using an auxiliary [2Fe-2S] cluster in BioB as the sulfur source (1-26b → 1-26c  
reaction, Figure 1-14B).91,92,96,99 The process is repeated once to form the thioether bond in 
biotin (1-27, Figure 1-14B). 
A similar C-S bond formation reaction is observed in E. coli’s lipoic acid 
biosynthetic pathway (Figure 1-15). In this pathway, an octanolytransferase (LipB) first 
transfers an n-octanoyl moiety 1-28 to a conserved lysine residue on the lipoyl carrier 
protein (1-29, Figure 1-15). Then, a lipoyl synthase, LipA, mediates the sulfur transfer. 
Like other radical SAM enzymes, the first [4Fe-4S] cluster of LipA undergoes reductive 
cleavage of SAM to produce a 5’-dAdo• (Figure 1-14A), which then abstracts a hydrogen 
atom from the C6 position of the substrate to form a substrate-based radical 1-29a (Figure 




cluster, while one of the Fe3+ ions is reduced to Fe2+ and is released from the iron-sulfur 
cluster, resulting in intermediate 1-29b. The cycle is repeated one more time to incorporate 
another sulfur atom into the C8-position of the octanoyl moiety to produce 1-29d (Figure 
1-15). In this mechanism, LipA also functions as the sulfur sources, and only supports a 
single turnover. Determining how the iron-sulfur cluster is regenerated to support catalytic 
turnovers has been a challenging question for decades. Recently, Booker et al. have 
demonstrated that, in E. coli, when the iron-sulfur cluster carrier protein IscU or Nfu is 
included in the reaction, LipA can catalyze multiple turnovers. In this case, Nfu or IscU 
replenishes the auxiliary [4Fe-4S] cluster of LipA to support multiple turnovers.125,126 
 
Figure 1-14 A radical type of sulfur insertion mechanism in the BioB reaction. (A) Reductive cleavage 





Figure 1-15 The proposed lipoic acid biosynthetic mechanism. In lipoic acid biosynthesis, a radical 
SAM enzyme LipA mediates the transfer of sulfurs from an auxiliary [4Fe-4S] cluster to the octanoyl-
LCP substrate. The auxiliary [4Fe-4S] cluster is then replenished for the next cycle by an iron-sulfur 
cluster maturation system. 
 
In addition to the aforementioned cases, another type of C-S bond formation 
strategy in the biosynthesis of subtilosin A, mediated by Radical SAM enzymes has been 
reported recently (Figure 1-16). In the biosynthesis of sactipeptides, a subclass of 
ribosomally synthesized and post-translationally modified peptides (RiPP),103,127 the 
thioether linkage is formed between a cysteine thiol and the α-carbon of another residue in 
the same peptide.128-131 Some recently characterized examples include subtilosin A, 




and thuricin H.131 In the biosynthesis of subtilosin A, AlbA is a radical SAM enzyme with 
two [4Fe-4S] clusters. The first cluster undergoes reductive cleavage of SAM to produce a 
5’-dAdo• (Figure 1-14A), which then abstracts a hydrogen from the α-position of the amino 
acid where the thioether bond will be formed (1-30 → 1-30a conversion, Figure 1-16). The 
role of the auxiliary [4Fe-4S] cluster in AlbA catalysis is not yet well-defined, however, 
two mechanisms have been proposed (Figure 1-16). In the first model (Pathway I, Figure 
1-16),127 SAM binds to the unique iron site of the first [4Fe-4S] cluster, while the sulfur 
group from the peptide substrate coordinates to one of the irons of the auxiliary [4Fe-4S] 
cluster (1-30b, Figure 1-16). Then the substrate-based radical reacts with the cysteine’s 
sulfur to form the thioether bond (1-30a → 1-30b conversion, Figure 6). Simultaneously, 
one electron is transferred from the substrate to reduce the auxiliary [4Fe-4S] cluster. In 
this model, the auxiliary [4Fe-4S] cluster serves as an electron acceptor. After the product 
is released, the reduced auxiliary cluster relays the electron back to the first [4Fe-4S] cluster 
to initiate another catalytic cycle. 
Alternatively, in Pathway II, the substrate-based radical 1-30a is oxidized by the 
auxiliary [4Fe-4S]2+ cluster (Figure 1-16). The intermediate is then trapped by the sulfur 
from a cysteine residue in the substrate to form the thioether (1-30c → 1-31 conversion, 
Figure 1-16). In this pathway, the auxiliary [4Fe-4S] cluster is also key to the redox-
chemistry required for the thioether formation, while a direct coordination between the 
substrate and the auxiliary [4Fe-4S] cluster is not necessary.132 Additional studies are 





Figure 1-16 Proposed mechanistic models of AlbA, which catalyzes the sactipeptide thioether linkage 
formation in the biosynthesis of subtilosin A.  
 
In addition to the anaerobic radical-type of C-S bond formation, the aerobic type of 
reaction has been reported in the biosynthesis of the antibiotic penicillin. In this pathway, 
isopenicillin N synthase (IPNS) is responsible for installing the -lactam and thiazolidine 
rings through an aerobic radical-type of sulfur insertion mechanism (Figure 1-17). IPNS is 
a mononuclear non-heme iron enzyme, which catalyzes a four-electron oxidation of the 
tripeptide -(L-α-aminoadipoyl)-L-cysteinyl-D-valine (LLD-ACV, 1-32) to isopenicillin 




FeIII-superoxo intermediate oxidizes the cysteine sulfur to generate a thiolaldehyde 1-32a, 
which is attacked by the valine amide to form the -lactam ring. Heterolytic cleavage of 
the O-O bond of the hydroperoxo intermediate generates the FeIV=O species 1-32b, which 
abstracts a hydrogen atom from the CVal,β position, resulting in a valinyl radical 1-32c. 
Subsequently, the thiazolidine ring is formed by combining the valinyl radical and a thiol 
radical to produce the final product, isopenicillin N 1-33 (Figure 1-17).134 
 
Figure 1-17 The proposed mechanistic model of IPNS involves two stages: the -lactam formation 





1.3.3 Oxidative C-S bond formation in ergothioneine and ovothiol biosyntheses 
The ionic- and radical-type of C-S bond formation are the two commonly used 
strategies in the biosyntheses of many sulfur-containing natural products. However, many 
of the recently discovered biosynthetic pathways for sulfur-containing natural products 
have not yet been biochemically characterized. Recent studies have revealed an 
unprecedented C-S bond formation reaction in the biosyntheses of ergothioneine and 
ovothiol.77-79,135,136 In these pathways, sulfur is incorporated through a combination of a 
mononuclear non-heme iron enzyme catalyzed the oxidative C-S bond formation reaction 
and a PLP-enzyme mediated C-S lyase reaction. This sulfur transfer strategy differs from 
all other examples discussed in the previous sections. 
Ergothioneine 1-5 and ovothiol (1-42a to 1-42c) are histidine-derivatives with a 
sulfur substitution at the - and -carbon of the histidine imidazole sidechain, respectively. 
Ergothioneine (1-5, Figure 1-18A) was first isolated from ergot by Tanret in 1909.137 
Feeding studies of ergothioneine-producing strains led to the structural characterizations 
of a few key intermediates. Culturing the ergothioneine-producing strain Claviceps 
purpurea with [2-14C]-acetate showed that L-His and ergothioneine have a similar labeling 
distribution pattern, suggesting that L-His is an ergothioneine biosynthetic precursor.138 
When another ergothioneine producer, Neurospora crassa, was fed with [14C]-His, it was 
efficiently incorporated into ergothioneine, whereas [14C]-thiohistidine was not.139 This 
work suggested that N,N,N-trimethyl-histidine (hercynine, 1-35) is most likely an 
intermediate in ergothioneine biosynthesis, too. The source of sulfur was also examined 




L-Cys, cystine) might serve as the sulfur sources for ergothioneine biosynthesis. Using 
[14C]-methyl labeled Met resulted in ergothioneine with [14C]-labeled methyl groups, 
suggesting that L-Met is the methyl source for ergothioneine production. 
  
 
Figure 1-18 Ergothioneine and ovothiol biosynthetic pathways. (A) Two aerobic and one anaerobic 




These early feeding studies suggested that ergothioneine biosynthesis most likely 
initiates with the methylation of the L-His amino group to produce hercynine 1-35 (Figure 
1-18A).140 This conclusion was further substantiated by the study using N. crassa cell 
extract, which catalyzes the conversion of L-His to hercynine using SAM as the methyl 
source.141,142 When [14C]-hercynine and L-Cys were incubated with the cell extract of N. 
crassa, the production of ergothioneine was observed. Interestingly, in the presence of 200 
M of hydroxylamine, hercynyl-cysteine sulfoxide 1-38 was accumulated. In addition, 
adding 1-38 to the cell extract of N. crassa resulted in the ergothioneine production.143 The 
results from these studies suggested that sulfoxide 1-38 might be another ergothioneine 
biosynthetic intermediate (Figure 1-18A). The identity of the enzymes responsible for these 
transformations in ergothioneine biosynthesis was discovered recently,78  and their 
biochemical properties correspond to the observations in the study of the N. crassa cell 
extract.  
This oxidative C-S bond formation reaction is present not only in the biosynthesis 
of ergothioneine, but also in the pathway of ovothiol, another histidine derivative. Ovothiol 
A 1-42a was first isolated from the eggs and ovaries of sea urchins (Figure 1-18B). 144 The 
initial characterization of ovothiol A biosynthetic pathway was conducted using the cell 
extracts from the ovothiol-producing organisms Crithidia fasciculate. In this work, 
Steenkamp et al. demonstrated that ovothiol is derived from L-His and L-Cys, additionally, 
the sulfur transfer occurs prior to methylation.145 Using the partially purified proteins from 




involves an iron enzyme catalyzed oxidative coupling reaction and a PLP-catalyzed C-S 
lyase reaction.146 Thus far, only the identity of the non-heme iron enzyme is known.136 
The intriguing results from feeding studies on ergothioneine-producing organisms 
motivated researchers to look for its biosynthetic gene cluster. Seebeck and co-workers 
discovered the ergothioneine biosynthetic gene cluster using a comparative genomic 
approach (Figure 1-18A).79 In one of the ergothioneine-producing organisms, 
Mycobacterium aviu, there are 78 annotated methyltransferases and among these genes, 29 
of them have homologs in N. crassa, another ergothioneine-producing species. Eliminating 
homologs from the ergothioneine non-producing species narrows the list down to 10 
methyltransferase candidates. Interestingly, one of them is located next to a PLP-containing 
enzyme in the context of a five-gene cluster, designated egtABCDE (EgtA – EgtE genes). 
The recombinant EgtD indeed catalyzes the methylation of L-His 1-34 and the methylation 
is processive (Figure 1-18A), resulting in a hercynine, 1-35 with only small amounts of 
mono- or di-methylhistidine products. This processivity is due to the fact that EgtD binds 
to dimethyl-histidine 70-fold stronger than to L-His.147  
In addition to a methyltransferase, the γ-glutamyl-cysteine ligase (EgtA) was also 
identified in the mycobacterial ergothioneine biosynthetic gene cluster suggesting that γ-
glutamyl-cysteine 1-35 is the sulfur source.79 Feeding results suggested that the oxidative 
C-S bond formation was mediated by an iron-dependent enzyme. Further studies revealed 
that EgtB catalyzes the oxidative coupling between hercynine and γ-glutamyl-cysteine to 
form a hercynyl--Glu-Cys sulfoxide sulfoxide 1-37 (Figure 1-18A). Subsequent cleavage 




The last step of the ergothioneine biosynthesis is catalyzed by a PLP-dependent C-S lyase 
(EgtE), whose activity has also been demonstrated in vitro.148,149 Recently, OvoA, an EgtB 
homolog, was identified from one of the ovothiol A producers, Erwinia tasmaniensis.136 
Recombinant OvoA catalyzes the oxidative coupling between L-His 1-34 and L-Cys to 
form hercynyl-cysteine sulfoxide 1-39 in vitro (Figure 1-18B). However, the proposed C-
S lyase and methyltransferase in ovothiol biosynthesis have not been characterized. 
In ergothioneine and ovothiol biosyntheses, the trans-sulfuration strategy differs 
from those discussed previously. A combination of a non-heme iron enzyme catalyzed 
oxidative C-S bond formation (EgtB, OvoA-catalysis) and a reductive C-S lyase represents 
one of the most efficient sulfur-transfer strategies in natural product biosyntheses. After 
the discovery of the mycobacterial EgtB gene, the functions of its homologs in fungi (N. 
crassa,150 Aspergillus fumigates,151) and the fission yeast (Schizosaccharomyces pombe152) 
have also been examined by genetic studies. A systematic analysis of all completed 
genomes in the NCBI database indicated that ergothioneine’s biosynthetic genes are widely 
distributed in actinobacteria,153 while EgtB and EgtD were primarily found in 
proteobacterial and cyanobacterial species.154 
Although, EgtB and OvoA both mediate the sulfoxide formation, they differ in their 
substrate selectivity and their C-S bond formation regioselectivity (Figure 1-18A vs. 1-
17B). In ergothioneine biosynthesis, EgtB uses hercynine and γ-glutamyl-cysteine as the 
substrates to form the C-S bond at the -position (Figure 1-18A). OvoA, on the other hand, 
uses L-His and L-Cys as the substrates resulting in the C-S bond forming at δ-position 




sulfinic acid 1-40 (Figure 1-18B), an activity solely reported in cysteine dioxygenase 
(CDO).155 Based on the EgtB and OvoA biochemical information and guided by the 
sequence similarity network analysis results, the Egt1 gene from fungal N. crassa was 
identified and characterized biochemically in vitro. The fungal Egt1 preferentially 
catalyzes the oxidative coupling between hercynine 1-35 and L-Cys to give hercyl-cysteine 
sulfoxide 1-38 (Figure 1-18A).78 These studies led to the elucidation of two aerobic 
ergothioneine biosynthetic pathways: the mycobacterial pathway79 (EgtA – EgtE, Figure 
1-18A), and the fungal N. crassa pathway78 (Egt1 and Egt2, Figure 1-18A). 
The discoveries of these aerobic ergothioneine biosynthetic pathways are in line 
with the function of ergothioneine as a cellular antioxidant. However, the recent discovery 
of an anaerobic ergothioneine biosynthesis challenges this proposition. Seebeck and co-
workers analyzed the genomes of  a green-sulfur bacterium Chlorobium limicola and 
identified Clim_1148 (EanA) as an EgtD homolog.156  C. limicola grows in illuminated 
anoxic waters and performs anaerobic photosynthesis using sulfides as the electron donor 
for carbon dioxide fixation. The recombinant EanA can catalyze the methylation of L-His 
1-34 to hercynine 1-35 (Figure 1-18). Analysis of the EanA gene neighborhood revealed a 
putative rhodanese-like sulfur transferase (EanB, Clim_1149). These pair of enzymes were 
found in at least 20 genomes from predominantly anaerobic bacteria and archaea. Using 
cysteine desulfurase (IscS) from E. coli, EanB mediates the sulfur transfer from cysteine 
to hercynine 1-35 to yield ergothioneine 1-5 (Figure 1-18A). The trans-sulfuration 
catalyzed by EanB is intriguing because this transformation differs from other rhodanase-




different ergothioneine biosynthetic pathways in nature: two aerobic and one anaerobic 
(Figure 1-18A).157 
In addition to the unprecedented C-S bond formation reaction, ergothioneine also 
processes intriguing physiological functions. Human enrich ergothioneine in many tissues 
to concentrations ranging from 100 M to 2 mM through an ergothioneine-specific 
transporter, OCTN1.158 The highest concentration are found in erythrocytes, bone marrow, 
liver, kidney, seminal fluid, the lens and cornea of eyes.158-161 Knockouts of OCTN1 in 
mice resulted in depletion of ergothioneine suggesting that OCTN1-mediated uptake is 
most likely the sole ergothioneine transporter in animals.162,163 Ergothioneine has been 
suggested to play a role complementary to that of glutathione in vivo.164 However, the 
reduction potential of ergothioneine (E0ˊ = - 0.06 V
1,165,166)  is significantly higher than that 
of glutathione (E0ˊ = - 0.25 V
167). Studies have proposed that ergothioneine primarily 
functions as an antioxidant to eradicate ROS and RNS,164 including hydroxyl radicals 
(•OH), peroxynitrite (ONOO-), nitrosoperoxycarbonate (ONOOCO2
-), and carbonate 
radical. Several human diseases have been suggested to be related to ergothioneine, 
including rheumatoid arthritis,168,169 Crohn’s disease,170,171 neurodegenerative diseases,172-
175 cardiovascular disorders,176 and diabetes.177 Ergothioneine can pass through the blood-
brain barrier172-174 and might serve as a protection mechanism against neurodegenerative 
diseases. The presence of ergothioneine in multiple tissues, the necessity of its transporter, 
its antioxidant, and its potential involvement in aging-related diseases, all suggest that 




research is needed to understand the physiological roles and functional mechanism of 
ergothioneine. 
Due to the wide distribution of ergothioneine in both aerobic and anaerobic 
microorganisms, it is tempting to assume that ergothioneine may have other biological 
functions besides its antioxidant activity.156,157 Recently, Zhao et al. reported the 
biochemical characterization of lincomycin A biosynthesis, in which ergothioneine plays 
a key role as part of a sugar activation mechanism (Figure 1-19).179 Lincomycin 1-43 is an 
antibiotic produced from Streptomyces lincolnensis.  Lincomycin possesses an N-methyl-
4-propyl-L-Pro (PPL) moiety and an unusual eight-carbon sugar (lincosamide) decorated 
with methylthiol group at the C1-position. In the licomycin A biosynthetic gene cluster, 
there is a DinB-2-like domain containing protein, LmbV. DinB-2 domain-containing 
proteins are a large superfamily with over ten thousand members, which are involved in 
transformations using small molecular thiols.180 LmbV was proposed to mediate the 
incorporation of the thiol group at the C1-position of lincosamide. In the ΔlmbV mutant, as 
anticipated, no lincomycin A was produced. Surprisingly, an ergothioneine S-conjugate 1-
40, was isolated from cell culture of this variant. Due to difficulties in the overexpression 
of LmbV, the biochemical characterization of this enzyme activity was performed using its 
homolog, CcbV. In CcbV reaction, using the ergothioneine S-conjugate 1-40 and 
mycothiol (MSH) as substrates, the production of MSH S-conjugate 1-41 was observed 
along with the formation of ergothioneine as the side-product (Figure 1-19).179 This finding 






Figure 1-19 Biosynthesis of lincomycin A shows the involvement of two small molecule thiols, 
ergothioneine (EGT) and mycothiol (MSH). 
 
Subsequent sequence analysis suggested that LmbT is a glycosyltransferase. LmbT 
mediates the equilibrium between GDP-lincosamide and the lincosamide-ergothioneine 
conjugate in vitro (Figure 1-19). The LmbT-catalyzed reaction exhibited an equilibrium 
constant (Keq) of 1.94 and the reaction slightly favors the GDP-lincosamide side 1-38. 




LmbN work in tandem to incorporate the PPL moiety to the lincosamide-ergothioneine 
conjugate to produce 1-40. LmbC encodes an adenylation protein, which activates PPL 
using ATP and transfers PPL onto the peptidyl carrier protein (PCP) domain of the LmbN 
protein.   LmbD then catalyzes the condensation between the activated PPL with the EGT 
S-conjugate 1-39 to yield 1-40. In the lincomycin-producing organism, S. lincolnensis, 
LmbE is an amidase homolog. As predicted, the ΔlmbE mutant strain accumulated an 
MSH-associated lincomycin analog 1-41. The recombinant LmbE rapidly converts 1-41 to 
1-O-(2-N-acetyl)-glucosamine-d-myo-inositol-3-phosphate (GlcNAc-Ins-3-P) and 1-42. 
Thus far, most of the critical steps in the biosynthesis of licomycin A 1-43 have been 
established, illuminating the involvement of two small molecular thiols, mycothiol and 
ergothioneine.  
Over the years, it was suggested that small molecule thiols are involved in 
providing protection against oxidative stress or employed as tools to detoxify electrophilic 
toxins. The discovery of the key roles played by ergothioneine in lincomycin A 
biosynthesis is the first example of its involvement in a natural product biosynthetic 
pathway. Several biosynthetic pathways have been suggested to involve the MSH-S-
conjugates. Given by the presence of ergothioneine across multiple life domains, it is likely 
that many more roles of ergothioneine await to be discovered.181,182 S-alk(en)yl-L-Cys 
sulfoxides have been discovered as metabolites in many plants and some of them are 
playing important biological roles, e.g., suppression of hypercholesterolemia,183 
stimulation of insulin secretion,184 and priming neutrophils for respiratory burst.185 The 




characterizing new trans-sulfuration strategies in nature, but also offer ample opportunities 
for future investigations on the biological functions of small molecular thiols. 
In this thesis, the mechanistic studies of the sulfoxide synthase and the C-S lyase in 
ergothioneine biosynthesis are presented. Additionally, the in vitro reconstitution of the 
ovothiol A biosynthesis and the mechanistic studies on the oxidative C-S bond formation 
in this pathway are described. This work contributes to a new body of knowledge on the 
biosynthesis of ergothioneine and ovothiol, which may pave the way for production of the 
two of them through a synthetic biology approach.  
Chapter 1 (this chapter) discusses the metabolism of sulfur in microorganisms 
including bacteria and archaea. Reducing-sulfur assimilatory pathways in microorganisms 
produce sulfide as the sulfur source for L-Met and L-Cys biosynthesis. These pathways are 
well studied. However, much less is known about sulfur metabolism of gastrointestinal 
microbes and how their role in intestinal health of the host. The links between sulfur 
metabolism and human health and diseases are discussed focusing on the emerging role of 
hydrogen sulfide as a signaling molecule. Finally, this chapter is concluded with the 
discussion of the mechanisms of sulfur incorporation in natural products biosyntheses. 
In Chapter 2 and Chapter 3, the biochemical and structural studies of the enzymes 
involved in the biosynthesis of ergothioneine are presented. Specifically, in Chapter 2, the 
study of the substrate promiscuity of the thermophilic sulfoxide synthase EgtB from 
Chloracidobacterium thermophiluim is described. Computational enzyme design was used 
to engineer this enzyme to facilitate the ergothioneine production. The discussion of 




crassa’s ergothioneine C-S lyase Egt2 in Chapter 3, in which the reductive C-S bond 
cleavage reaction was explored to provide valuable insight into this chemical 
transformation as well as the factors governing the substrate specificity of this C-S lyase. 
In Chapter 4 and Chapter 5, the focus is shifted toward the study of another small 
molecular thiol, ovothiol, biosynthetic pathway. The in vitro reconstitution of ovothiol A 
biosynthesis from E. tasmaniensis is discussed in Chapter 4, demonstrating that OvoA 
exhibits sulfoxide synthase and methyltransferase activities, while OvoB was identified as 
a PLP-dependent C-S lyase. Structural and biochemical studies also shed light on the 
mechanism of the reductive C-S bond cleavage mediated by OvoB. In Chapter 5, the 
mechanism of OvoA-catalysis is presented. Using amber-codon suppression system to 
incorporate unnatural amino acid, the role of the active site Tyr417 was explored via kinetic 
isotope studies. The results suggested Tyr417 plays a redox role in OvoA-catalysis. 
In summary, in my thesis work, the trans-sulfuration reactions in the biosyntheses 
of ergothioneine and ovothiol were examined, providing a new body of knowledge on the 
understudied sulfur transfer strategies. The mechanistic and biochemical understanding of 
these pathways pave the way to for developing biosynthetic pathways for producing these 
high value compounds through metabolic engineering/synthetic biology approaches. The 
success of this work has also laid the groundwork for future in-depth mechanistic 
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Chapter 2 Structure-guided Engineering of Sulfoxide Synthase from 
Chloracidobacterium thermophiluim in Ergothioneine Biosynthesis 
Reproduced with permission from ACS Catal. 2019, 9, 8, 6955-6961, and 
Biochemistry 2018, 57, 24, 3309-3325, Copyright © 2020 American Chemical Society 
 
2.1 Introduction 
2.1.1 Aerobic and anaerobic ergothioneine biosyntheses  
Ergothioneine, a histidine-derived thiol, is a small molecule antioxidant against 
reactive oxygen species (ROS) and reactive nitrogen species (RNS).1 Animals cannot 
synthesize ergothioneine and must obtain it form dietary sources through an ergothioneine-
specific transporter, OCTN-1.2 Data suggest that ergothioneine exhibits several beneficial 
effects in many pathological conditions such as rheumatoid arthritis,3,4 Crohn’s disease,5,6 
neurodegenerative diseases,7-10 and diabetes.11 Due to these potential health benefits, the 
study of ergothioneine biosynthetic pathway is of great interest in the research community. 
Two aerobic biosynthetic pathways of ergothioneine have been reported (Figure 2-1). 
Through comparative genomic analysis, the gene cluster of ergothioneine biosynthesis in 
Mycobacterium smegmatis was reported.12 In this pathway, using L-Glu and L-Cys as 
substrates, a ligase, EgtA, mediates the formation of -Glu-Cys 2-3. The methyltransferase, 
EgtD, methylates L-His to afford hercynine 2-2 in a processive fashion. Then, a non-heme 
iron sulfoxide synthase, EgtB, catalyzes the oxidative coupling between hercynine and -
Glu-Cys, resulting in a sulfoxide 2-4, which is subjected to cleavage of glutamate portion 




mediates the C-S bond cleavage resulting in ergothioneine 2-6 as the final product (Figure 
2-1).12-15 In contrast to the mycobacterial pathway, the fungal Neurospora crassa 
ergothioneine biosynthesis contains only three genes: a non-heme iron enzyme sulfoxide 
synthase (Egt1), a PLP-dependent C-S lyase (Egt2), and an unknown methyltransferase 
(Figure 2-1).12,14,16 The identity of the sulfoxide synthase was determined through a 
sequence similarity network analysis of EgtB homologs, in which the fungal gene cluster 
is separated from the mycobacterium (EgtB) cluster. Subsequent analysis of Egt1 using the 
String database based on gene co-occurrence revealed Egt2 as a PLP-dependent C-S 
lyase.16 Biochemical characterizations of these two genes further confirmed their predicted 
functions from the bioinformatic analysis (Figure 2-1).  
In both the mycobacterial and the fungal ergothioneine biosyntheses, the central 
steps are the oxidative coupling C-S bond formation mediated by non-heme iron sulfoxide 
synthases (EgtB/Egt1) and the reductive C-S bond cleavage reaction catalyzed by PLP-
dependent lyases (EgtE/Egt2), which differ from other reported sulfur-transfer strategies 
discussed in Chapter 1.17 In addition to the aerobic pathways, a recent study reported an 
anaerobic ergothioneine biosynthesis in a green-sulfur bacterium Chlorobium limicola 
(Figure 2-1).18  In this pathway, a methyltransferase, EanA, mediates the methylation of L-
His 2-1 to afford hercynine 2-2. Intriguingly, a rhodanese-like EanB is proposed to mediate 
the sulfur transfer from a protein-bound persulfide to the hercynine accepter.18 This 
discovery suggests that there exists at least three different ergothioneine biosynthetic 





Figure 2-1 Aerobic and anaerobic ergothioneine biosynthetic pathways. 
 
2.1.2 Rational enzyme design for tuning the substrate specificity 
Despite similarities in their chemical transformations, EgtB and Egt1 show 
preference in their substrate selectivity: EgtB sulfoxidizes hercynine 2-2 and -Glu-Cys 
while Egt1 employs hercynine 2-2 and L-Cys as substrates. The structure of the 
Mycobacterium thermoresistibile sulfoxide synthase (EgtBMth) was reported, providing 
insight into the substrate recognition of this enzyme.20,21 However, lacking the structure of 
Egt1, how nature fine tunes the substrate specificity of EgtB and Egt1 is poorly understood. 
To explore the structure-function relationships, rational tools for engineering substrate 
specificity can be applied. Rational enzyme design was first developed for protein 
engineering in 1978 and has remained useful since.22 In this approach, the protein structure 




2-2) to achieve the desired substrate specificity and enantioselectivity.23 In protein 
engineering, protein dynamics/protein folding play key roles, and in many cases, it is 
challenging to predict activity outcomes. To address these challenges, several robust 
structure prediction algorithms have been developed in recent years, including Rosetta 
Design.24,25  In this chapter, some of my recent efforts by making use of rational enzyme 
design will be summarized. 
 
 
Figure 2-2 Overview of rational enzyme design using Rosetta Design package. 
 
Similar to other structure prediction algorithms, Rosetta Design explores the 
relevant conformations of residues of interest to optimize the interactions between the 
protein and ligand. Rosetta Design is also equipped with a function to accurately evaluate 
the global energy of the resulting structural models. The first step in the Rosetta Design 
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ligand (Figure 2-2). Generally, these inter- and intra-molecular interactions include 
hydrogen bonds, salt bridges, disulfide bonds, electrostatic interactions, and hydrophobic 
interactions. In this process, the rotamers of the productive binding residues are oriented 
so that the catalytic interactions with the desired ligand are as close to ideal as possible. 
Subsequently, the identity of the productive binding residues is optimized to stabilize the 
interactions between the protein and ligand of interest. This process results in thousands of 
designed variants, which are then ranked based on their global energy including Van der 
Waals repulsion, electrostatic interactions, and hydrogen bonds. The lower the energy, the 
more stable the variant structure. Then, the variants with lowest global energy are further 
evaluated manually through structural analysis. Rounds of iterative Rosetta Design lead to 
the predicted variants, whose activity are validated through experimental studies.25     
In this chapter, a thermophilic Chloracidobacterium thermophiluim sulfoxide 
synthase, EgtBCth from ergothioneine biosynthesis was identified through protein similarity 
network analysis. Biochemical characterization shows that EgtBCth exhibits substrate 
promiscuity, mediating the oxidative coupling between two pairs of substrates: 
hercynine/-Glu-Cys and hercynine/L-Cys. Structural information of EgtBCth provides 
insights into its substrate preference. Additionally, using Rosetta Design, the EgtBCth was 
engineered to fine tune its substrate specificity toward hercynine and L-Cys, providing a 
better understanding of the substrate preferences of the sulfoxide synthase in ergothioneine 
biosynthesis. The thermostable EgtBCth also paved the way for further production of 




2.2 Material and Methods 
2.2.1 General materials and equipment 
Reagents were purchased from Sigma-Aldrich and Fisher Scientific unless 
otherwise indicated. pASK-IBA3+ plasmid was purchased from IBA, Göttingen. 
Escherichia Coli BL21(DE3) and NEB5α competent cells were purchased from New 
England Biolabs. DNA polymerase, DNA ladder, PCR product purification kits, and 
plasmid extraction kits were purchased from New England Biolabs. Oligonucleotides used 
in PCR amplification were obtained from Invitrogen and used without further purification. 
SDS-PAGE and agarose gel electrophoresis were performed with a PowerPac power 
supply (Bio-Rad). The SDS-PAGE gel running system was obtained from Bio-Rad and 
imaged using the ChemiDocTM MP Imaging System.    
The hercynine and -Glu-Cys substrates were synthesized following a reported 
procedure.26 Nuclear magnetic resonance (1H and 13C NMR) spectra were recorded using 
Agilent 500 (500 MHz VNMRS). Mass spectrometric analysis was performed using LC-
MS on an LTQ-FT-ICR mass spectrometer (Thermo Scientific). UV-Vis spectra were 
recorded with the Varian Cary Bio 100 spectrophotometer. Cell membranes were disrupted 
using CL18 Dismembrator (Fisher Scientific). Centrifugations were carried out using 
Avanti J-HC (Beckman). pH values were measured using a Fisher pH meter AE150. 
Oxygen-free experiments were conducted in the glove box (Coy Laboratory). Oxygen 




2.2.2 Protein similarity network analysis  
The protein similarity network analysis was performed by Ronghai Cheng, a 
graduate student in the Liu Lab. To systematically analyze the sulfoxide synthase 
candidates, 21475 sequences with either a DinB_2 domain (Pfam ID: PF12867) or a FGE 
sulfatase domain (Pfam ID: PF03781) were retrieved from Pfam protein family database.27 
Among these, 3000 sequences were randomly selected for protein similarity network 
analysis. The protein similarity network was constructed by all-to-all blast of these 3000 
sequences. The E value cut off was 10-50. The protein similarity network was visualized 
with Cytoscape.  
2.2.3 Protein overexpression and purification  
The gene Cabther_A1318 (EgtBCth) was codon-optimized for the E. coli 
overexpression system by Genscript. The gene was then sub-cloned into the pASK-
IBA3plus (IBA) expression vector using the EcoRI and XhoI restriction sites. The plasmid 
was then transformed into BL21(DE3) competent cells and one colony was inoculated in 
LB media supplemented with 100 µg/mL of ampicillin at 37 C overnight. Then, 10 mL of 
this overnight culture was inoculated to 1 L LB medium supplemented with 100 µg/mL of 
ampicillin and 0.1 mM ferrous ammonium sulfate. Cells were culture at 37 C until OD600 
reached 0.8, and protein overexpression was induced with the addition of 
anhydrotetracycline (AHT) to 250 ng/L final concentration. Cells were cultured for 14 hr 
at 25 C before harvesting by centrifugation.   
The following procedure was carried out under anaerobic condition at 4 C unless 




lysis buffer (100 mM Tris-HCl, 50 mM NaCl buffer pH 8.0). Then, lysozyme was added 
to 1 mg/mL final concentration and the mixture was incubated on ice for 30 mins. Prior to 
sonication, ferrous ammonium sulfate and sodium ascorbate were added to 0.1 mM, and 
0.2 mM final concentrations, respectively. Cells were lysed by sonication (18 cycles of 8 
sec on, 59 sec off) and the cell debris was removed by centrifugation at 20,000 g for 45 
min. The supernatant was then incubated with 15 mL Strep-Tactin resin (IBA) on ice for 
30 mins with gentle agitation. The column was then washed with lysis buffer until OD280 
< 0.05. Subsequently, the desired protein was eluted using 2.5 mM desthiobiotin in lysis 
buffer. The elution fractions were combined and concentrated using an ultrafiltrator 
(Millipore). The protein was flash frozen using liquid nitrogen and stored in -80 C. 
Approximately 2 mg of purified protein was obtained from one gram of wet cells. 
The EgtBCth selenomethionine derivative was obtained following a similar 
procedure to that of wild-type. However, the LB medium was replaced with minimal 
medium. 1 L of minimal medium contained 5% glycerol, 12.8 g Na2HPO4•7H2O, 3 g 
KH2PO4, 0.5 g NaCl, 1 g NH4Cl, 0.2 % glucose, 0.1 mM CaCl2, and 2.0 mM MgSO4) 
supplemented with 10 mL of 100× amino acid mixture (100 mg L-Lys, 100 mg L-Thr, 100 
mg L-Phe, 50 mg L-Leu, 50 mg L-Ile, and 50 mg L-Val in 10 mL H2O) and 10 mL of 100× 
Se-Met solution (60 mg Se-Met in 10 mL H2O) for cell culture.  
The EgtBCth mutants were generated using the Q5 Site-directed mutagenesis kit 
following the suggested protocol (New England Biolabs). A 10-µL PCR reaction 
containing 0.5 µM forward primer, 0.5 µM reverse primer, and 5 ng DNA template in 1X 




DNA template was digested with the  KLD treatment. A 5-µL reaction contained 1 µL 
PCR product and 1X KLD Enzyme Mix in 1X KLD reaction buffer. The KLD treated 
product was then transformed into NEB5 competent cells. The plasmids were extracted 
using the Ecospin column (Epoch Life Science). The plasmids were sequenced (Genewiz) 
to identify the positive clone. The variant proteins were overexpressed and purified 
following the procedure for wild-type EgtBCth.  
2.2.4 Amino acid analysis of EgtBCth 
The purified EgtBCth was subjected to amino acid analysis (AAA Service 
Laboratory). The calculated molar extinction coefficient at 280 nm was 12.1 × 104 M-1cm-
1 with respect to the protein concentration determined from amino acid analysis. The 
correction factor for the Bradford assay from the amino acid analysis was 0.95.  
2.2.5 Iron content determination of EgtBCth using atomic emission spectroscopy 
The iron content determination of EgtBCth after purification was carried. To release 
the iron cofactor into solution, the EgtBCth protein was diluted with 1% HNO3 to 1.0 mg/mL 
final concentration. Then, the precipitated protein was removed by centrifugation at 15,000 
rpm for 10 min. The sample was prepared in triplicates. The iron standard curve was 
constructed by measuring the intensity at 259.940 nm with concentrations ranging from 0 
to 1.5 ppm of analytical-grade Iron Reference Standard Solution prepared with 1% NHO3 
using atomic emission spectroscopy (Agilent 4200 MP-AES). The average intensity for the 




standard curve was 17.4 ± 0.5 µM from 18.9 µM of EgtBcth protein. This result suggested 
that there was 0.92 iron per one EgtBCth monomer. 
2.2.6 1H NMR activity assay and product purification.  
For routine reaction analysis, a typical 1-mL reaction containing 1 mM hercynine, 
1 mM L-Cys (or -Glu-Cys), 1 mM TCEP, 0.2 mM sodium ascorbate, and 10 µM EgtBCth, 
was set up at 28 C for 2 hrs. The protein was then removed using a centrifugal filter 
column (Amicon). The reaction mixture was lyophilized and analyzed by 1H NMR. 
For product characterization, a reaction similar to the above conditions was set up, 
however, the reaction volume was scaled up to 10 mL. The product was isolated using the 
Dowex 50WX8-100 ion-exchange resin in the H+ form following a reported procedure.16 
The impurities were washed away with water and the product was eluted with 10% 
NH4OH. The fractions were monitored by TLC under the UV light and pooled before rotary 
evaporated to remove ammonia. The pooled fractions were then lyophilized, and the 
product was characterized by 1H-NMR and high-resolution mass spectrometry. 
Hercynyl--Glu-Cys sulfoxide 2-4: 1H NMR (500 MHz, D2O) δ 2.06-2.15 (m, 2H), 
δ 2.43 (m, 2H), δ 3.21 (s, 9H), δ 3.31 (dd, J=13.8, 11.7 Hz 1H), δ 3.40 (dd, J=14.0, 3.4 Hz 
1H), δ 3.62 (dd, J=13.6, 9.2 Hz, 1H), δ 3.85 (dd, J=14.0, 4.3 Hz, 1H), δ 3.98 (t, J=6.6 Hz, 
1H), δ 4.10 (dd, J=11.9, 4.0 Hz, 1H), δ 4.74 (dd, J=9.5, 4.3 Hz, 1H), δ 7.34 (s, 1H). HRMS 
(ESI): Calculated value for hercynyl--Glu-Cys sulfoxide as [M-H]- (negative mode) form 
was m/z 460.1508 and found m/z 460.1505.  
Hercynyl-cysteine sulfoxide 2-5: 1H NMR (500 MHz, D2O) δ 3.13 (m, 11 H), δ 




Hz, 1H), δ 3.97  (dd, J = 8.2, 4.4 Hz, 1H), δ 7.15 (s, 1H). HRMS (ESI): Calculated value 
for this as [M-H]- (negative mode) form was m/z 331.1082 and found m/z 331.1078. 
2.2.7 Steady-state kinetic study of wild-type and variants of EgtBCth 
The kinetic parameters of EgtBCth was determined using the oxygen probe. For 
hercynine concentration dependence studies, a 1-mL reaction contained 2 mM L-Cys, 2 
mM TCEP, 0.2 mM sodium ascorbate, 1.5 µM EgtBCth, and 0.03 – 4 mM of hercynine in 
50 mM KPi pH 8.0. A similar reaction was setup for L-Cys concentration dependence, 
except hercynine concentration was kept at 2 mM and L-Cys concentration was 0.05 – 4 
mM. Similar experimental set up was carried out for reactions using the hercynine and -
Glu-Cys as substrates, except that the enzyme concentration was increased to 2 µM. For 
the EgtBCth mutants, the experimental condition for kinetic analysis remained largely 
unchanged. For the EgtBCth-A420Y and EgtBCth-D52L variants, the enzyme concentration in 
the assay was adjusted to 2 µM. For EgtBCth-D52L/A420Y variant, the enzyme concentration 
in the assay was 1.5 µM.   
2.2.8 Crystallization, structure determination, and refinement  
This experiment was conducted by Dr. Seema Irani from the lab from Prof. Jessie 
Zhang at the University of Texas Austin. Crystallization screening trays with EgtBCth at a 
concentration of ~20 mg/ml were set up using the Phenix crystallization robotic system 
(Art Robinson Instruments). Several hits were identified and optimized using vapor 




0.1-0.2M sodium acetate, 0.1M Tris-acetate pH 6.0-6.5, and 3-8% PEG 4000 at 4 ºC, with 
a 1:2 ratio of protein to mother liquor. 
To obtain the ligand protein binary complex structures, both co-crystallization and 
soaking methods were attempted. For co-crystallization, 10 mM hercynine was incubated 
with EgtBCth at ~20 mg/ml for 1 hr on ice before setup and crystallized under identical 
conditions to the the EgtBCth protein alone. For soaking, pre-formed crystals were soaked 
in mother liquor containing 10 mM hercynine for 12 hr at 4 ºC. The crystals were 
subsequently cryo-protected in a cryogenic solution containing the same mother liquor with 
30% glycerol, before vitrification in liquid nitrogen.  
The selenomethionine-containing EgtBCth protein was crystalized under similar 
conditions as the wild-type enzyme and phasing was performed using single wavelength 
anomalous dispersion (SAD) data and Phenix Autosol.28  
2.2.9 Modeling of EgtBCth bound to both hercynine/-Glu-Cys and hercynine/L-Cys 
In collaboration with Dr. Seema Irani from the lab of Prof. Jessie Zhang at 
University of Texas Austin, the model of EgtBCth bound to both substrates was generated. 
The complex structure of EgtBCth bound to hercynine was superimposed with the tertiary 
structure of EgtBMth bound to dimethyl histidine and -Glu-Cys (PDB: 4X8D). Residues 
that coordinated the cysteine portion of the -Glu-Cys substrate remained conserved in both 
structures, whereas the residues interacting with the glutamyl end of the substrate appeared 
to be flipped. The position of the substrate from the previously reported structure (PDB: 




structure. In addition, the model of L-Cys substrate bound to EgtBCth structure was also 
generated following a similar approach.  
2.2.10 Protein engineering using Rosetta Enzyme Design  
In collaboration with Ronghai Cheng, a graduate student in the Liu Lab, protein 
engineering was performed using Rosetta Enzyme Design. Random mutagenesis of active 
site residues of EgtBCth was performed with a combination of the Pymol mutagenesis 
wizard and a custom Python scripts following a previously reported procedure.25 The 
model of EgtBCth bound to hercynine and L-Cys was used as the starting point. To find the 
valid rotamers for each specific mutation, the “minimizer” algorithm from Rosetta 3.0 was 
used to globally minimize the energy of each rotamers. The specific parameters for the 
“minimizer: are “-run:min_type lbfgs_armijo_nonmonotone, -run:min_tolerance 0.005”. 
The model with the smallest global energy was used as the most valid rotamer for each of 
specific mutants. Global energies for all mutants were calculated and ranked by the Rosetta 
3.0 scoring function “score_jd2”. Default parameters were used for “score_jd2”. The 
variant structures that had lower scores were then inspected manually in conjunction with 




2.3 Results and Discussion 
Egt1 and EgtB share similar regioselectivity of the oxidative C-S bond formation 
but differ in their substrate selectivity: EgtB catalyzes the oxidative coupling between 
hercynine and -Glu-Cys while Egt1 prefers hercynine and L-Cys as the substrates. This 
discovery immediately raised the questions as to what factors govern the substrate 
selectivity. Thus far, only the EgtBMth structure from a thermophilic M. thermoresistibile 
is available.20 Our attempts to crystallize N. crassa Egt1 failed. Owning to the lack of Egt1 
structure, the factors controlling the substrate specificity between EgtB and Egt1 remain to 
be explored.   
2.3.1 Identify a sulfoxide synthase from a thermophile 
To search for a proper sulfoxide synthase to study the factors governing substrate 
selectivity, 21,475 protein sequences containing either a DinB_2 domain (Pfam ID: 
PF12867) or a FGE sulfatase domain (Pfam ID: PF03781) were retrieved from the Pfam 
protein family database.27 3,000 sequences out of 21,476 sequences were randomly 
selected for protein similarity network analysis at an E-value cut off of 10-50 (Figure 2-3). 
The protein similarity network was visualized with Cytoscape, which revealed a small 
cluster located between the clusters of EgtB and Egt1 (Figure 2-3 and Table 2-1). Among 
these sequences, Cabther_A1318 (EgtBCth) from thermophilic C. thermophilum was 






Figure 2-3 Sequence similarity network analysis of ergothioneine sulfoxide synthases. 
 
# Accession Code Organism Annotation 
1 CAN97242 Sorangium cellulosum 5-histidylcysteine sulfoxide synthase 
2 WP_062916112 Paraburkholderia caribensis ergothioneine biosynthesis protein EgtB 
3 WP_046312457 Pontibacter korlensis ergothioneine biosynthesis protein EgtB 
Table 2-1 List of other genes from the same node of EgtBCth retrieved from sequence 
similarity network analysis 
 
2.3.2 EgtBCth protein purification and characterizations 
From the bioinformatic analysis, EgtBCth was predicted as a homolog of the non-
heme iron enzyme sulfoxide synthase, EgtBMth. Due to this reason, ferrous ammonium 
sulfate was supplemented to the culture medium to improve the overexpression level and 
stability of EgtBCth. Through this approach, approximately 5 mg of protein was 
overexpressed from one gram of wet cell. Because in presence of a ferrous center, the 
protein is sensitive to oxidation by oxygen, thus, we purified EgtBCth protein under 
anaerobic condition, in which 2 mg of purified EgtBCth protein can be obtained from 1 gram 







homogeneity (Figure 2-4). Subsequent amino acid analysis and UV-Vis absorption 
spectrometry provided the molar extinction coefficient of EgtBCth at 280 nm of 12.1 × 10
4 
M-1cm-1. Notably, the UV-Vis spectrum of purified EgtBCth reveals an unexpected 
absorption feature at 450 nm, in addition to a typical protein absorption at 280 nm (Figure 
2-4). This spectroscopic feature differs from other reported non-heme iron enzyme 
sulfoxide synthases.16,26,29 Further characterization of this chromophore should be 
performed to determine its identity. Additionally, as iron is essential for catalysis, the iron 
content was determined to be 0.92 iron per one monomer of EgtBCth using atomic emission 
spectroscopy (Figure 2-5).    
 
Figure 2-4 Characterization of purified EgtBCth by SDS-PAGE analysis (A) and UV-Vis absorption 
spectrometry (B). 
   






















Figure 2-5 Iron content determination of purified EgtBCth. 
 
2.3.3 EgtBCth exhibits both EgtB- and Egt1-type of activities 
After pure EgtBCth protein was obtained, the predicted function of EgtBCth as a 
sulfoxide synthase from bioinformatic analysis was examined. Notably, -Glu-Cys was 
sensitive to hydrolysis and oxidation. Due to this reason, the substrate solution was 
prepared anaerobically and analyzed by 1H-NMR assay before use (Figure 2-6). Using 
hercynine and -Glu-Cys as substrates, a peak with a chemical shift of 7.11 ppm was 
observed, suggesting the formation of a new C-S bond at the -position of hercynyl 
imidazole. When L-Cys and hercynine were used as the substrate, a coupling product with 
the same chemical shift was observed (Figure 2-7). These biochemical results suggest that 
EgtBCth is indeed a sulfoxide synthase, and shows substrate promiscuity, having both EgtB- 
and Egt1-type of activities. This observation aligns well with the protein similarity network 







































Figure 2-7 1H-NMR analysis of the reaction using the wild-type EgtBCth as the catalyst. (A) Reaction of 
EgtBCth using hercynine and -Glu-Cys as the substrates. (B) Reaction of EgtBCth using hercynine and 
L-Cys as the substrates. 
 
In addition, the products from large-scale EgtBCth reaction were isolated using 
cation exchange chromatography. Using either -Glu-Cys or L-Cys as the sulfur donor, 1H 
NMR analysis of the isolated products shows a signal corresponding to the -position 
hydrogen of hercynyl imidazole of sulfoxide product (Figure 2-8 and Figure 2-9). This 
result further confirms the regioselectivity of the EgtBCth, which is the same as that of EgtB- 
and Egt1-type of enzymes.12,16 The purified products were subjected to high-resolution 
mass spectrometry analysis. The expected mass spectrometric result, [M-H]-, for the 
hercynyl--Glu-Cys sulfoxide under negative mode form was m/z 460.1508 and found m/z 
460.1505 (Figure 2-8). Similarly, the expected mass spectrometric result, [M-H]-, for 
hercynyl-cysteine sulfoxide under negative mode form was m/z 331.1082 and found m/z 
















the assignment of EgtBCth as a sulfoxide synthase, showing both Egt1- and EgtB-type of 
activities. 
 
Figure 2-8 Characterization of the hercynyl--Glu-Cys sulfoxide product from the EgtBCth reaction. 
(A) 1H NMR (500 MHz, D2O) δ 2.06-2.15 (m, 2H), δ 2.43 (m, 2H), δ 3.21 (s, 9H), δ 3.31 (dd, J=13.8, 11.7 
Hz 1H), δ 3.40 (dd, J=14.0, 3.4 Hz 1H), δ 3.62 (dd, J=13.6, 9.2 Hz, 1H), δ 3.85 (dd, J=14.0, 4.3 Hz, 1H), 
δ 3.98 (t, J=6.6 Hz, 1H), δ 4.10 (dd, J=11.9, 4.0 Hz, 1H), δ 4.74 (dd, J=9.5, 4.3 Hz, 1H), δ 7.34 (s, 1H). 
(B) HRMS (ESI): Calculated value for the hercynyl--Glu-Cys sulfoxide as [M-H]- (negative mode) 


























Figure 2-9 Characterization of the hercynyl-cysteine sulfoxide from the EgtBCth reaction. (A) 1H NMR 
(500 MHz, D2O) δ 3.13 (m, 11 H), δ 3.61 (dd, J = 14.4, 8.2 Hz, 1H), δ 3.69 (dd, J = 14.4, 4.4 Hz, 1H), δ 
3.78 (dd, J = 11.7, 3.9 Hz, 1H), δ 3.97  (dd, J = 8.2, 4.4 Hz, 1H), δ 7.15 (s, 1H). (B) HRMS (ESI): 



















2.3.4 Steady state kinetic analysis of EgtBCth 
The product characterizations provide information regarding the substrate 
specificity of EgtBCth, however, the catalytic efficiency for these substrates remains to be 
explored. To determine the steady-state kinetic parameters of EgtBCth, oxygen consumption 
assay was conducted. Notably, the oxygen-sensitive nature of this enzyme resulted in a 
50% decrease in activity after exposure to an aerobic environment for 0.5 hr. To avoid this 
issue, the purified EgtBCth was diluted with anaerobic buffer and stored under an anaerobic 
environment in a small aliquot during the kinetic measurement. Using hercynine and -
Glu-Cys as substrates, the kcat of the reaction was ~ 18 min
-1 with a KM for hercynine of 
41.4  3.5 M and for -Glu-Cys of 5.9 0.9 mM (Figure 2-10, and Table 2-2). The Km for 
hercynine of EgtBCth is comparable to that of EgtBMth (KM for hercynine of 39  3 M). 
However, the Km for -Glu-Cys of EgtBCth is approximately 1000-fold larger than that of 
EgtBMth.
20 This result suggested that although EgtBCth can catalyze the oxidative coupling 
between hercynine and -Glu-Cys, its catalytic efficiency is lower than that of EgtBMth. 
 A set of similar experiments were performed to measure the kinetic parameters of 
EgtBCth when hercynine and L-Cys were the substrates. The catalytic efficiency of EgtBCth 
increased by ~ 42-fold, exhibiting a kcat of  26 min
-1. In this reaction, EgtBCth has a KM of 
87.7  7.6 M and 205  18 M, for hercynine and L-Cys, respectively (Figure 2-11, and 
Table 2-2). The catalytic efficiency of EgtBCth is comparable that of Egt1.
16 These 
biochemical studies show that EgtBCth has the same C-S bond formation regioselectivity 






Figure 2-10  Kinetic analysis of wild-type EgtBCth with hercynine and -Glu-Cys. (A) For hercynine 
concentration dependence, a 1-mL reaction contained 15 mM -Glu-Cys, 2 mM TCEP, 0.2 mM 
ascorbate, 2 µM EgtBCth, and varied concentrations of hercynine (0.015 – 1.0 mM) in 50 mM KPi pH 
8.0. (B) A similar reaction was setup for -Glu-Cys concentration dependence, except hercynine 
concentration was kept at 1 mM and -Glu-Cys concentration was varied (1 – 30 mM). EgtBCth 
exhibited a KM for hercynine of 41.4 ± 3.5 µM and a KM for -Glu-Cys of 5.9 ± 0.9 mM with a kcat of 
17.5 ± 0.4 min-1. 
 
Figure 2-11  Kinetic analysis of wild-type EgtBCth with hercynine and L-Cys. (A) For hercynine 
concentration dependence, a 1-mL reaction contained 2 mM L-Cys, 2 mM TCEP, 0.2 mM ascorbate, 
1.5 µM EgtBCth, and varied concentration of hercynine (0.03 – 4 mM) in 50 mM KPi pH 8.0. (B) Similar 
conditions were setup for L-Cys dependence, except hercynine was kept at 2 mM and L-Cys was varied 
(0.05 – 4 mM). EgtBCth exhibited a KM for hercynine of 87.7 ± 7.6 µM and a KM for L-Cys of 205 ± 18 
µM with a kcat of 26.6 ± 0.7 min-1. 
 








































































































































2.3.5 Characterization of the cysteine dioxygenase activity of EgtBCth 
In previous studies of EgtB and Egt1, both enzymes exhibit low level of cysteine 
dioxygenase activity.16,21,26,30,31 Thus, the EgtBCth reaction was analyzed for cysteine 
dioxygenase activity under both Egt1- and EgtB-type of conditions (Figure 2-12). The 
oxidation of -Glu-Cys and L-Cys gives rise to a distinctive set of signals for their -
hydrogens in 1H-NMR spectra.16,26,30,31 Indeed, there is a low level of cysteine dioxygenase 
activity. The ratio between sulfoxide and cysteine oxidation activity in EgtBCth reaction 
was quantified based on 1H-NMR.16,21  
 
Figure 2-12 Ratios of sulfoxide synthase and cysteine dioxygenase activity of EgtBCth under EgtB-type 
(A) and Egt1-type (B) of reaction conditions. 
 
In Figure 2-13, when hercynine and -Glu-Cys were the substrates, the ratio 
between the products from sulfoxide synthase and cysteine dioxygenase activities was 
quantified using ethyl viologen as an internal standard. The ratio between the proton on 




viologen (labelled 4 in blue), and the ratio between the β-hydrogen of -Glu-Cys sulfinic 
acid (labelled 3 in red) and the ethyl group of ethyl viologen (labelled 1 in blue) were used 
to quantify the ratio of the two products (Figure 2-13). In EgtBCth wild-type reaction, the 
ratio between hercynyl--Glu-Cys sulfoxide and -Glu-Cys sulfinic acid products was 3.17: 
1. This ratio suggests that there was 75 % of coupling product and 25% of -Glu-Cys 
sulfinic acid produced in the reaction mediated by wild-type EgtBCth (Table 2-2).   
A similar experiment was carried out with hercynine and L-Cys as the substrates 
for the wild-type EgtBCth reaction. In Figure 2-14, with ethyl viologen as an internal 
standard, the ratio between the proton of coupling product (labelled 5 in pink) and the ratio 
between the β-hydrogen of the cysteine sulfinic acid (labelled 3 in red) was 2.56: 1. This 
result suggests that 72% of the coupling product was produced in the wild-type EgtBCth 
reaction (Table 2-2). The level of cysteine dioxygenase activity observed in wild-type 
EgtBCth reaction is comparable to that of Egt1.
16 Additionally, regardless of the sulfur 
donor, either -Glu-Cys or L-Cys, the level of cysteine oxidation activity is not altered 
significantly. These results are different from what we observed in the OvoA and Egt1 





Figure 2-13 1H-NMR spectrum of the wild-type EgtBCth reaction using hercynine and -Glu-Cys as the 
substrates for coupling product quantification. (A) Expanded region between 6.5 ppm - 9.5 ppm. (B) 
Expanded region between 1.0 – 4.0 ppm. This result suggests that there was 75 % of coupling product 































Figure 2-14 1H-NMR spectrum of the EgtBCth wild-type reaction using hercynine and L-Cys as the 
substrates for products quantification. (A) Expanded region between 6.5 ppm - 9.5 ppm. (B) Expanded 
region between 1.0 – 4.0 ppm. This result shows that there was 72 % of coupling product in the reaction 




































2.3.6 EgtBCth structural determination and analysis 
With this interesting biochemical information, in collaboration with Dr. Seema 
Irani of Prof. Jessie Zhang’s laboratory at the University of Texas Austin, we initiated the 
crystallographic studies of EgtBCth. Apo-EgtBCth crystallized in a cubic form with a space 
group of P21 and diffracted to 2.5 Å in a synchrotron beam source (PDB ID: 6O6M). A 
single wavelength anomalous dispersion (SAD) technique was used for de novo phase 
determination and the structure solution using selenomethionine incorporated EgtBCth 
crystals (Table 2-3). The crystallographic asymmetric unit is composed of four protein 
molecules (Figure 2-15). EgtBCth exists as a tetramer. For each monomer, electron densities 
were resolved for residues 17 to 433, except an inter-domain loop of 10 residues (184 to 
193) which is missing due to its high flexibility (Figure 2-15). Each monomer is composed 
of an N-terminal helical domain (residue 17 to 183) and a C-terminal domain that consists 
of an α-ββ-α fold (residue 194 to 433). A Dali32 search revealed that the N-terminal domain 
most closely resembles the damage-inducible protein Din-B (PDB ID: 5WK5033) and the 
C-terminal domain is structurally similar to the formylglycine generating enzyme (PDB 







 EgtBCth Se-Met EgtBCth EgtBCth with hercynine 
Accession Number  6O6M 6O6L 
Space group P 1 21 1 P 1 21 1 P 1 21 1 
Cell dimensions    
a, b, c (Å) 85.3, 137.1, 85.4 85.3,137.3, 85.4 85.2, 137.5, 85.2 
α, β, γ (°) 90.0, 92.4, 90.0 90.0, 92.43, 90.0 90.0, 92.37, 90.0 
Resolution (Å) 
50.00 - 2.30 
(2.34 - 2.30)[a] 
50 - 2.5 
(2.54 - 2.50) 
50 - 2.25 
(2.29 - 2.25) 
Rsym 0.087 (0.334) 0.170 (0.604) 0.139 (0.585) 
I/σI 26.6 (5.2) 7.5 (1.8) 8.6(1.5) 
Completeness (%) 100(100) 100 (99.8) 99.6 (95.4) 
Redundancy 6.9 (7.0) 3.8 (3.7) 4.0 (3.7) 
Wavelength 0.97942 0.97648 0.97648 
Refinement    
Resolution (Å) 45.86 - 2.51 45.83 - 2.25 
No. reflections 67215 92239 
Rwork/ Rfree[b] 0.1853/0.2257 0.1877/0.2241 
No. atoms   
Protein 13089 13062 
Ligand - 56 
Ligand (Fe) 4 4 
Solvent 504 651 
B-factors (Å2)   
Protein 17.8 20.9 
Ligand - 14.4 
Ligand (Fe) 19.7 26.6 
Solvent 16.6 19.7 
R.m.s deviations   
Bond lengths (Å) 0.003 0.012 
Bond angles (º) 0.656 1.086 
Ramachandran Favoured (%) 97.8 97.6 
Ramachandran Outliers (%) 0.0 0.0 
[a] Represents statistics for the outmost shell 
[b] Rfree test set comprised of 2.1% of the unique reflections (max of 2000 spots)  




The active site of EgtBCth is located at the interface between the N- and C-terminal 
domains for each monomer where a mononuclear non-heme iron is coordinated by His62, 
His153, His157, and three water molecules in an octahedral arrangement (Figure 2-15). 
Upon soaking or co-crystallizing EgtBCth crystals with hercynine, close to the metal ion, 
strong positive density was observed (Figure 2-16A). A comparison between the structures 
of EgtBCth and the EgtBCth•hercynine binary complex, indicated no significant 
conformational changes (Figure 2-16B). In the EgtBCth•hercynine binary complex ((PDB 
ID: 6O6L), hercynine coordinates to the iron center through its imidazole’s ɛ-nitrogen 
(Figure 2-16A). The hercynine imidazole’s -nitrogen forms hydrogen bonds with Gln156 
(3.4 Å) and the hydroxyl group of Tyr93 (3.6 Å). In addition to the dipolar contact with 
Asn414, the trimethylated amino group of hercynine has cation-π interactions with the 
sidechains of Phe415 (4.7 Å) and Phe416 (5.1 Å).  
 
 
Figure 2-15 The structures of EgtBCth. (A) Overall structure of EgtBCth in the tetrameric configuration 
with each monomer labeled. In Monomer A, the N-terminal domain (residue 17 to 183) is shown in 
blue and the C- terminal domain (residue 194 to 433) is shown in pink. The iron cofactor present at the 
active site of each monomer is shown as a brown sphere. (B) The 2mFo-DFc map of the iron 
coordination site of EgtBCth contoured at 1.5σ (blue mesh), the metal ion is shown as a brown sphere 
and the coordinating residues are represented in sticks. Ordered water molecules coordinating the iron 






Figure 2-16 Comparing the structure of EgtBCth and EgtBCth•hercynine. (A) The active site of EgtBCth 
co-crystallized with hercynine (shown in green stick).  (B) Superimposition of the structure of EgtBCth 
(shown in white) and EgtBCth•hercynine (shown in blue, with the metal ion represented as a sphere and 
the hercynine as sticks). 
 
Despite the lack of overall sequence similarity between EgtBCth and EgtBMth, an 
active site comparison of the two homologous enzymes reveals several conserved residues, 
suggesting a similar substrate recognition network and catalytic mechanism. The residues 
used to coordinate the iron center are faithfully conserved in EgtBCth and EgtBMth (Figure 
2-17A). Additionally, the residues involved in hercynine binding between these two 
structures are conserved (Gln137, Asn414, and Trp415 in EgtBMth vs. Gln156, Asn414, and 
Phe415 in EgtBCth, Figure 2-17). The binding pocket for the co-substrate -Glu-Cys/L-Cys 
is close to the iron center in EgtBMth. A similar pocket also exists in EgtBCth. Since the 
EgtBCth•hercynine•Cys and the EgtBCth•hercynine•-Glu-Cys tertiary complexes were 
resistant to our crystallization efforts. Therefore, guided by the structure of M. 
thermoresistibile EgtBMth and dimethyl histidine -Glu-Cys tertiary complex (PDB ID: 
4X8D, Figure 2-17), we created a  model of EgtBCth•hercynine•-Glu-Cys complex (Figure 


















in the binding of the cysteinyl portion of -Glu-Cys are identical for both EgtBMth and 
EgtBCth (Figure 2-17 A). They share two conserved Arg residues involved in the binding 
of  the 1-carboxylate group of -Glu-Cys: Arg87 and Arg90 in EgtBMth vs. Arg103 and 
Arg106 in EgtBCth (Figure 2-17). These pairs of arginine residues also form salt bridges 
with the carboxylate of L-Cys. The thiol groups of -Glu-Cys and L-Cys replace one of the 
iron-center water ligands. 
 
 
Figure 2-17 Structural comparison and modeling of EgtBCth. (A) The previously reported structure of 
EgtBMth•dimethyl histidine•-Glu-Cys complex (PDB ID: 4X8D) superimposed on the EgtBCth•herycine 
complex (shown in green). The side chains of the EgtBMth residues interacting with the -Glu-Cys are 
shown in sticks (white) and numbered with a superscript (ˊ), the corresponding residues in the EgtBCth 
structure are shown as blue sticks. (B) The putative -Glu-Cys binding mode of EgtBCth (shown as 
yellow sticks). The potential interactions between -Glu-Cys and active site residues of EgtBCth were 
depicted as black dashed lines, and the side chains of the interacting residues are shown as blue sticks.  
 
2.3.7 Structure-guided engineering of EgtBCth towards Egt1-type activity 
Based on the structural model in Figure 2-17, the regions of the active site in EgtB-
Cth anchoring the glutamyl portion of -Glu-Cys vary between EgtBMth and EgtBCth.  The 
Asp416 and Arg420 residues of EgtBMth interacting with -Glu-Cys are replaced with 
Ala420 and Phe416 in EgtBCth (Figure 2-17). Therefore, some hydrogen bonding and salt 





the modeled EgtBCth•hercynine•γ-Glu-Cys complex. However, favorable hydrogen bond 
interaction between the γ-Glu-Cys glutamyl group and Gln393 and Asp52 residues of the 
EgtBCth led to the binding of -Glu-Cys in EgtBCth as an alternative rotamer (Figure 2-17B) 
relative to that in EgtBMth. Overall, EgtBCth has a more open active site relative to that of 
EgtBMth
20 for co-substrate recognition, which might account for both the Egt1- and EgtB-
types of activities in EgtBCth.    
Thus far, the structure of Egt1 has not been reported. To analyze the substrate 
specificity in these enzymes, I built the Egt1 model using the I-TASSER program using 
EgtBMth and EgtBCth structures  as the guide (Figure 2-18A).
35 In this Egt1 model, the 
histidine ligands (His370, His463, and His467) and the binding pocket for hercynine are 
conserved (Figure 2-18A). EgtBCth is flexible and can recognize either -Glu-Cys or L-Cys 
as the sulfur donor and its active site pocket is more open than that of EgtBMth. I 
hypothesized that residues next to the -Glu-Cys are the ones controlling EgtBCth substrate 
selectivity (Figure 2-18A and Figure 2-18B). The structural comparison of these three 
enzymes highlgihted three non-conserved residues (Asp52, Phe416, and Ala420) in EgtB-
Cth active site relative to that of EgtBMth and Egt1 (Figure 2-18A and Figure 2-18B). These 
residues were chosen as the starting point to engineer EgtBCth activity more toward the 
Egt1-type.  
In collaboration with Ronghai Cheng, a graduate student in the Liu Lab, Rosetta 
Design was employed to optimize the active site environment for substrate binding.36 By 
using the Rosetta energy function and conformational sampling of side chain rotamers, 




and L-Cys were used as the substrates. The top 20 variants listed in Table 2-3 were further 
evaluated through Pymol to assess the interaction between the variants and substrates. In 
Figure 2-18, the variants were further compared with Egt1 sequences retrieved from the 
protein sequence similarity network analysis, which shows conserved Leu360 and Tyr820 
among Egt1 homologs, but are not conserved in EgtBCth (Asp52 and Ala420). Surprisingly, 
the D52L and A420Y variants were the top 20 variants predicted by Rosetta Design, which 
warrants further examination of the role of these residues. Taking all these factors into 







Figure 2-18 Structural comparison of EgtBCth, EgtBMth, and Egt1. (A) Structure alignment between 
EgtBCth (in light blue/teal) and EgtBMth (blue, PDB: 4X8D). The non-conserved residues involved in the 
interacting with the sulfur donor are labelled in red. The iron center is the brown sphere. (B) Structural 
comparison between EgtBCth (in light blue/teal) and Egt1 (in light pink) shows the non-conserved 
residue potentially for controlling the sulfur donor selectivity (labelled in red). For all these enzymes, 
the conserved residues interacting with hercynine (green stick) are labelled in black. (C) Partial 
sequence alignment of some Egt1 homologs retrieved from the Pfam database show a conserved Leu 
and Tyr (red box). (D) Surface representation of the active site of EgtBCth with the modelled -Glu-Cys, 
residues that are located near the glutamyl end are shown in yellow. (E) The active site of EgtBMth 
complexed with -Glu-Cys (PDB ID: 4X8D) with the corresponding residues in the active site 




















































Egt1_N           842 SWATHPRIAGRKSFVNWYQRNYPYAWVGARVVRDL--- 
S3DCJ9_GLAL2     823 SWATHPRIAGRKTFVNWYQRNYPYAWAGARLVRDI--- 
J4G0R2_9APHY     591 SYATIPRLGDRRTVRNFYQHNYPYPWVGARVAYDF--- 
B2WFD7_PYRTR     805 SWATHPRIAGRKTFVNWYQRNYPYMWAGARIVSDV--- 
S2JSM7_MUCC1     837 SWATHPRIAERRSFRNWYQAGYPYVFSGFRLCH----- 
K5X7Z4_PHACS     379 SFATAPRLGERRTVRNFYQHNYPYPWVAARVCYDI--- 
A8NRV0_COPC7     822 SYATVPRIANRRSFRNWYQRNYPYAWIGGRIAYDLPPN 
K2RKJ5_MACPH     843 SWATHPRIAGRKSFVNWFQRNYPYCWTTARIVRDI--- 
A0A1C1C993_9EUR  810 SWATVPRIALKKTFVNWYQRNYPYVWCTARLVRDIAV- 
Q2UD95_ASPOR     811 SWATHPRVAGRTTFVNWYQHNYPYTWAGARLVRDL--- 
 
Egt1_N           367 RSALPTLDDWEALWATWDVVTRQMLPQ-EELLEKPIKLRNACIFYLGHIPTFLDIQLTKT 
S3DCJ9_GLAL2     362 ATTVPSVDDWLNLWKVWDIVTRKMIPE-QDLLEKPIKLRNACIFYLGHIPTFLDIQLCKV 
J4G0R2_9APHY     187 PYGTPSLSEFQDGWRAWDLITLGMIPP-SLLHSKPIDLRHKPLFYLGHLPTFLNLLMTAY 
B2WFD7_PYRTR     338 AKPVPSLTEWQELWKAWDAVSKQMIPE-EELLSKPIKLRNECIFYLGHIPTFLDIHIARA 
S2JSM7_MUCC1     432 IETLPSLHEWQELWKSWDVVTQQMLNHRKMLFERPIALRHPFIFYLGHIPAFLDIQLSRH 
K5X7Z4_PHACS       1 -----------------------MIPA-ALLHAQPIELRHRPLFYIGHLPTFNALLLTKK 
A8NRV0_COPC7     418 PFSFPTRGDWEDMWEVWNTITLGMIPP-SMLHEKPIDLRHICLFYLGHIPTFLDIHLSRL 
K2RKJ5_MACPH     369 PKPLPSLTEWEQIWSAWDAVTEDMISD-EELMEKPIKLRNECIFYLGHIPTFLDIHLSRA 
A0A1C1C993_9EUR  344 ASPIPSQNDWRQLWAAWDTVTKSMVPR-DELLNKPIKLRNDLIFYLGHIPTFADIHYTKA 















1 -1170.13 D52HIS_F416GLU_A420ASP 11 -1162.81 D52ILE_F416GLU_A420CYS 
2 -1169.53 D52HIS_F416ILE_A420ALA 12 -1162.78 D52ILE_F416GLN_A420ALA 
3 -1167.37 D52LEU_F416GLY_A420TYR 13 -1162.76 D52ILE_F416GLY_A420TRP 
4 -1166.03 D52ILE_F416LYS_A420PHE 14 -1162.67 D52ILE_F416ALA_A420THR 
5 -1165.05 D52HIS_F416LEU_A420VAL 15 -1162.62 D52TRP_F416SER_A420HIS 
6 -1164.86 D52ILE_F416ALA_A420CYS 16 -1162.3 D52ILE_F416GLU_A420THR 
7 -1164.83 D52TRP_F416GLN_A420GLY 17 -1162.08 D52ILE_F416LYS_A420SER 
8 -1164.54 D52ILE_F416GLY_A420LYS 18 -1161.81 D52GLY_F416THR_A420TYR 
9 -1164.3 D52ILE_F416ALA_A420SER 19 -1161.75 D52HIS_F416CYS_A420ALA 
10 -1163.97 D52HIS_F416THR_A420VAL 20 -1161.58 D52ILE_F416ALA_A420PHE 
Table 2-4 List of top 20 EgtBCth mutants predicted from Rosetta Enzyme Design. 
 
2.3.8 Biochemical characterization of EgtBCth variants 
The activity of EgtBCth-A420Y was characterized following the same methods as the 
wild-type enzyme. 1H-NMR analysis shows that the EgtBCth-A420Y mutant remains active 
when -Glu-Cys or L-Cys are sulfur donors and  the C-S bond is formed at the imidazole 
sidechain -position similar to that of wild-type EgtBCth (Figure 2-19), while with altered 
kinetic parameters. Using hercynine and -Glu-Cys as substrates, EgtBCth-A420Y has kcat of 
17.4 ±  0.3 min-1, which is close to that of the wild-type (Table 2-2). However, the 
Michaelis constants are ~ 2-fold lower for both substrates (a KM of 13.2 ± 1.3 µM for 
hercynine, and a KM of 3.1 ± 0.3 mM for -Glu-Cys, Figure 2-20). When hercynine and 
L-Cys are the substrates, the KM for L-Cys was lowered by 10-fold (205±18 µM for wild-




the substrate selectivity of EgtBCth-A420Y toward the Egt1-type of activity (Table 2-2, Figure 
2-19 and Figure 2-21).  
 
 
Figure 2-19 1H-NMR analysis of EgtBCth-A420Y reactions. (A) Reaction of EgtBCth-A420Y using hercynine 



















Figure 2-20 Kinetic analysis of EgtBCth-A420Y with hercynine and -Glu-Cys as the substrates. (A) For 
hercynine concentration dependence, a 1-mL reaction contained 10 mM -Glu-Cys, 2 mM TCEP, 0.2 
mM sodium ascorbate, 1.5 µM EgtBCth-A420Y and varied concentration of hercynine (0.005 – 0.8 mM) in 
50 mM KPi pH 8.0. (B) Similar conditions were setup for -Glu-Cys concentration dependence, except 
that hercynine concentration was kept at 1 mM and -Glu-Cys concentration was varied (1 – 14 mM). 
EgtBCth-A420Y exhibited a KM for hercynine of 13.2 ± 1.3 µM and a KM for -Glu-Cys of 3.1 ± 0.3 mM 
with a kcat of 17.4 ± 0.3 min-1.  
 
 
Figure 2-21 Kinetic analysis of EgtBCth-A420Y with hercynine and L-Cys as the substrates. (A) For 
hercynine concentration dependence, a 1-mL reaction contained 2 mM L-Cys, 2 mM TCEP, 0.2 mM 
sodium ascorbate, 1.5 µM EgtBCth, and varied concentration of hercynine (0.03 – 1 mM) in 50 mM KPi 
pH 8.0. (B) Similar conditions were setup for L-Cys dependent, except that hercynine concentration 
was kept at 2 mM and L-Cys concentration was varied (0.05 – 2 mM). EgtBCth A420Y exhibited a KM 
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In addition to the kinetic information, the cysteine dioxygenase activity of this 
variant was assessed. 1H NMR characterization of the EgtBCth-A420Y variant supports the 
importance of this residue in controlling the reaction selectivity. In the EgtBCth-A420Y 
reaction, the ratio between hercynyl--Glu-Cys sulfoxide and -Glu-Cys sulfinic acid 
product was 1.54: 1, corresponding to 61 % of the coupling product, which is lower than 
the 75% observed in wild-type EgtBCth (Table 2-2 and Figure 2-22), indicating an increased 
cysteine dioxygenase activity. The results from both kinetic analysis and 1H-NMR 
quantification showed that the mutation of Ala420 tuned the activity of EgtBCth toward 
Egt1-type of activity. Interestingly, when hercynine and L-Cys were used as the substrates, 
the amount of sulfoxide was 76% in EgtBCth-A420Y, which is approximately the same level 







Figure 2-22 1H-NMR spectrum of the EgtBCth-A420Y reaction using hercynine and -Glu-Cys as the 
substrates for coupling product quantification. (A) Expanded region between 6.5 ppm - 9.5 ppm. (B) 
Expanded region between 1.0 – 4.0 ppm. This result suggests that there was 61 % of coupling product 
































Figure 2-23 1H-NMR spectrum of EgtBCth-A420Y reaction using hercynine and L-Cys as the substrates 
for coupling product quantification. (A) Expanded region between 6.5 ppm - 9.5 ppm. (B) Expanded 
region between 1.0 – 4.0 ppm. In EgtBCth-A420Y reaction, the ratio between hercynyl-cysteine sulfoxide 
and cysteine sulfinic acid product was 3.21: 1. This ratio suggests that there was 76 % of coupling 
































Intriguingly, structural analysis shows that this Ala420 does not directly interact 
with the substrates. However, since the EgtBCth-A420Y mutant altered the substrate 
selectivity, this suggests that the change from a small residue (Ala) to bulky residue such 
as Tyr reduces the active site pocket, favoring the smaller L-Cys binding. This result might 
explain the conservancy of this Tyr among Egt1 homologs. 
Both kinetic analysis by O2 consumption assay and 
1H-NMR analysis were also 
repeated using the EgtBCth-D52L mutant. 
1H-NMR analysis shows that the regioselectivity 
of EgtBCth-D52L remains unchanged (Figure 2-24). However, when -Glu-Cys was used as 
the sulfur donor, the turnover of EgtBCth-D52L was decreased slightly (17.5 ± 0.4 min-1 for 
wild-type vs. 12.9 ± 0.2 min-1) and the Michalis constants remains largely unchanged 
(Table 2-2 and Figure 2-25). Most importantly, when -Glu-Cys was used as the sulfur 
donor, the amount of sulfoxide in EgtBCth-D52L reaction decreased to ~50% of the products 
mixture (Figure 2-26). Thus far, these results suggested that the structure-guided 






Figure 2-24 1H-NMR analysis of the EgtBCth-D52L reactions. (A) Reaction of EgtBCth-D52L using hercynine 




Figure 2-25 Kinetic analysis of the EgtBCth-D52L mutant with hercynine and -Glu-Cys as the substrates. 
(A) For hercynine concentration dependence, a 1-mL reaction contained 10 mM -Glu-Cys, 2 mM 
TCEP, 0.2 mM sodium ascorbate, 1.5 µM EgtBCth-D52L, and various concentrations of hercynine (0.005 
– 0.5 mM) in 50 mM KPi pH 8.0. (B) Similar conditions were setup for -Glu-Cys dependence, except 
hercynine concentration was kept at 1 mM and -Glu-Cys concentration was varied (1 – 20 mM). 
EgtBCth-D52L exhibited a KM for hercynine of 19.6 ± 1.4 µM and a KM for -Glu-Cys of 3.9 ± 0.3 mM 
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Figure 2-26 1H-NMR spectrum of the EgtBCth-D52L reaction using hercynine and -Glu-Cys as the 
substrates for coupling product quantification. (A) Expanded region between 6.5 ppm - 9.5 ppm. (B) 
Expanded region between 1.0 – 4.0 ppm. In EgtBCth-D52L reaction, the ratio between hercynyl--Glu-
Cys sulfoxide and -Glu-Cys sulfinic acid products was 1: 1. This ratio suggests that there was 50 % of 
coupling product this reaction. 
 
When L-Cys was used as the sulfur donor, the kinetic parameters of EgtBCth_D52L 
variant are comparable to that of the wild-type (KM for hercynine of 13.9 ± 0.9 µM, KM 
for L-Cys of 47.3 ± 2.4 µM with a kcat of 27.6 ± 0.5 min-1 in Figure 2-27). 1H-NMR 





























cysteine sulfinic acid products was 2.24: 1, which suggests that the sulfoxide accounts for 
~69% of the product mixture (Figure 2-27). This level of the hercynyl-cysteine sulfoxide 
product is comparable to the wild-type activity (Table 2-2). The EgtBCth_D52L might disrupt 
the hydrogen bond between Asp52 and glutamyl group of γ-Glu-Cys, which in turn alters 
the substrate selectivity of EgtBCth. Therefore, Asp52 might also contribute to the substrate 
selectivity, which leads to differentiation between Egt1- and EgtB-type of activities. 
 
 
Figure 2-27 Kinetic analysis of EgtBCth-D52L with hercynine and L-Cys as the substrates. (A) For 
hercynine concentration dependence, a 1-mL reaction contained 2 mM L-Cys, 2 mM TCEP, 0.2 mM 
sodium ascorbate, 1.5 µM EgtBCth-D52L, and various concentration of hercynine (0.005 – 0.6 mM) in 50 
mM KPi pH 8.0. (B) Similar conditions were setup for L-Cys concentration dependence, except 
hercynine concentration was kept at 2 mM and L-Cys concentration was varied (0.1 – 2 mM). EgtBCth-
D52L exhibited a KM for hercynine of 13.9 ± 0.9 µM and a KM for L-Cys of 47.3 ± 2.4 µM with a kcat of 
27.6 ± 0.5 min-1. 
 




















































Figure 2-28 1H-NMR spectrum of EgtBCth-D52L reaction using hercynine and L-Cys as the substrates for 
coupling product quantification. (A) Expanded region between 6.5 ppm - 9.5 ppm. (B) Expanded 
region between 1.0 – 4.0 ppm. In EgtBCth-D52L reaction, the ratio between hercynyl-cysteine sulfoxide 
and cysteine sulfinic acid product was 2.24: 1. This ratio suggests that there was 69 % of coupling 








































The promising results from EgtBCth-A420Y and EgtBCth-D52L variants motivated us to 
further characterize the activity of EgtBCth-D52L-A420Y double mutant. Typical 
1H-NMR 
analysis showed that the regioselectivity of the C-S bond formation of this variant remained 
the same as that of the wild-type (Figure 2-29). Subsequent kinetic characterization using 
hercynine and -Glu-Cys as substrates showed that EgtBCth-D52L-A420Y has kinetic 
parameters very similar to that of the wild-type EgtBcth (Figure 2-30). However, Figure 
2-31 shows that the ratio between hercynyl--Glu-Cys sulfoxide and -Glu-Cys sulfinic 
acid products was 1.1: 1. This ratio suggests that there was 52 % of coupling product in the 
reaction mediated by EgtBCth-D52L-A420Y when hercynine and --Glu-Cys were used as the 
substrate (Figure 2-31).  
 
Figure 2-29 1H-NMR analysis of the EgtBCth-D52L-A420Y reactions. Top: Reaction of EgtBCth-D52L-A420Y 
using hercynine and -Glu-Cys as the substrates shows the coupling product at δ 7.13. Bottom: 
Reaction of EgtBCth-D52L-A420Y using hercynine and L-Cys as the substrates shows the coupling product 


















Figure 2-30 Kinetic analysis of the EgtBCth-D52L-A420Y with hercynine and -Glu-Cys as the substrates. 
(A) For hercynine concentration dependence, a 1-mL reaction contained 10 mM -Glu-Cys, 2 mM 
TCEP, 0.2 mM sodium ascorbate, 1.5 µM EgtBCth-D52L-A420Y, and various concentration of hercynine 
(0.08 – 2 mM) in 50 mM KPi pH 8.0. (B) Similar conditions were setup for -Glu-Cys dependence, 
except hercynine concentration was kept at 1 mM and -Glu-Cys concentration was varied (2 – 25 
mM). EgtBCth-D52L-A420Y mutant exhibited a KM for hercynine of 15.1 ± 1.3 µM and a KM for -Glu-Cys 
of 4.2 ± 0.5 mM with a kcat of 18.6 ± 0.4 min-1. 































































Figure 2-31 1H-NMR spectrum of the EgtBCth-D52L-A420Y reaction using hercynine and -Glu-Cys as the 
substrates for coupling product quantification. (A) Expanded region between 6.5 ppm - 9.5 ppm. (B) 
Expanded region between 1.0 – 4.0 ppm. In the EgtBCth-D52L-A420Y reaction, there was 52 % of coupling 
product. 
 
The EgtBCth-D52L-A420Y was biochemically characterized for Egt1-type of activity. 
Through steady-state kinetic analysis, using hercynine and L-Cys as the substrates, the 
kinetic parameters of EgtBCth-D52L-A420Y are: kcat of 32.7 ± 0.3 min-1, Km of 23.3±1.2 µM 
for hercynine and Km of 48.7±3.5 µM for L-Cys (Table 2-2 and Figure 2-32). Additionally, 
































sulfinic acid product is 2.93: 1. Therefore, in EgtBCth-D52L-A420Y reaction, when hercynine 
and L-Cys are the substrate, the sulfoxide is ~75% of product mixture, which is comparable 
to that of the wild-type (Table 2-2 and Figure 2-33). The results show that EgtBCth-D52L-
A420Y variant exhibits ~6-fold higher catalytic efficiency (kcat/Km) than that of wild-type in 
Egt1-type of activity. This improved catalytic proficiency supports the success in 
engineering EgtBCth toward the Egt1-type of activity. 
 
 
Figure 2-32 Kinetic analysis of EgtBCth-D52L-A420Y mutant with hercynine and L-Cys as the substrates. 
(A) For hercynine dependence, a 1-mL reaction contained 2 mM L-Cys, 2 mM TCEP, 0.2 mM sodium 
ascorbate, 1.5 µM EgtBCth variant, and varied concentration of hercynine (0.01 – 1 mM) in 50 mM KPi 
pH 8.0. (B) Similar conditions were setup for L-Cys concentration dependence, except hercynine 
concentration was kept at 2 mM and L-Cys concentration was varied (0.02 – 2 mM). The EgtBCth-D52L-
A420Y mutant exhibited a KM for hercynine of 23.3 ± 1.2 µM and a KM for L-Cys of 48.7 ± 3.5 µM with 
a kcat of 32.7 ± 0.3 min-1. 
 



















































Figure 2-33 1H-NMR spectrum of the EgtBCth-D52L-A420Y reaction using hercynine and L-Cys as the 
substrates for coupling product quantification. (A) Expanded region between 6.5 ppm - 9.5 ppm. (B) 
Expanded region between 1.0 – 4.0 ppm. In EgtBCth-D52L-A420Y reaction, the ratio between hercynyl-






































2.4 Conclusions and Future Directions 
One of the central steps in the aerobic ergothioneine biosynthesis is the oxidative 
C-S bond formation reaction catalyzed by mononuclear non-heme iron sulfoxide synthases 
(EgtB and Egt1). However, the factors governing the substrate specificity between EgtB 
and Egt1 are poorly understood. Thus far, only the crystal structure of M. thermoresistibile 
EgtBMth sulfoxide synthase was available. In this work, through sequence similarity 
network analysis, a thermophilic sulfoxide synthase, EgtBCth, was identified. Biochemical 
characterization revealed that EgtBCth exhibits both EgtB- and Egt1-type of activities, 
providing an opportunity to understand the substrate specificity of this sulfoxide synthase. 
Guided by the structural information, the computational enzyme engineering was 
performed using Rosetta Design to tune the activity of EgtBCth toward the Egt1-type of 
activity. The three mutants obtained from Rosetta Design were chosen for detailed 
biochemical characterizations (D52L, A420Y, and D52L/A420Y variants). Indeed, even 
with a single mutation, the substrate specificity of EgtBCth_A420Y and EgtBCth_D52L was tuned 
toward Egt1-type of activity. For EgtBCth-D52L-A420Y variant, the catalytic efficiency was 
improved to 180-fold more favoring Egt1-type, showing the success in engineering EgtB-
Cth toward Egt1-type of activity.  
The success in identifying a thermophilic sulfoxide synthase and engineering its 
activity toward Egt1-type of reaction might open avenues for a more robust ergothioneine 
production through metabolic engineering and synthetic biology approach. Additionally, 




sulfoxide synthase through computational approaches such as density function and 
quantum mechanics/molecular mechanics studies, which might provide valuable insights 
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3.1 Introduction 
3.1.1 A generic mechanism of C-S lyase reactions 
In the aerobic biosynthesis of ergothioneine, the central steps for the trans-
sulfuration reaction are: the oxidative coupling C-S bond formation reactions mediated by 
non-heme iron sulfoxide synthases (EgtB/Egt1), and the pyridoxal-5'-phosphate (PLP)-
dependent C-S lyases (EgtE/Egt2). In Chapter 2, the substrate promiscuity of the 
thermophilic sulfoxide synthase EgtBCth is present, leaving the C-S lyase reaction in 
ergothioneine biosynthesis to be explored. Most PLP-dependent C-S lyases mediate α,β- 
or α,-elimination using thiol (RSH) or thioether (RSR) as the substrate. Among these, the 
C-S lyases in the bacterial degradation of sulfur-containing amino acid have been studied 
extensively.1-4 In these reactions, common substrate includes : L-Cys 3-1, L-cystathionine 
3-2, and L-Met 3-3 (Figure 3-1A). Spectroscopic, structural, and biochemical studies have 
illuminated a generic mechanism for an α,β-elimination type of C-S lyases is shown in 
Figure 3-1B.2-4 In this mechanism, the binding of the PLP cofactor to the enzyme results 
in the formation of an internal aldimine intermediate 3-4a through an active site Lys. Upon 




undergoes a proton abstraction (Figure 3-1B). The resulting quinonoid intermediate 3-4c 
further undergoes elimination of RSH which generates the PLP-derived aminoacrylate 3-
4d. Protonation of intermediate 3-4d and trans-aldimination leads to iminopropionate 
formation, which undergoes hydrolysis to produce pyruvate and, ammonia, returning the 
enzyme to the resting state for the next cycle.   
 
 
Figure 3-1 Substrates and key intermediate in C-S lyase reaction. (A) Common substrates for 
degradation of sulfur-containing amino acids. (B) Key intermediate steps in C-S lyase catalysis.  
 
3.1.2 Reductive C-S lyase reaction in ergothioneine biosynthesis 
While most C-S lyases employ thioether as the substrate 6-8, the C-S lyase 
(EgtE/Egt2) in ergothioneine biosynthesis are among the very few lyases that use 
sulfoxides as the substrates.9,10 A recent biochemical characterization of Mycobacterium 




3-7 as its substrates; while pyruvate and ammonia are produced as the side-products (Figure 
3-2A).10 Using thioether 3-5 as the substrate, ergothioneine was produced in a reductant-
independent manner. When hercynyl-cysteine sulfoxide 3-7 was used as the substrate in 
the absence of a reductant, ergothioneine 3-6 and ergothioneine-2-sulfinic acid 3-8b were 
isolated in a ratio of 1: 1 (Figure 3-2B). A plausible explanation for this result is that 
ergothioneine sulfenic acid 3-8 is the product from EgtE-catalysis. After intermediate 3-8 
is released from the EgtE active site, a disproportionation reaction between two molecules 
of ergothioneine sulfenic acid 3-8 results in ergothioneine 3-6 and ergothioneine-2-sulfinic 
acid 3-8b (Figure 3-2B). The spontaneous decomposition of ergothioneine sulfinic acid 3-
8b produces hercynine 3-9 and SO2. In the presence of DTT, ergothioneine sulfenic acid 
3-8 might be reduced to ergothioneine (Figure 3-2A).10  
Biochemical characterizations of EgtE illuminated its preference for the sulfoxide 
substrate over the thioether. However, the factors governing substrate specificity of this C-
S lyase remain to be explored. Additionally, the sulfoxide C-S lyase reaction has been 
proposed to be coupled to a reduction process, yet, how these two processes take place is 
not well understood.10 Due to the difficulties faced in obtaining EgtE crystals, we chose 
the fungal homolog, Egt2, for further investigation. In this chapter, the ergothioneine PLP-
dependent C-S lyase Egt2 was characterized structurally and mechanistically. The 
structural studies revealed a cation-π interaction between the sulfoxide substrate and the 
enzyme, which might be a major contributing factor for Egt2’s preference of the sulfoxide 
over the thioether as its substrate. Using mutagenesis and structural biology, three distinct 




intermediate, the sulfenic acid intermediate, and the aminoacrylate geminal diamine 
intermediate. Chemical trapping and high-resolution mass spectrometry were used to 
provide additional biochemical evidence to support the information obtained in 
crystallographic studies.  
 
 
Figure 3-2 EgtE reactions. (A) The C-S lyase EgtE reactions with thioether or sulfoxide substrates. (B) 






3.2 Material and Methods 
3.2.1 General materials and equipment 
All reagents and equipment used are similar to those indicated in Chapter 2 unless 
otherwise specified.   
3.2.2 Egt2 protein expression and purification  
The Egt2 (NCU11365) gene was codon-optimized for Escherichia coli 
overexpression through GenScript. The N. Crassa Egt2 protein was overexpressed and 
purified as described previously with some modifications.11 The Egt2-pASK-IBA3+ 
plasmid was transformed into BL21(DE3) competent cells. One colony was inoculated in 
LB medium supplemented with ampicillin (100 µg/mL). Then, 10 mL of this overnight 
culture was transferred to 1 L of LB medium supplemented with ampicillin (100 µg/mL) 
and 0.1 mM PLP and incubated at 37 °C while shaking at 170 rpm. When OD600 reached 
0.8, the protein expression was induced using anhydrotetracycline (AHT) to a 200 µg/L 
final concentration. The cell culture was incubated at 25 °C while shaking at 170 rpm for 
16 hr before harvesting by centrifugation. 
5 g of wet cells were resuspended in 25 mL of lysis buffer (100 mM Tris-HCl, 50 
mM NaCl, pH 8.0) and incubated with 1.0 mg/mL final concentration of lysozyme on ice 
for 30 mins. Cell membranes were disrupted by sonication (20 cycles of 30s bursts) and 
the cell debris was removed by centrifugation at 20,000 g for 30 mins, at 4 °C. The 
supernatant was then incubated with Strep-Tactin resin on ice for 30 mins with gentle 




was then eluted using 2.5 mM desthiobiotin in lysis buffer. Then, the eluted protein was 
reconstituted with 1 mM PLP in 25 mM HEPES buffer at pH 7.5 containing 50 mM NaCl 
and 10 mM β-mercaptoethanol (BME) with overnight incubation at 4 °C. The reconstituted 
Egt2 was concentrated using ultrafiltrator (Amicon) and stored at -80 °C until biochemical 
studies. A typical yield is approximately 4 mg of purified protein per gram of wet cell. 
 For crystallization, the reconstituted Egt2 protein was further purified using size-
exclusion chromatography to near homogeneity, as visualized on SDS-PAGE. The purified 
protein was concentrated and stored at -80 °C until crystallographic screening.  
The Egt2Y134F and Egt2C156A were obtained using site-directed mutagenesis kit 
(Stratagene). The mutants were then overexpressed and purified following a procedure 
similar to that of the wild-type enzyme. 
3.2.3 Amino acid analysis of Egt2 
The purified Egt2 was subjected to amino acid analysis (AAA Service Laboratory). 
The calculated molar extinction coefficient at 280 nm was 5.29 × 104 M-1cm-1 based on the 
results from the amino acid analysis. The correction factor between the Bradford assay and 
the amino acid analysis was 0.90.  
3.2.4 PLP content determination  
The Egt2 wild-type and mutant proteins were treated with 0.2 N NaOH to release 
the PLP cofactor into the solution. The protein concentration was determined and the PLP 
content was then calculated using 390 = 6600 M
-1cm-1.12 For Egt2 wild-type and Egt2Y134F, 




3.2.5 Preparation of sulfoxide substrate 
A 10-mL reaction mixture containing 1.0 mM L-hercynine, 1.5 mM L-Cys, 1.0 mM 
dithiothreitol (DTT), 0.2 mM ascorbate, and 12 µM Egt1 was set up in 50 mM KPi pH 8.0. 
The reaction was incubated aerobically at 28 °C for 2 hr. Then, the Egt1 protein was 
removed via ultrafiltration. The reaction product was then purified using the Dowex-50 8X 
cation-exchange chromatography in the H+ form. Specifically, after loading the reaction 
mixture onto the column, the resin was washed with H2O until the pH of the wash was 
close to neutral. This step requires approximately 5-fold of the column volume (CV). Then, 
the sulfoxide product was eluted with approximately three CV of 3% NH4OH and the 
elution was monitored by TLC. The elution fractions containing the desired compound 
were pooled and NH4 was removed via rotatory evaporation. Subsequently, the solvent was 
removed via lyophilization. The purified compound was then characterized by 1H NMR 
and high-resolution mass spectrometry (HRMS). 
Hercynyl-cysteine sulfoxide: 1H NMR (500 MHz, D2O) δ 3.10-3.19 (m, 13H), δ 
3.48 (dd, J = 3.9, 15.1 Hz, 1H), δ 3.65 (dd, J = 3.9, 8.8 Hz, 1H), δ 3.77 (dd, J = 3.9, 11.9, 
1H), δ 7.12 (s, 1 H). The calculated [M-H]- in the negative mode for the sulfoxide substrate 
was m/z 333.1233 and found m/z 333.1246.  
3.2.6 Quantification of pyruvate from the Egt2 reaction 
The amount of pyruvate from the Egt2 reaction was calculated based on the amount 
of dinitrophenylhydrazine derivative determined by 1H NMR spectra. An Egt2 reaction 
containing 1.0 mM hercynyl-cysteine sulfoxide, 1.0 mM DTT, and 2.0 µM Egt2 in 50 mM 




4-fluorophenylhydrazine was added to the reaction mixture to a 2 mM final concentration 
and incubated at 50 C for 3 hr. 4-Fluorophenylhydrazine derivatizes pyruvate to a 
hydrazine adduct, which converts the solvent-exchangeable methyl group on pyruvate to 
non-exchangeable ones. The reaction was then lyophilized and characterized by 1H NMR 
using ethyl viologen as an internal standard.  
3.2.7 Determination of ammonium production from the Egt2 reaction 
To prepare ammonium-free substrate, 7 µL of 91 mM sulfoxide substrate was 
adjusted to pH 13.0 using NaOH and lyophilized. The dry substrate was re-dissolved into 
100 µL of H2O and lyophilized. This process was repeated three times to remove 
ammonium. The final powder was dissolved in 100 µL H2O and neutralized with HCl. The 
substrate was aliquoted into two portions: one as the control and the other for Egt2 reaction. 
A 1-mL reaction containing 5.0 μM Egt2, 0.32 mM substrate, 0.5 mM DTT in 
50 mM KPi buffer, pH 8.0 was incubated at 28 °C for 1 hour. The control reaction 
containing the same component as the above reaction except that heat-denatured Egt2 was 
used. Then, 100 µL of Nessler’s reagent was added to the reaction mixture and the 
absorbance at 462 nm was recorded. 
3.2.8 Characterization of ergothioneine from the Egt2 reaction 
A reaction containing 1.0 µM Egt2, 2.0 mM sulfoxide substrate in 10 mL of 50 mM 
KPi buffer pH 8.0 was incubated at 28 C for 1 hr. After the reaction was completed, the 
protein was removed by ultrafiltration. Ergothioneine was purified through Dowex50 




purification. The elution fractions containing ergothioneine were then rotatory evaporated 
and lyophilized. The purified product was then characterized by 1H NMR and HRMS. 
Ergothioneine: 1H NMR (500 MHz, D2O) δ 3.05 (t, J = 12.5 Hz, 1 H), δ 3.12 (dd, J 
= 3.4, 12.5 Hz, 1 H), δ 3.14 (s, 9 H), δ 3.75 (dd, J = 3.6, 10.2 Hz, 1 H), δ 6.66 (s, 1 H). The 
calculated [M-H]- in negative mode for ergothioneine was m/z 228.0812 and found m/z 
228.0824.  
3.2.9 Crystallization of Egt2 and data collection  
This experiment was carried out by Dr. Seema Irani from Prof. Yan Zhang’s Lab, 
at the University of Texas, Austin. Systematic optimization of crystallization conditions of 
Egt2 led to crystals with a plate morphology in 24% PEG3350, 0.2 M sodium formate, and 
50 mM Tris-HCl at pH 8.0. Wild-type Egt2 and the selenomethionine derivative crystals 
were cryo-protected in a solution containing 30% glycerol, 27.5% PEG 3350, 0.2 M 
sodium formate, and 50 mM Tris-HCl at pH 8.0 before vitrification in liquid nitrogen. 
Platinum derivative crystals used in phasing were obtained by soaking wild-type Egt2 
crystals in mother liquor containing 4.0 mM potassium chloroplatinate (K2PtCl4) at 4C 
for 2 hr prior to crystal harvesting.  
The co-crystallization of Egt2 and the substrate setup included the Egt2Y134F variant 
incubated with 100 µM of the sulfoxide substrate for five minutes before crystallization 
under a similar condition.  The crystals obtained at pH 7.0 was transferred to a cryo buffer 
containing mother liquor at pH 8.0 and 30% glycerol. The multiple anomalous dispersion 
(MAD) data for the platinum derivative and the single anomalous dispersion (SAD) data 




Berkeley beamline BL 5.0.3. The datasets for the Egt2Y134F co-crystallized with the 
substrates were collected at Advanced Photon Source (APS), Chicago, BL 23–ID-B. The 
diffraction data were integrated and scaled using HKL2000.13 
3.2.10 Structure determination and refinement  
This study was carried out by Dr. Seema Irani from Prof. Yan Zhang’s Lab, at the 
University of Texas, Austin. MAD datasets from the platinum derivative crystals provided 
a partial solution which was used for phasing selenomethionine SAD data in Phenix 
Autosol.14 The structure was refined using Phenix Refine excluding ~2000 diffraction spots 
(1.2%-1.5% of the data) as the Rfree flag.
15 The structures of ligands were prepared in 
jLigand.16 Iterative cycles of optimization were carried out using Phenix.Refine17 followed 
by manual rebuilding in COOT.18 The final structures have ~ 96% of the residues with 
Ramachandran19 favored phi/psi angles with the exception of G225 as outlier, which is 
located in a loop interacting with the cofactor and shows excellent electron density. 
3.2.11 Steady-state kinetic analysis of the Egt2 reaction 
The steady-state kinetic parameters of Egt2 were determined using a coupled assay 
as reported in M. smegmatis EgtE enzyme  studies.10 To measure Egt2 activity, a typical 
1-mL reaction contained 0.13 mM NADH, 1.0 mM DTT, 22.5 U/mL lactate dehydrogenase 
(2000-fold of Egt2 activity in the assay), 10 nM wild-type Egt2, and variable 
concentrations of sulfoxide substrate (0.05 - 3 mM) in the assay buffer (25 mM NaOAc, 
25 mM MES, 25 mM glycine, and 75 mM Tris) adjusted to the desired pH of 7 or 8. The 




GraphPad Prism. For Egt2Y134F and Egt2C156A mutant kinetic studies, a similar 
experimental set up was carried out. 
3.2.12 Chemical trapping and isolation of the sulfenic acid intermediate in Egt2-catalysis  
A chemical trapping using 1,3-cyclohexanedione was performed to trap the sulfenic 
acid intermediate in the Egt2 reaction following a reported procedure.10 A 5-mL reaction 
contained 3.5 mM sulfoxide substrate, 165 mM 1,3-cyclohexanedione (50-fold of substrate 
concentration), and 4.0 µM of Egt2 in 100 mM KPi buffer pH 8.0. The reaction was stirred 
at 28 C for 1 hr. The reaction was lyophilized and purified using cellulose resin packed 
with iPrOH: ACN = 4.5: 2.5 (1 × 20 cm). The column was washed with 18 × 5.0 mL of 
iPrOH: ACN = 4.5: 2.5. The adduct was eluted with iPrOH: ACN: 0.1 M NH4HCO3 = 4.5: 
2.5: 3. The adduct was lyophilized and characterized by 1H NMR and HRMS. 
3.2.13 Egt2 protein modification analysis by tandem mass spectrometry 
This experiment was performed in collaboration with Yang Tang, a graduate 
student from Prof. Costello’s lab at BU Medical campus. In a 1-mL assay, a single-turnover 
reaction containing 489 µM Egt2 wild-type or Egt2C156A and 489 µM sulfoxide substrate 
in 50 mM KPi, pH 8.0, was incubated at 28 °C for 15 min. The wild-type reaction was 
divided into two portions: one was treated with DTT at 10 mM final concentration and the 
other was not. Both Egt2 wild-type and Egt2C156A protein before the reaction were also 
analyzed by tandem mass spectrometry as the control.  
After the single-turnover reaction, the proteins were denatured using 6 M urea in 




NH4HCO3 was added and sequencing grade modified trypsin (Promega US) was added to 
the mixture in a 1:100 (w/w) ratio. The protein was digested overnight at 37 °C and purified 
using C-18 spin columns (Thermo Scientific, Rockford, IL). A 6550i Funnel Quadrupole 
Time-of-Flight (Q-TOF) mass spectrometer coupled to a 1200 series HPLC-Chip Cube 
interface equipped with a Polaris-HR-Chip-3C18 LC chip (Agilent Corp, Santa Clara, CA) 
was used for the peptide sequencing. The total peptide digestion mixture was separated by 
a reversed phase nanoLC, followed by MS/MS analysis with collision-induced dissociation 
(CID) as the fragmentation method. Targeted peptides were identified by comparing the 
experimental MS/MS product ions to the expected values predicted by Protein Prospector 
from the University of California, San Francisco and manual interpretation.  
3.2.14 Characterization of the Egt2 product in the absence of reductant 
A 10-mL reaction containing 1.0 µM Egt2, 2.0 mM sulfoxide substrate, 2.0 mM 
DTT, and 50 mM KPi buffer pH 8.0 was incubated at 28 C for 1 hr. The Egt2 protein was 
removed by ultrafiltration and the product was purified following a reported procedure.10 
After purification, the product was characterized by 1H NMR and HRMS.  
Ergothineine-2-sulfinic acid: 1H-NMR (500 MHz, D2O) δ 1.83 (dt, J = 6.3, 12.8, 2 
H), δ 2.35 (t, J = 6.3, 4 H), δ 2.98 (dd, J = 6.3, 12.8, 2 H), δ 3.02 (dd, J = 3.9, 11.6 Hz, 1 H), 
δ 3.09 (s, 9 H), δ 3.73 (dd, J = 4.4, 10.8 Hz, 1 H), δ 3.74 (dd, J = 3.9, 11.7 Hz, 1 H), δ 6.68 





3.3 Results and Discussion 
3.3.1 Purification and analysis of recombinant Egt2 
In the biosynthetic pathway of ergothioneine, the sulfur is transferred from L-Cys 
to the imidazole sidechain of L-His via a combination of a mononuclear non-heme iron 
enzyme-catalyzed oxidative C-S bond formation and a PLP-mediated C-S lyase reaction. 
In this process, the C-S lyase reaction has been proposed to be coupled with a reduction 
process based on the recent characterization of M. smegmatis EgtE.10 However, how the 
C-S lyase reaction is coupled with the reduction process remains to be addressed. The M. 
smegmatis EgtE enzyme was resistant to crystallization, thus, the N. crassa C-S lyase Egt2 
was selected for further structural and biochemical studies. The Egt2 was overexpressed 
and purified following reported procedures with slight modification.11 Approximately 4 
mg of purified proteins were obtained per gram of wet cells. The protein was purified to > 
95% homogeneity (Figure 3-3). Notably, the protein can be concentrated up to 1 mM 
without noticeable precipitation. The UV-Vis absorption spectrum of the protein shows a 
peak at 420 nm which corresponds to the presence of the PLP cofactor in the enzyme. For 
Egt2 wild-type, the PLP content per monomer was determined to be 0.83 following a 
reported procedure.12 The Egt2 sulfoxide substrate 3-7 was synthesized enzymatically 






Figure 3-3 Characterization of recombinant Egt2. (A) The UV-Vis absorption spectrum of Egt2 shows 
a peak at 420 nm which corresponds to the PLP cofactor. (B) SDS-PAGE analysis of purified Egt2 
using Strep-tactin resin. Lane M, protein marker, and Egt2. 












Figure 3-4 Characterization of sulfoxide substrate prepared through the enzymatic reaction of Egt1 
from N. crassa. (A) 1H NMR spectrum of the sulfoxide substrate 4: δ 3.10-3.19 (m, 13H), δ 3.48 (dd, 
J = 3.9, 15.1 Hz, 1H), δ 3.65 (dd, J = 3.9, 8.8 Hz, 1H), δ 3.77 (dd, J = 3.9, 11.9, 1H), δ 7.12 (s, 1H). (B) 
Molecular ion region in the HRMS spectrum of the sulfoxide substrate. The calculated [M-H]- in 
















































3.3.2 Biochemical characterization of the Egt2 reaction 
The Egt2 activity analysis was carried out following the studies of M. smegmatis 
EgtE enzyme.10 In the presence of DTT as the reductant, the production of ergothioneine 
3-6 was detected (Figure 3-5). In addition, pyruvate and ammonia were proposed as the 
side products of this reaction. Using [13C]-labeled sulfoxide 3-7b substrate in the presence 
of reductant, 13C-NMR analysis of the Egt2 reaction spiked with authentic pyruvate is 
consistent with the production of [3-13C]-pyruvate (Figure 3-6). Moreover, the ratio 
between ergothioneine and pyruvate produced in the Egt2 reaction was also quantified. 4-
Fluorophenylhydrazine derivatizes pyruvate to a hydrazine adduct, converting the solvent-
exchangeable methyl group on pyruvate to a non-exchangeable one. The reaction was then 
lyophilized and characterized by 1H NMR. However, the chemical shift for the methyl 
group of the pyruvate adduct is 1.88 (s, 3H) while that of ergothioneine imidazole hydrogen 
was 6.63 ppm, hence, direct quantification between these two signals may be inaccurate 
since they are located on different sides of the large water signal. To solve the issue, ethyl 
viologen was chosen as an internal standard since its signals are present at both low and 
high fields: δ 1.54 (t, 7.2 Hz, 6H), δ 8.37 (d, 6.5 Hz, 4H), and δ 8.98 (d, 6.5 Hz, 4H). The 
ratio between ergothioneine and pyruvate calculated using ethyl viologen as an internal 







Figure 3-5 Characterization of ergothioneine. (A) 1H NMR spectrum of ergothioneine from the Egt2 
reaction with DTT as reductant: δ 3.05 (t, J = 12.5 Hz, 1H), δ 3.12 (dd, J = 3.4, 12.5 Hz, 1H), δ 3.14 (s, 
9H), δ 3.75 (dd, J = 3.6, 10.2 Hz, 1H), δ 6.66 (s, 1 H). (B) Molecular ion region of the HRMS spectrum 
of ergothioneine from the Egt2 reaction. The calculated [M-H]- in negative mode for the compound 















































Figure 3-6 Pyruvate production from the Egt2 reaction. (A) 13C-NMR spectrum of [13C]-labeled 
sulfoxide substrate from N. crassa Egt1. (125 MHz, D2O) of [13C]-labeled sulfoxide substrate: δ 52.52. 
(B) 13C-NMR spectrum of the Egt2 reaction shows the presence of [3-13C]-pyruvate as the product in 












Figure 3-7 Characterization of Egt2-mediated C-S cleavage. Quantifying the ratio between pyruvate 
and ergothioneine produced in the Egt2 reaction using 1H-NMR analysis. Top: expanded regions 
between 6.4 ppm to 9.2 ppm; Bottom: expanded regions between 1.0 ppm to 2.5 ppm. 
 
The production of ammonia from the Egt2 reaction was quantified by a colorimetric 
assay using Nessler’s reagent, a solution containing potassium tetraiodomercurate(II) 
(K2[HgI4]), which reacts with ammonia under basic condition to give a yellow-colored 
species (Figure 3-8A). 21 In the presence of DTT as reductant, the Egt2-catalyzed C-S lyase 
reaction using hercynyl-cysteine sulfoxide  as the substrate afforded ergothioneine, 
pyruvate and ammonia in a ratio of  1:1:1. Taking advantage of pyruvate production and 
the reaction stoichiometry, the kinetic properties of wild-type Egt2 were subsequently 
measured using a colorimetric assay by coupling the Egt2-catalysis with the lactate 



















DTT at pH 8.0, the kinetic parameters of wild-type Egt2 were: kcat of 8.7 ± 0.1 s
-1 and a Km 
of 155 ± 10 M (Figure 3-8B). 
 
 
Figure 3-8 Characterization of the Egt2 protein. (A) NH4+ titration standard curve prepared using 
(NH4)2SO4. The A462 of the Egt2 reaction sample was 0.7333 ± 0.06 (shown in blue). The amount of 
NH4+ produced from the Egt2 reaction was determined to be ~ 1:1. (B) Egt2 wild-type steady-state 
kinetic analysis at 25°C. A 1-mL assay contained 0.13 mM NADH, 1 mM DTT, 22.5 U/mL LDH (2000× 
of Egt2 activity in the assay) in a universal buffer (25 mM NaOAc, 25 mM MES, 25 mM glycine, and 
75 mM Tris) pH 8.0 and various amount of sulfoxide substrate, and 10 nM Egt2. The coupled assay 
was monitored at 340 nm and the data was fitted by GraphPad Prism. Wild-type Egt2 exhibited a Km 
for the sulfoxide substrate of 155.2 ± 9.6 µM and kcat of 8.7 ± 0.1 s-1.  
 
3.3.3 Overall structure of wild-type Egt2 
The initial biochemical characterization of Egt2 confirmed the C-S lyase activity 
of this enzyme. To further understand the substrate specificity, the structure of Egt2 was 
obtained with X-ray diffraction data collected with synchrotron beam sources at the 
Advanced Photon Source (APS) and the Advanced Light Source (ALS). As there was little 
homology with known structures, molecular replacement did not produce any reasonable 
solutions. The multi-wavelength anomalous dispersion (MAD) dataset for the platinum 
derivative of wild-type Egt2 provided a partial solution, including key secondary structural 
elements, which was then used as the initial phasing for the selenomethionine derivative 
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crystals. The final structure was solved with single anomalous dispersion (SAD) of the 
selenomethionine derivative crystals of wild-type Egt2 with a resolution of 2.3 Å (Table 





Egt2 + Platnium Soaking 
MAD dataset 
 Egt2 Se-Met 
SAD dataset 
Data collection Peak Inflection Remote  
Space group P 1 21 1 P 1 21 1 P 1 21 1 P 1 21 1 
Cell 
dimensions 
    







α, β, γ (°) 90.0, 91.2, 90.0 90.0, 91.4, 90.0 
90.0, 91.4, 
90.0 
90.0, 91.3, 90.0 
Resolution (Å) 
50.00 - 3.50 
(3.56 - 3.50) * 
50.00-3.5 
(3.56 - 3.50) 
50.00 - 3.5 
(3.56 - 3.5) 
50.00 - 2.8 
(2.85 - 2.80) 
Rsym 0.117 (0.219) 0.130 (0.241) 0.090(0.145) 0.106 (0.300) 
I/σI 10.86 (4.94) 11.23(4.63) 12.76 (6.00) 12.21(3.11) 
Completeness 
(%) 
99.6(99.6) 99.90 (99.90) 99.6 (99.8) 99.7 (98.3) 
Redundancy 3.4 (3.4) 3.9 (3.9) 3.7 (3.7) 3.7 (3.5) 
Wavelength 1.07209 1.07236 1.04267 0.97648 
*Highest resolution shell is shown in parenthesis.  


















Accession Number 5UTS 5V1X 5V12 
Space group P 1 21 1 P 1 21 1 P 1 21 1 
Cell dimensions    
a, b, c (Å) 103.8, 195.3, 107.8 103.9,195.1,107.6 104.0, 195.2,110.1 
α, β, γ (°) 90.0, 91.3, 90.0 90.0, 91.3, 90.0 90.0, 91.5, 90.0 
Resolution (Å) 
50.00 - 2.30 
(2.34 - 2.30) 
50 - 2.57 
(2.61 - 2.57) 
50 - 2.45 
(2.49 - 2.45) 
Rsym 0.129 (0.529) 0.140 (0.630) 0.140 (0.763) 
I/σI 11.45 (1.79) 10.69 (1.50) 8.46 (1.41) 
Completeness (%) 91.00(61.20) 99.4 (95.3) 91.2 (81.8) 
Redundancy 5.9 (5.0) 3.1 (2.9) 2.9 (2.8) 
Wavelength 0.97648 1.03320 1.03320 
Refinement    
Resolution (Å) 
49.36 - 2.30 
(2.37 - 2.30) 
48.82 - 2.56  
(2.62 - 2.56) 
49.58 - 2.45  
(2.51 - 2.45) 
No. reflections 154894 135254 146021 
Rwork/ Rfree 0.2101/0.2410 0.2225/0.2793 0.2220/0.2717 
No. atoms    
Protein 27984 27978 27896 
Ligand/ion 21 44/15 32/24 
Water 992 299 412 
B-factors (Å2)    
Protein 32.0 51.3 41.6 
Ligand - 62.8 66.1 
Ligand 
(formate ion) 
32.3 47.2 41.9 
Water 29.3 44.2 38.5 
R.m.s deviations    
Bond lengths (Å) 0.004 0.004 0.004 
Bond angles (º) 0.601 0.632 0.607 
Table 3-2 Data collection and refinement statistics 
 
The wild-type Egt2 crystals exhibit a P21 space group with eight molecules per 
asymmetric unit. The final model of N. crassa Egt2 includes residues 21 to 470, with the 
first 20 residues of the N-terminus and the last three residues of the C-terminus disordered 
(Figure 3-9A). This crystallographic observation of dimer formation is consistent with its 




wild-type Egt2 monomer is comprised of three domains: The N-terminal domain (residues 
21-99), the central catalytic domain in which PLP is covalently bound (residues 100-282), 
and the C-terminal domain (residues 295-470). Structurally, the central catalytic domain 
of Egt2 exhibits a classic α/β fold with seven  strands wrapped within seven α helices 
(Figure 3-9A), similarly to the conserved folding in type I PLP-dependent enzymes 23. The 
N-terminal domain of Egt2 spans the active sites of both monomers, with an extended loop 
forming part of its own active site, while probing the neighboring active site with a pair of 
long α helices (Figure 3-9A). Consisting of three β-sheets and six α-helices, the C-terminal 
domain of Egt2 spans ~60 Å and forms a lid that shelters the PLP-binding pocket and the 
active site from the bulky solvent (Figure 3-9B). No homologs have been identified for the 
N- or C-terminal domains of Egt2, thus, this enzyme represents a novel subfamily of type 
I PLP-dependent enzymes. 
The active site of wild-type Egt2, located at the interface of the two dimers, is 
enclosed in a narrow, elongated tunnel of ~13 Å. The active site (volume measured ~600 
Å3 using the Dogsite program)24 is formed mainly by the central catalytic and the C-
terminal domains, along with contributions from the N-terminal and C-terminal domains 
of the neighboring monomer (Figure 3-9B). Strong positive densities near the side chain 
of Lys247 is consistent with the formation of an internal aldimine with the PLP cofactor, 
which is stabilized by extensive interactions between PLP and the protein (Figure 3-9C). 
The pyridine ring of PLP aligns parallel to the aromatic ring of Tyr134 via π-π stacking 
interactions and the orientation in this plane is defined by a salt bridge between Asp221 




PLP-dependent enzymes.2 An extensive network of hydrophilic interactions is formed 
between the phosphate group of the PLP and hydrophilic sidechain of Thr307, Thr107, and 
Asn244. The position of the PLP cofactor is further anchored by a potential salt bridge 
between its phosphate and His246 (Figure 3-9D). 
 
 
Figure 3-9 Overall structure of Egt2. (A) A ribbon representation of the overall structure of the Egt2 
dimer. For Monomer 1 the N-terminal domain (residue 21-99) is shown in pink, the central domain 
(residue 100-282) in green, the C-terminal domain (residue 293-470) in blue and the inter-domain loop 
(residue 283-294) is shown in red. The PLP cofactor and Lys247 adduct are represented as yellow 
sticks. Monomer 2 is shown in grey. (B) Surface representation of the active site of Egt2 in monomer 
1. (C) Internal aldimine formed by Lys247 and PLP are shown with 2mFo-DFc map contoured to 1σ. 
(D) The Egt2 and PLP cofactor interaction network. Residues interacting with PLP were represented 







3.3.4 Recognition of the substrates by Egt2 
To capture the wild-type Egt2•substrate complex formation or the snapshots of the 
intermediates in the reaction cycle, the active site residues were mutated in an attempt to 
slow down the chemical reaction rate. An inspection of the PLP-binding pocket identified 
eight conserved residues near the active site (Asp221, Gln224, Tyr134, Ser47, Ser196, 
Cys137, Thr307, and His276), which could potentially reduce the turnover number of Egt2-
catalysis. The mutants corresponding to these residues were then generated. These variants 
were then crystallized in the presence of the hercynyl-cysteine sulfoxide substrate. Among 
these, Egt2Y134F formed crystals and diffracted to a resolution of 2.6 Å (Table 3-2). The 
structure of Egt2Y134F showed no significant change in the folding when compared to the 
wild-type Egt2. Notably, a strong positive density was observed within the catalytic pocket 
close to the PLP C4ˊ-position, which is consistent with the chemical structure of the 
sulfoxide substrate before the formation of a covalent adduct between the substrate and 
PLP (Figure 3-10A). Therefore, the structure captured herein is the Egt2Y134F•substrate 
binary complex prior to external aldimine intermediate formation.  
The cysteine moiety of the substrate forms extensive interactions with the enzyme 
(Figure 3-10B). In addition to forming a salt bridge with Arg438, the cysteine carboxylate 
group forms hydrogen bonds with Gln224 and Ser196 and its amino group forms a 
hydrogen bond with the side chain of Ser47 (Figure 3-10B). The substrate sulfoxide group 
is sandwiched between the benzyl rings of Phe134 and Phe48. The aromatic side chain of 
Phe134 is in the same position in the Egt2Y134F as Tyr134 in Egt2 wild-type, indicating no 




hydroxyl group at distances favorable for hydrogen bonding interactions to the amino 
group of the substrate imidazole ring and the sulfoxide group (3.0 Å and 3.5 Å, 
respectively, Figure 3-10B). Unlike the cysteine moiety, the histidine moiety of the 
substrate is only loosely associated with the enzyme through bonding with the imidazole 
ring of His276 (Figure 3-10B). 
 
 
Figure 3-10 Structure of the Egt2Y134F•substrate binary complex. (A) Sulfoxide substrate in Egt2Y134F 
with 2mFo-DFc map contoured to 0.75σ. The PLP is shown as yellow sticks. Monomer 2 is colored grey. 
Inset is the 2D chemical structure of the substrate. (B) Interactions between Egt2Y134F with tyrosine 
modeled at the Phe134 position (grey sticks) and its substrate. (C) Cation-π interactions between the 









The structure of the Egt2Y134F•substrate binary complex reveals the structural 
rationale for its unique substrate specificity, which prefers a sulfoxide over a thioether 
unlike other C-S lyases. In the recent characterization of EgtE, an Egt2 homolog from M. 
smegmatis ergothioneine biosynthesis, the kcat/Km for the sulfoxide substrate is 52-fold 
greater than that for the thioether substrate.10 The complex structure of Egt2Y134F with the 
substrate 3-7 provides a plausible explanation for the Egt2 substrate specificity, 
highlighting the cation-π interactions between the sulfoxide of the substrate and the 
phenylalanine residues in the active site (Figure 3-10C). Cation-π interactions are formed 
as a result of the electrostatic, dispersive and induction forces between a positively charged 
group and a π system.25 The oxidation of the thioether groups (e.g., methionine) 
significantly strengthens their interactions with the aromatic groups between 0.5 to 1.5 
kcal/mol, corresponding to a binding preference of five- to sixteen-fold.26 The structure of 
the Egt2Y134F•substrate binary complex has a prominent cation-π interaction between the 
sulfoxide group of the substrate and Phe48 at a distance of  4.9 Å and could also have an 
off-centered cation-π interaction with Phe134 at a distance of  4.4 Å (Figure 3-10C). To 
provide a comparison to the sulfoxide substrate, the complex structure of Egt2Y134F with 
the thioether substrate at a resolution of 2.55 Å was obtained (Figure 3-10D).  While the 
structure revealed that the thioether substrate assumes the same binding mode as that of the 
sulfoxide substrate, the aminoacrylate of the thioether substrate moiety shows much less 
density, indicating a weaker interaction and/or higher flexibility. The observation in these 
structures suggests that the stronger cation-π interactions in sulfoxide substrate structure 




3.3.5 Capturing the ergothioneine sulfenic acid in the Egt2 structure  
Structural analysis revealed the close proximity of Tyr134 to the sulfoxide 
substrate, suggesting its potential role in catalysis. To understand the function of Tyr134, 
the kinetic activity of Egt2Y134F was characterized: Km of 743.2 ± 52.5 M and kcat of 3.6 
± 0.1 s-1 at pH 7.0 (Figure 3-11A). Egt2Y134F exhibits ~ 12-fold lower catalytic efficiency 
than that of wild-type, suggesting the potential role in acid/base catalysis of Egt2 reaction. 
Subsequent pH-dependent kinetic analysis of Egt2Y134F revealed increased C-S lyase 
activity with pH (Figure 3-11B). With respect to this kinetic result, the in-situ C-S bond 
cleavage reaction in Egt2 crystals by increasing the pH conditions of the mother liquor was 
explored. The increase in pH might promote the chemical reaction and be captured by X-
ray crystallography. After rounds of iterative manual building, the density is most 
consistent with the structure of ergothioneine sulfenic acid (Figure 3-12A). The most 
significant difference between this structure with the substrate-bound Egt2Y134F at pH 7.0 
is the loss of aminoacrylate moiety density. In the complex structure of the sulfoxide 
substrate with Egt2Y134F (Figure 3-10), an extensive interaction was observed for the 
aminoacrylate moiety of the substrate with the enzyme. With the increasing pH, the only 
residue density near Arg438 is consistent with a formate ion from the crystallization buffer 
forming a salt bridge interaction (Figure 3-12A). Most importantly, the sulfur atom shows 
no connecting electron density to the region that would be occupied by the aminoacrylate 
moiety. This observation suggests that the chemical reaction occurred and the intermediate 






Figure 3-11 Egt2Y134F steady-state kinetic analysis at 25°C. (A) A 1-mL assay contained 0.13 mM 
NADH, 1 mM DTT, 22.5 U/mL LDH (2000× of Egt2 activity in the assay) in a universal buffer (25 mM 
NaOAc, 25 mM MES, 25 mM glycine, and 75 mM Tris) pH 8.0, various amount of sulfoxide substrate, 
and 12 nM Egt2Y134F. The assay was monitored at 340 nm and the data was fitted by GraphPad Prism. 
Egt2Y134F exhibited a Km of 743.2 ± 52.5 M and kcat of 3.6 ± 0.1 s-1 (B) log(kcat/Km) under varying pH 
for the Egt2Y134F. Kinetic data higher than pH 8.5 was not shown since protein lost all activity due to 
unfolding. 
 
Compared with the structure of the Egt2Y134F•substrate binary complex, C-S bond 
cleavage allows the sulfenic group to move 1.6 Å closer to PLP, forming a triad among the 
sulfenic acid and the oxygen atoms of the phosphate group of PLP (Figure 3-12B). The 
sulfenic acid is further stabilized by the cation-π interaction between the partial positive 
charge on the sulfur atom and the aromatic ring of Phe48 at a distance of ~ 5 Å (Figure 
3-12B). The imidazole ring of the ergothioneine sulfenic acid intermediate is sandwiched 
between the side chains of Arg75 and His276. The N-trimethylamine is stabilized by a 
cation-π interaction with Phe304 from the neighboring monomer.  




















































Figure 3-12  Snapshot of the sulfenic acid intermediate in Egt2-catalysis. (A) The ergothioneine sulfenic 
acid intermediate bound at the active site is shown with 2mFo-DFc map contoured to 0.8σ with 2D 
structure in the inset. (B) The interaction network of the ergothioneine sulfenic acid intermediate in 
the active site of Egt2Y134F. (C) The Egt2 reaction in the presence of 1,3-cyclohexanedione shows the 
appearance of a new peak at 6.86 ppm while the control reaction without trapping reagent in D shows 
formation of ergothioneine and ergothioneine-2-sulfinic acid, respectively. (E) The 2mFo-DFc map of 
the geminal diamine intermediate contoured to 1σ with structure shown in the inset. 
 
When M. smegmatis EgtE enzyme was characterized in solution, the involvement 
of a sulfenic acid intermediate was proposed.10 Sulfenic acid compounds are widely 




chemistry.27 Unlike sulfinic or sulfonic acid, sulfenic acid is reactive and labile. Hence, it 
is unlikely to directly visualize a sulfenic acid moiety during a chemical reaction pathway 
unless it is stabilized by other factors such as a steric, electronic, or hydrogen bonding 
environment.28 For example, the crystal structures of small molecular sulfenic acids such 
as thiophenetriptycene-8-sulfenic acid, (4-tert-butyl-2,6-bis[(2,2'',6,6''-tetramethyl-m-
terphenyl-2'-yl)methyl]phenyl) sulfenic acid (Bmt-SOH), and 4,6-demethoxyl triazine-2 
sulfenic acid have been obtained due to their chemical scaffolds, which restricts further 
reaction.29 In the biological system, protein sulfenic acid is an important post-translational 
modification as part of a signaling pathways in response to an oxidative environment.30 In 
the protein environment, the sulfenic acid is a precursor to a disulfide bond31 or a cyclic 
sulfenyl-amide (as found in tyrosine phosphatase).32 In extremely rare cases, for example, 
methionine sulfoxide reductase,33 phosphatase cdc25B,34 peptidyl prolyl isomerase 
(Pin1),35 and redox-sensitive transcription factors (SarZ),36 a free cysteine sulfenic acid is 
observed due to its stabilization by a hydrogen bonding network.  
3.3.6 Verifying the involvement of the sulfenic acid intermediate in Egt2 catalysis  
The visualization of a potential ergothioneine sulfenic acid intermediate captured 
in the Egt2Y134F structure is an important piece of evidence in understanding the mechanism 
of this C-S lyase. To corroborate the structural observation of the existence of sulfenic acid 
in the wild-type Egt2 reaction, a chemical sulfenic acid intermediate trapping experiment 
in solution using 1,3-cyclohexanedione, which reacts selectively with the sulfenic acid 
group to give a thioether derivative, was carried out.10,28 1H-NMR analysis of these 




observed (Figure 3-12C). However, in the control reaction without 1,3-cyclohexanedione, 
two signals (6.65 ppm and 6.87 ppm) were present (Figure 3-12D). The difference in NMR 
signals between these two reaction conditions suggested that Egt2 may release the reactive 
sulfenic acid intermediate into solution, which can then be trapped by 1,3-
cyclohexanedione. The proposed adduct was isolated and characterized as ergothioneine 
sulfenic acid-1,3-cyclohexanedione adduct (Figure 3-13).10 Therefore, chemical trapping 
results in solution support the crystallographic observation which suggests the presence of 





Figure 3-13 Characterization of the ergothioneine sulfenic acid-1,3-cyclohexanedione adduct. (A) 1H-
NMR spectrum: δ 1.83 (dt, J = 6.3, 12.8, 2H), δ 2.35 (t, J = 6.3, 4H), δ 2.98 (dd, J = 6.3, 12.8, 2H), δ 3.02 
(dd, J = 3.9, 11.6 Hz, 1H), δ 3.09 (s, 9H), δ 3.73 (dd, J = 4.4, 10.8 Hz, 1H), δ 3.74 (dd, J = 3.9, 11.7 Hz, 
1H), δ 6.68 (s, 1 H). (B) Molecular ion region of the HRMS spectrum of ergothioneine sulfenic acid-
1,3-cyclohexanedione adduct. Calculated value for the adduct [M+H]+ (positive mode) was m/z 
340.1326, and found m/z 340.1336. 




































3.3.7 The aminoacrylate germinal diamine intermediate in Egt2 reaction 
Besides the sulfenic acid intermediate, careful inspection of the active sites of the 
Egt2Y134F structure at pH 8.0 revealed the aminoacrylate geminal diamine intermediate 
(Figure 3-12E). This intermediate is formed immediately prior to the release of pyruvate 
and the regeneration of the PLP intra-aldimine bond for the next catalytic cycle. In this 
structure, the aminoacrylate is stabilized by a salt bridge interaction between its carboxylate 
group and Arg75 from the adjacent monomer (Figure 3-12 E). Although this intermediate 
is presumed to be produced concurrently with the sulfenic acid intermediate, the density 
for the sulfenic acid intermediate in the active site containing the aminoacrylate was not 
observed. Superimposition of the active site containing the two intermediates shows an 
over-crowded active site. It is highly possible that the sulfenic acid species might have been 
released from the active site before the aminoacrylate geminal diamine intermediate forms.  
To understand the role of Tyr134F in the Egt2-mediated reaction, the alignment of 
wild-type Egt2 and seventeen of its closest homologs from a Basic Local Alignment Search 
Tool (BLAST) search using ClutsalOmega,37 revealed that the residue Tyr134 was strictly 
conserved (Figure 3-14A). Several members of the type I PLP-dependent enzyme family 
have an active site tyrosine that plays a key role in PLP binding, e.g., aspartate 
aminotransferase,21 aminolevulinate synthase,38 cystathionine -lyase,39 and cystalysin.40 
The extensive interaction formed by Tyr134 with the sulfoxide substrate as well as PLP 
binding highlights its importance for substrate recognition for Egt2. In other cases, an 
active site tyrosine is reported to act as a general acid/base to facilitate catalysis (e.g., 




lyase (PDB ID: 1ELQ) and cysteine desulfurase (PDB ID: 4Q76) as the closest Egt2 
structural homologs. The superimposition of these three structures revealed that the Tyr134 
in Egt2 is replaced by a histidine in the cysteine/cystine C-S lyase and cysteine desulfurase 
(Figure 3-14). The histidine imidazole ring stacks with the PLP pyridine ring and functions 
as a base to deprotonate the substrate amine group and to initiate the transition from the 
internal aldimine into the external aldimine intermediate.43,44 This finding highlights that 
the active site tyrosine residue at a position comparable to wild-type Egt2 has a dual role 
both in the substrate binding and subsequent catalysis. This observation is consistent with 
the biochemical characterization of Egt2Y134F, in which the reduced activity of this variant 
fits its role as a general acid/base candidate. The mutation of Tyr134 did reduce, but not 






Figure 3-14 Tyr134 is conserved among Egt2 homologs. (A) Sequence alignment of seventeen Egt2 
homologs using ClustalOmega. The conserved Tyr134 is highlighted in yellow.  (B) Superimposition of 
the wild-type Egt2 structure with structures of cysteine C-S lyase (PDB: 1ELQ) and cysteine 
desulfurase (PDB: 4Q76). The PLP cofactor for all the three structures is shown as sticks; the one 
corresponding to Egt2 is shown in yellow, the structurally conserved residues interacting with the PLP 
are shown as sticks. Labeling of the residues is according to the Egt2 sequence. The Tyr134 in Egt2 is 
shown in yellow sticks. 
 
3.3.8 The reduction of the sulfenic acid intermediate in Egt2-catalysis 
The presence of the sulfenic acid intermediate in the catalytic cycle determined by 
the X-ray crystallography and the chemical trapping experiment immediately raises the 
next key question regarding the wild-type Egt2 catalysis: how is the C-S lyase activity 
coupled to the reduction of this sulfenic acid intermediate?  There are two possible 






reduced to ergothioneine. The labile sulfenic acid species may be reduced by a thiol group 
on the Egt2 protein itself or be released directly into solution and reduced by other cellular 
reductants. Examination of the Egt2Y134F crystal structure revealed a Cys156 located next 
to the exit of the active site, suggesting the possibility of sulfenic acid reduction by the 
thiol of Cys156 (Figure 3-15A). To test if the sulfenic acid can form a covalent adduct with 
the thiol of Cys156 in Egt2, a single-turnover experiment in the absence of DTT for wild-
type Egt2 was performed. A control sample containing only Egt2 was set up. The digested 
peptides were then analyzed by ESI-LC/MS/MS, which showed no modification of Cys156 
on Egt2 prior to single-turnover reaction (Figure 3-15B). In another sample, equal molar 
ratio of protein and substrate were incubated together, which was then subjected to 
proteolysis by trypsin. MS/MS analysis of the peptides from the single-turnover reaction 
shows that the Cys156 of Egt2 is covalently modified with a sulfenic acid adduct (Figure 
3-15C). When the labeled wild-type protein was treated with DTT, the peptide containing 
Cys156 in its thiol form was regenerated (Figure 3-16A). In a control reaction, the MS/MS 
analysis of the Egt2C156A variant from the single-turnover reaction indicated that the 
corresponding peptide was not modified (Figure 3-16B and Figure 3-16C). All the evidence 
supports modification at the Cys156 position by forming an adduct with the sulfenic acid 






Figure 3-15 Reactions of the sulfenic acid intermediate. (A) Surface representation of the active site of 
Egt2Y134F shown in sticks and the Cys156 lying at the exit of the binding pocket (in orange). (B) MS/MS 
spectrum of a tryptic peptide of the wild-type Egt2 (residues 156-173) before single-turnover reaction.  
The parent ion has the signal with m/z 1003.998. (C)  MS/MS spectrum of a tryptic peptide of the wild-
type Egt2 (residues 154-173) after the single turnover reaction. The non-specific cleavage of trypsin at 





Figure 3-16 MS/MS analysis of Egt2 wild-type and Egt2C156A from the single-turnover reactions. (A) 
MS/MS spectrum of a tryptic peptide (residue 156-173, doubly-charged parent ion at m/z 1003.9993) 
from wild-type Egt2 reaction with excess DTT shows no peptide modification. (B) MS/MS spectrum of 
a tryptic peptide from Egt2C156A before the single-turnover reaction (residues 156-173, triply-charged 
parent ion at m/z 659.0121). Modification was not observed. (C) MS/MS analysis of a tryptic peptide 
from Egt2C156A after the single-turnover reaction (residue 156-173, the doubly-charged parent ion at 





In the presence of DTT as the reductant, wild-type Egt2 produced ergothioneine as 
the sole product, as shown by 1H-NMR assay (Figure 3-5). However, in the absence of the 
reductant DTT, chemical characterization of the reaction by wild-type Egt2 reveals the 
existence of ergothioneine and ergothioneine-2-sulfinic acid (Figure 3-12D) as products. 
The ergothioneine-2-sulfinic acid intermediate was isolated and characterized, providing 
another line of evidence supporting the sulfenic acid formation in Egt2-catalysis (Figure 
3-17). This result can be explained by the disproportionation of the sulfenic acid 
intermediate to a thiosulfinate, which is further hydrolyzed to produce ergothioneine and 
ergothioneine-2-sulfinic acid in a 1:1 ratio similar to that of EgtE-catalysis reported 
recently (Figure 3-2).10 The result suggests that, in the absence of reductants, wild-type 
Egt2 can also release the sulfenic acid intermediate directly to the solution. Based on the 
above results, two non-exclusive mechanisms for Egt2 catalysis are envision. After its 
formation, the ergothioneine sulfenic acid can be reduced by Cys156 to form a disulfide 
bond, which is further reduced by cellular thiol reduction system to release ergothioneine 
and restore Cys156 for the next cycle. Alternatively, ergothioneine sulfenic acid may be 
directly released to the solution and reduced by intracellular reductants to produce 
ergothioneine. In vivo, such a reduction system can be provided by other intracellular thiols 







Figure 3-17 Ergothioneine-2-sulfinic acid characterization. (A) Characterization of ergothineine-2-
sulfinic acid isolated from the Egt2 reaction in the absence of reductant: 1H NMR spectrum of 
ergothioneine-2-sulfinic acid: δ 2.99-3.16 (m, 11H), δ 3.73 (dd, J = 3.8, 11.7 Hz, 1H), δ 6.85 (s, 1 H). (B) 
Molecular ion region of the HRMS spectrum of ergothineine-2-sulfinic acid. Calculated value for the 

































3.3.9 Proposed mechanism of the Egt2-mediated C-S lyase reaction 
Based on the biochemical and structural data, a mechanistic model for Egt2-
catalysis was proposed (Figure 3-18). Similar to other PLP-containing enzymes, the first 
step is the formation of external aldimine intermediate 3-7a between the PLP cofactor and 
the sulfoxide substrate 3-7 resulting in a Schiff base. Subsequently, a base abstract a proton 
on the Cys α-carbon producing the quinonoid intermediate 3-7b. In Egt2-catalysis, Tyr134 
can potentially function as a base. However, biochemical results suggested that Tyr134 is 
not the only residue serving this role. The subsequent C-S bond cleavage produces the 
ergothioneine sulfenic acid 3-8 and the PLP-based aminoacrylate intermediate 3-7c, the 
latter undergoes the amine exchange with Lys247 at the active site forming intermediate, 
leading to the formation of pyruvate and ammonia as the side-products. When the 
ergothioneine sulfenic acid is released, the Cys156 located at the exit of the substrate 
binding pocket then traps this species, forming a disulfide adduct 3-8c. The adduct can be 
further reduced by a reductant such as DTT or a thiol-reduction system (e.g., the 
thioredoxin/thioredoxin reductase pair), releasing ergothioneine 3-6 as the final product 
and regenerating Cys156 for the next cycle (Pathway I, Figure 3-18). Alternatively, the 
sulfenic acid intermediate 3-8 might be released from the active site to the solution directly, 
which can be then reduced by a thiol reduction system (e.g., glutathione or the 
thioredoxin/thioredoxin reductase pair) to yield ergothioneine as a final product (Pathway 







Figure 3-18 The proposed Egt2 catalytic mechanism showing the involvement of the ergothioneine 
sulfenic acid, which could form a covalent adduct with Cys156 (pathway I) or get released directly into 





3.4 Conclusions and Future Directions 
In ergothioneine biosynthesis, the sulfur transfer strategy involves the oxidative C-
S bond formation mediated by sulfoxide synthases, EgtB/Egt1, and the PLP-dependent 
lyases, EgtE/Egt2. This trans-sulfuration reactiom differs from all other reported strategies 
in natural product biosyntheses. The activity of the sulfoxide synthase EgtBCth from 
thermophilic bacteria has been reconstituted in vitro as discussed in Chapter 2. Thus, in 
this chapter, the biochemical and structural studies of the C-S lyase reaction mediated by 
Egt2 in ergothioneine biosynthesis is presented. Egt2 catalyzes the C-S bond cleavage of 
sulfoxide substrate, unlike other C-S lyases which prefer thioether substrates. Structural 
studies revealed that the cation-π interactions between Egt2 and sulfoxide substrate, which 
primarily contribute to Egt2 substrate preference on sulfoxide over thioether. Additionally, 
the C-S lyase reaction of Egt2 was proposed to couple with a reduction process. However, 
this process is poorly understood. In this work, the reactive sulfenic acid species was 
observed in crystallographic studies. Using chemical trapping and mass spectrometry, the 
involvement of the sulfenic acid intermediate in Egt2 catalysis was verified. However, how 
this reaction is coupled with a reduction system in vivo is not clear. Further studies can be 
performed to identify cellular reductant, which is responsible for the reduction of the 
sulfenic acid intermediate from Egt2-catalysis. The cellular reductants such as small-
molecule glutathione, thioredoxin/thioredoxin reductase system, and glutaredoxin can be 
tested for the reduction of sulfenic acid. This study shed light on the reductive C-S lyase 




and the C-S lyase Egt2 allowed the reconstitution of ergothioneine in vitro. This work may 
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Chapter 4 In vitro Reconstitution of the Ovothiol A Biosynthesis 
Reproduced with permission from Org. Lett. 2018, 20, 17, 5427-5430, and 
Biochemistry 2018, 57, 24, 3309-3325, Copyright © 2020 American Chemical Society 
4.1 Introduction 
4.1.1 Biological functions and biochemical properties of ovothiols 
Sulfur-containing natural products are widely distributed in nature, and include 
classes of compounds such as amino acids, nucleotides, enzyme cofactors, and secondary 
metabolites.1-7 In Chapter 2 and Chapter 3, the mechanistic and biochemical studies of the 
enzymes involved in the biosynthetic pathways of thiolhistidine ergothioneine 4-1 are 
described. In addition to ergothioneine, ovothiol is another thiolhistidine derivative (4-2 to 
4-4). Unlike ergothioneine, ovothiol has the sulfur substitution at the -carbon of the 
imidazole side-chain instead of the -carbon position (Figure 4-1A).8,9 Depending on the 
degree of methylation at the amino group, there are three forms of ovothiol: A (4-2, 
unmethylated), B (4-3, mono-methylated), and C (4-4, di-methylated, Figure 4-1A). 
Ovothiol A was first isolated from the eggs and ovaries of sea urchins Paracentrotus lividus 
and Arbacia lixula.10 It was found as a common metabolite among marine invertebrates 
such as the asteroid Astropecten aurantiacus, the octopus Octopus vulgaris, and the 
mottled sea star Evasterias troschelii.11,12 Similarly, ovothiol B and C were isolated from 
the eggs of the scallop Chlamys hastata and of the sea urchin Strongylocentrous 
purpuratus.9 Ovothiol A and its derivative 5-mercaptohistidine are incorporated in other 
secondary metabolites in marine invertebrates. For instance, the iron-binding purple 




found to contain a dihydroxyphenylalanine core (DOPA) with two ovothiol A or 5-
mercaptohistidine moieties (4-5 and 4-6, Figure 4-1A).13 Additionally, ovothiol is 
incorporated into some pyrroloiminoquinone alkaloids such as discorhabdins J 4-7 and 
discorhabdins K 4-8, which were isolated from the marine sponge Latrunculia brevis 
(Figure 4-1A).14,15  
 
Figure 4-1 Sulfur-containing metabolite and tyrosinase reaction. (A) Ergothioneine, ovothiol, and 
mercaptohistidine-containing marine invertebrate metabolites. (B) Reaction of tyrosinase. 
 
The incorporation of ovothiol A and its derivatives are achieved through thioether 
liankges. The biosynthesis of adenochromines has been proposed to involve the oxidation 




nucleophilic attack of the thiolate of ovothiol onto DOPA quinone affords the intermediate 
4-11 (Figure 4-1B). The isolated adenochromine products exist as a mixture of isomers 
suggesting that the nucleophilic attack of the thiolate is a non-enzymatic process.13 This 
observation agree with the biochemical properties and the high cellular abundance 
(millimolar level) of ovothiol in marine organisms. The pKa of the thiol (1.4) group on 
ovothiol A is significantly more acidic than other natural thiols.16-18 As a result, ovothiol A 
exists predominantly in the thiolate form under physiological conditions. Ovothiol may be 
acting as a nucleophile that forms thioether linkages with other electrophilic metabolites 
via nucleophilic catalysis.  
In addition to being a nucleophile, ovothiol is also a potent antioxidant. Ovothiol A 
can scavenge peroxides and radical to form ovothiol A disulfide.19,20 However, the 
disulfide form of ovothiol A is unstable and is, therefore, reduced by glutathione. The 
resulting glutathione disulfide can then be regenerated by a NAD(P)H-dependent 
glutathione reductase.21 Due to this biochemical property, ovothiol A has been proposed to 
primarily function as a radical and peroxide scavenger. However, recent studies reported 
the discovery of ovothiol A from the protozoan Crithidia fasciculata, suggesting that 
ovothiol-producing organisms are not limited to marine invertebrates.12 Additional studies 
revealed the production of ovothiol in parasitic trypanosomatids such as Leishnania 
donovani and Trypanosoma cruzi.15 A recent study on the parasitic trypanosomatids 
revealed that trypanothione, a small-molecule thiol, is more reactive toward hydrogen 
peroxide than ovothiol A suggesting that ovothiol A is unlikely the primary cellular 




significant oxidative bursts, in which high concentration of nitric oxide is produced by 
macrophages. Small-molecule thiols such as cysteine and glutathione (GSH) can then react 
with nitric oxide resulting in S-nitrosothiols. In this process, ovothiol A might reduce the 
resulting S-nitrosothiols that protect parasitic trypanosomatides from oxidative stress.15,22 
Due to this potential biological function, trypanosomal ovothiol A biosynthesis might be a 
target for anti-parasitic therapeutic development. Additionally, ovothiol A has also been 
demonstrated to induce autophagy in human liver carcinoma cell lines, suggesting 
functions other than solely being a redox agent.23 Ovothiol A exhibits potent antioxidant 
activity and other important biological activities, however, more research is needed to 
unravel the biological functions and mechanism of action of this thiol. 
4.1.2 Ergothioneine and ovothiol biosynthetic pathways 
Despite the increasing knowledge on the biological functions of ovothiol, much less 
is known about its biosynthetic pathway. Recall the early study of ovothiol biosynthetic 
pathway discussed in Chapter 1, in which the cell extracts of ovothiol-producing organism 
were used to determine the enzymes involved in this pathway. Using the ovothiol-
producing organism Crithidia fasciculate, Steenkamp et al. demonstrated that the 
biosynthesis of ovothiol A involves an iron enzyme catalyzed oxidative coupling reaction 
and a pyridoxal phosphate (PLP)-catalyzed C-S lyase reaction.24 Due the potential for 
therapeutic use, the biosynthetic pathway of ovothiol has received considerable interest. 





Recently, two aerobic ergothioneine biosynthetic pathways were discovered: the 
Mycobacterium smegmatis pathway (EgtA – EgtE, Figure 4-2),26-33 and the fungal 
Neurospora crassa pathway (Egt1, Egt2, and an unidentified methyltransferase (MTase) 
(Figure 4-2).34,35 In these two pathways, the two key steps include an oxidative C-S bond 
formation by a non-heme iron enzyme EgtB and Egt1 and a reductive C-S lyase reaction 
by EgtE and Egt2. Such a trans-sulfuration strategy differs from all other sulfur transfer 
reactions reported.5,36 Due to the similarity in the oxidative C-S bond formation reaction in 
ergothioneine and ovothiol, Seebeck et al rationalized that there might be distant EgtB 
homologs in ovothiol-producing organisms responsible for the 5-histidyl-cysteine 
sulfoxide 4-16 formation (OvoAs). Using M. smegmatis EgtB as the query sequence, more 
than 80 OvoA homologs were identified in genomes ranging from proteobacteria to uni- 
and multicellular eukaryotes. OvoA from the trypanosimatides Erwinia tasmaniensis and 
Trypanosoma cruzi were further characterized biochemically. Seebeck et al showed that 
OvoA is a non-heme iron enzyme that catalyzes the oxidative coupling between L-His and 
L-Cys in the ovothiol biosynthetic pathway (Figure 4-2).25,37-41 However, the identity of 
the C-S lyase and the MTase in the biosynthesis of ovothiol are not known. 
In this chapter, the remaining steps of ovothiol A biosynthesis were reconstituted 
in vitro. Through bioinformatic and biochemical studies, we demonstrated that 
ETA_14770 (OvoB), a PLP-dependent C-S lyase, is responsible for the 5-
mercaptohistidine 4-17 production. Additionally, OvoA was discovered as a bi-functional 
enzyme, catalyzing both the oxidative C-S bond formation reaction and the methylation of 




biosynthetic pathway, two unique features proposed in literature were also examined: a 
potential cysteine-recycling mechanism of the C-S lyase (OvoB) and the selectivity of the 
π-N methyltransferase. Reconstitution of the ovothiol A biosynthetic pathway provides 
new avenue to produce this high value thiol through metabolic engineering/synthetic 
biology approaches.  
 
 






4.2 Material and Methods 
4.2.1 General materials and equipment 
All reagents and equipment used are similar to that indicated in Chapter 2 unless 
otherwise specified. Protein expression vector pET28a(+) was purchased from Novagen. 
Methyl transferase activity was characterized using MTase-Glo assay from Promega.  
4.2.2 Identification of ovothiol C-S lyase via bioinformatic analysis 
This study was carried out by Ronghai Cheng, a graduate student in the Liu lab. 
Using the protein family information from the pfam database,42 the genome of E. 
tasmaniensis was analyzed to construct a protein-protein family network using Cytoscape 
3.6.0.43 This resulted in 16 genes from aminotransferase class I and II, a protein family for 
C-S lyase activity. These candidates were then further analyzed for their relationship with 
OvoA through the String Database.44   
4.2.3 Protein overexpression and purification 
Recombinant OvoA was prepared as previously reported.37 The ETA_14770 
(OvoB) gene from E. tasmaniensis was codon-optimized for Escherichia coli 
overexpression by Genscript and sub-cloned into the NcoI and XhoI sites of pET28a(+) 
vector (Novagen). The plasmid was transformed into E. coli BL21(DE3) for protein 
overexpression. A single colony was inoculated in 50 mL of LB media supplemented with 
kanamycin (50 μg/L) and incubated overnight at 37C. Then, 10 mL of this overnight 




mM PLP. When the OD600 reached 0.8, protein overexpression was induced using 0.1 mM 
IPTG. The culture was incubated at 16C for 8 hr before harvesting by centrifugation and 
storage at -80C.  
To purify OvoB, 5 g cells were resuspended in 25 mL of lysis buffer (100 mM Tris-
HCl, 50 mM NaCl, pH 8.0) with 1.0 mg/mL lysozyme and incubated on ice for 30 min. 
Cells were disrupted by sonication and the cell debris was separated by centrifugation at 
20,000 rpm for 30 min. The supernatant was loaded onto a nickel-NTA column (GE 
Healthcare), which was equilibrated with lysis buffer. The column was washed with lysis 
buffer containing 20 mM imidazole until A280 < 0.05. The protein was eluted with lysis 
buffer containing 250 mM imidazole and concentrated using ultrafiltration. Excess 
imidazole was removed by dialysis against the lysis buffer and stored at -80 C. For 
crystallographic studies, OvoB was further purified using size-exclusion chromatography 
to near homogeneity as shown by SDS-PAGE analysis. Approximately 10 mg of purified 
protein is obtained from one gram of wet cells. 
4.2.4 Determination of PLP content 
The PLP cofactor content in OvoB was determined following the reported 
protocol45 and as discussed in Chapter 3. In brief, OvoB was treated with 0.2 N NaOH to 
release the PLP cofactor. The absorbance of the resulting solution was measured at 390 
nm. The PLP content was calculated using 390 = 6600 M
-1cm-1.45 For OvoB, the PLP 




4.2.5 Kinetic parameter determination of OvoB-catalysis 
Since pyruvate is produced as one of the side-products in this reaction, the kinetic 
parameters were measured by coupling the C-S lyase reaction with lactate dehydrogenase 
(LDH) and monitoring the nicotinamide adenine dinucleotide (NADH) consumption rate.46 
A 1-mL assay at 25°C contained 0.13 mM NADH, 1 mM dithiothreitol (DTT), 22.5 U/mL 
LDH (~500-fold of OvoB activity in the assay) in a 50 mM KPi, pH 8.0 buffer and various 
amounts of substrate 4-15 or 4-16, and OvoB (10 nM for sulfoxide 4-15 and 6 nM for 
sulfoxide 4-16). The coupled assay was monitored at 340 nm using Varian Cary Bio 100 
spectrophotometer and the data was fitted by GraphPad Prism.  
In addition, the OvoB-type of activity mediated by ergothioneine C-S lyase, Egt2, 
was also characterized. The kinetic parameters for Egt2 were determined using a method 
similar to that of OvoB, except that 150 nM Egt2 was used for the assays. Moreover, the 
turnover of PLP in the C-S lyase reaction was determined using a similar procedure, except 
that the substrate 4-16 concentration was kept constant at 2 mM and the PLP concentration 
was varied (40 – 200 nM).  
4.2.6 Isolation and characterizations of products from OvoB-catalysis 
Sulfoxides 4-15 and 4-16 were prepared as previously reported for the OvoB 
reaction.34,37 A 10-mL reaction containing 1 µM OvoB, 2 mM sulfoxide 4-15 or 4-16, and 
2 mM DTT in 50 mM KPi buffer, pH 8.0 was set up at 28C for 1 hr. Then, 5-
mercaptohistidine was isolated following the reported procedure (~3 mg, 80% yield).33 The 




Ergothioneine: 1H NMR (500 MHz, D2O) δ 3.00 (dd, J = 11.8, 14.0 Hz, 1H), δ 3.07 
(dd, J = 2.5, 12.3 Hz, 1H), δ 3.11 (s, 9H), δ 3.75 (dd, J = 3.9, 11.8 Hz, 1H), δ 6.61 (s, 1 H). 
HRMS (ESI) calculated value for ergothioneine as [M-H]- was m/z 228.0812 and found 
m/z 228.0824. 
5-mercaptohistidine 4-17: 1H NMR (500 MHz, D2O) δ 3.03 (dd, J = 7.4, 13.8 Hz, 
1H), δ 3.17 (dd, J = 4.8, 13.9 Hz, 1H), δ 3.91 (dd, J = 4.7, 6.8 Hz, 1H), δ 8.12 (s, 1H). 
HRMS (ESI) calculated value for compound 4-17 as [M+H]+ was m/z 188.0488, and found 
m/z 188.0495. 
5-mercaptohistidine disulfide 4-17a: 1H NMR (500 MHz, D2O) δ 2.29 (dd, J = 7.1, 
15.1 Hz, 2H), δ 2.41 (dd, J = 5.1, 15.2 Hz, 2H), δ 3.53 (dd, J = 5.2, 8.1 Hz, 2H), δ 7.71 (s, 
2H). HRSM (ESI) calculated value for compound 4-17a as [M+H]+ was m/z 373.0747, and 
found m/z 373.0761. 
4.2.7 Quantification of pyruvate formation from the OvoB and PLP reactions 
The amount of pyruvate from the OvoB reaction was calculated based on the 
amount of the hydrazine adduct which was determined by 1H NMR spectra following the 
procedures outlined in Chapter 3. A 2-mL reaction containing 1 mM sulfoxide 4-16,1 mM 
DTT, and 2 µM OvoB in 50 mM KPi buffer, pH 8.0, was setup at 28C for 1 hr. The 
solvent-exchangeable methyl group of pyruvate was converted to non-exchangeable 
protons by adding 4-fluorophenylhydrazine (2 mM final concentration) to the reaction 
mixture and incubated at 50C for 3 hr to afford the dinitrophenylhydrazine derivative. 
After completion, the reaction was lyophilized and characterized by 1H NMR with ethyl 




4.2.8 Quantification of ammonia from the OvoB and PLP reactions  
In addition to pyruvate and 5-mercaptohistidine, NH3 was also proposed as a 
product of the OvoB reaction and was quantified following a reported study in Chapter 3.35 
A 1-mL reaction containing 5.0 μM OvoB, 0.32 mM ammonium-free substrate, and 
0.5 mM DTT in 50 mM KPi buffer pH 8.0, was incubated at 28 °C for one hour. The control 
reaction contained the same components as the above reaction except that heat-denatured 
OvoB was added instead of active OvoB. Then, 100 µL of Nessler’s reagent, a solution 
containing K2[HgI4], which reacts with ammonia under basic condition to yield yellow-
colored species, was added to the reaction mixture. To monitor quantify the ammonia 
produced from OvoB reaction, the absorbance at 462 nm was recorded.47 The concentration 
of ammonia was derived from the standard curve. 
4.2.9 Chemical trapping of the sulfenic acid intermediate from the OvoB reaction 
The sulfenic acid intermediate from OvoB catalysis was trapped using chemical 
trapping following reported procedures.33 A 5-mL reaction mixture at 28C contained 2 
µM OvoB, 3.5 mM sulfoxide 4-16 and 165 mM 1,3-dicyclonehexane (50-fold of substrate 
concentration) in 50 mM KPi buffer, pH 8.0. After one hour, the reaction was lyophilized, 
and the desired adduct was purified using a cellulose resin following reported procedures.33 
In brief, the cellulose column was prepared with iPrOH: ACN = 4.5 : 2.5. The product was 
loaded onto the column and washed with iPrOH: ACN = 4.5: 2.5. The desired product was 
then eluted with iPrOH: ACN: 0.1 M NH4HCO3 = 4.5: 2.5: 3. The fractions containing 
product was pooled and rotor evaporated. The sulfenic acid adduct was then characterized 




4.2.10 Crystallization and data collection of structure of OvoB 
This experiment was performed by Dr. Pei Huang from Prof. Lixin Zhang’s lab at 
East China University of Science and Technology and Yujuan Cai, a graduate student in 
Prof. Jiahai Zhou at Shanghai Institute of Organic Chemistry. Crystals of high diffraction 
quality were obtained using wild-type OvoB. Crystallization trials were carried out using 
sitting-drop vapor diffusion in a 96-well plate with a drop size of 2 µL (1 µL of protein 
sample incubated with substrate 4-16 plus 1 µL of mother liquor). In total, 1152 
commercially available conditions were tested at 16C. Crystals were obtained in 0.08 M 
sodium cacodylate (pH 6.5), 0.16 M calcium acetate, 14.4 % (w/v) PEG8000 and 20% 
(v/v) glycerol at 16C. The crystals were quickly soaked in a reservoir solution containing 
10% glycol and 5 mM of 4-16 prior to being flash frozen in liquid nitrogen. Data was 
collected at BL19U1 beamline in Shanghai Synchrotron Radiation Facility at the 
wavelength of 0.97791 Å and processed with the HKL3000 package.48  
4.2.11 Structural determination and refinement of OvoB 
This experiment was performed by Dr. Pei Huang from Prof. Lixin Zhang’s lab at 
East China University of Science and Technology and Yujuan Cai, a graduate student in 
Prof. Jiahai Zhou’s lab at Shanghai Institute of Organic Chemistry. The structure of PLP-
containing OvoB was determined by molecular replacement using the PHENIX program 
package49 and the atomic coordinates in PDB ID 4DGT as a searching model. PLP was 
manually added into the structure based on the omit Fo–Fc map and iterative cycles of 
refinement were carried out using COOT50 and PHENIX.49 A random selection of 5% 




to assess the overall quality of the structural models. Structural figures were prepared using 
PyMol. 
4.2.12 OvoA methyltransferase reaction and product isolation  
A 10-mL reaction mixture contained 50 µM OvoA, 1 mM 5-mercaptohistidine 4-
17, 2 mM SAM, 1 mM DTT, 1 mM Mg(OAc)2 in 50 mM KPi, pH 8.0 buffer. The reaction 
was set up at 28C for 2 hr. OvoA protein was removed by ultrafiltration and the reaction 
mixture was purified using DOWEX 50W (H+ form) following a similar protocol used for 
the ergothioneine purification outlined in Chapter 3.33 The ovothiol-containing fractions 
were combined, lyophilized, and subjected to further purification using HPLC (C18 reverse 
phase column, 250 x 10 mm, mobile phase: 1 mL/min flow of H2O with 2% ACN). The 
final product was obtained as a white solid (~1.2 mg, 60%). The purified product was then 
characterized by NMR and MS. 
Ovothiol A9: 1H NMR (500 MHz, D2O) δ 2.49 (dd, J = 7.6, 13.7 Hz, 1H), δ 2.58 
(dd, J = 4.7, 13.9 Hz, 1H), δ 3.33 (s, 3H), δ 3.92 (dd, J = 4.6, 8.9 Hz, 1H), δ 8.25 (s, 1H). 
HRSM (ESI) calculated value for compound (2-1) as [M+H]+ form was m/z 202.0645, and 
found m/z 202.0652. 
Ovothiol A disulfide9: 1H NMR (500 MHz, D2O) δ 2.48 (dd, J = 7.2, 14.7 Hz, 2H), 
δ 2.57 (dd, J = 5.7, 14.9 Hz, 2H), δ 3.48 (s, 6H), δ 3.63 (dd, J = 5.4, 8.9 Hz, 2H), δ 7.75 (s, 
2H. HRMS (ESI) calculated value for ovothiol A disulfide as [M+H]+ form was m/z 




4.2.13 Kinetic parameter determination of the OvoA methyltransferase activity  
The kinetic parameters of OvoA methyltransferase activity was determined by 
measuring the rate of S-adenosyl homocysteine (SAH) formation, which is produced in 1: 
1 ratio with ovothiol A. The analysis was conducted through a commercial enzymatic assay 
system from Promega, MTase-Glo9 (Figure 4-3). For the SAM concentration dependence 
assay, in a 96-well plate, a 20-µL reaction mixture containing 10 nM OvoA, 30 µM 5-
mercaptohistidine, 1.0 mM EDTA, 3.0 mM MgCl2, 1.0 mM DTT, 0.1 mg/mL BSA, and 
50 mM NaCl in 20 mM Tris-HCl, pH 8.0 buffer, was set up in 96-well plates at 25°C. The 
reactions were run in duplicates. The reaction was quenched at different time points (5, 10, 
and 20 min) with TFA to a 0.1% final concentration. Then, 5 µL of MTase-Glo Reagent 
was added to the quenched reaction mixture and incubated at 25°C for 30 min to convert 
SAH to ADP. MTase-Glo Detection Solution (25-µL) was subsequently added and 
incubated for 30 min at 25°C to convert ADP to ATP. Luminescence was generated via the 
luciferase reaction and was measured using SpectraMax M5. The amount of SAH was 
derived from the SAH standard curve which was generated using MTase-Glo. The amount 
of product was plotted versus time to determine the rate of OvoA methyltransferase 
activity. This rate was then plotted against varying SAM concentrations (1.25 – 30 µM) 
and the resulting curve was fitted using GraphPad Prism. The same reaction setup was 
carried out for the 5-mercaptohistidine concentration dependence assay, except that the 
SAM concentration was kept constant at 30 µM and 5-mercaptohistidine concentration was 






Figure 4-3 OvoA methyltransferase activity was measured by a coupled assay (MTaseGlo, Promega), 
in which the production of SAH from the OvoA reaction was converted to ATP through a series of 
enzymes listed in the scheme. Then, the ATP produced was used to produce luminescence by luciferase 





4.3 Results and Discussion 
Ovothiol A has been established as a potent radical and peroxide scavenger. This 
small-molecule thiol also plays important roles in the trypanosomatid infection. In addition 
to its antioxidant properties, ovothiol A also exhibits anti-proliferation activity against 
human liver carcinoma cell lines. The potential therapeutic use of ovothiol A has motivated 
researchers to understand the biosynthetic pathway of this compound. Unlike the 
information on its biological function, much less is known about the biosynthesis of 
ovothiol. Thus far, only the sulfoxide synthase responsible for oxidative coupling between 
L-His and L-Cys in the ovothiol pathway has  been reported (Figure 4-2).25,34,37,39-41 The 
lack of a complete biosynthetic pathway hinders the production of ovothiol A. To 
overcome this issue, herein, the enzymes responsible for the remaining steps in ovothiol A 
biosynthesis have been identified. 
4.3.1 Identification of the ovothiol C-S lyase through bioinformatic analysis  
To search for the ovothiol C-S lyase, the E. tasmaniensis genome was analyzed to 
generate a protein-protein family network using Cytoscape 3.6.043 based on the protein 
family information from the pfam database.42 As a results, 16 genes belonging to 
aminotransferase class I and II (Figure 4-4A) were identified as C-S lyase candidates.33,34 
Then, the String database was used to further analyze the relationship between OvoA and 
these 16 candidates based on gene co-occurrence, fusion, gene neighborhoods, and 
functional association information.44 The String database’s analysis suggested that 




Though E. tasmaniensis has not been reported as an ergothioneine producer, ETA_14770 
has been used as an ergothioneine C-S lyase,26 which raises the question of ETA_14770’s 
true function. To address this issue, ETA_14770 was overexpressed and purified (Figure 
4-5). ETA_14770 was purified to > 95% homogeneity and the UV-Vis absorption spectrum 
exhibits an absorption at 420 nm corresponding to the presence of a PLP cofactor. The PLP 
content of ETA_14770 was determined to be 0.80 per one monomer. 
 
Figure 4-4 E. tasmaniensis genome analysis. (A) The protein-protein family network (partial) analysis 
of E. tasmaniensis genome, in which 16 proteins, including ETA_14770 (OvoB, highlighted in red), 
were classified as aminotransferase class I and II (shown in indent). (B) Bioinformatic analysis using 
String database shows that the potential C-S lyase (OvoB, Gene ID: ETA_14770) might be functionally 







Figure 4-5 Analysis of the purified OvoB protein. (A) SDS-PAGE of purified OvoB protein. (B) UV-
Vis absorption spectrum of purified OvoB at pH 8.0 shows the absorption feature centered at ~ 422 
nm, which is due to the PLP cofactor.55 
 
4.3.2 Biochemical characterization of ETA_14770 activity  
The bioinformatic analysis suggested that ETA_14770 from E. tasmaniensis might 
be functionally linked to OvoA in ovothiol biosynthesis, possibly catalyzing a C-S lyase 
reaction. However, the ETA_14770 has been applied as an ergothioneine C−S lyase, albeit 
the lack of ergothioneine production in E. tasmaniensis.26 This raises the question of the 
ETA_14770 identity. To verify the reported ergothioneine C-S lyase activity, the reactions 
of recombinant ETA_14770 were carried out using hercynyl-cysteine sulfoxide 4-15 as the 
substrate. 1H-NMR analysis revealed a proton at  6.65 ppm, characteristic of 
ergothioneine formation (Figure 4-6). Similar to ergothioneine C-S lyase Egt2, the kinetic 
parameters of ETA_14770 were measured by coupling the catalysis with pyruvate 
reduction by lactate dehydrogenase (Table 4-1 and Figure 4-7).56 Indeed, ETA_14770 can 
recognize compound 4-15 as a substrate with a Km of 0.70  0.06 mM and can catalyze the 
reaction with a kcat of 16.4  0.6 s































isolated and characterized following the reported procedure.33 Subsequent characterization 
further confirmed the identity of this compound as ergothioneine 4-1 (Figure 4-8). This 
result suggested that ETA_14770 might function as a C-S lyase in the ergothioneine 
biosynthetic pathway. To examine if ETA_14770 could serve as a C-S lyase in ovothiol 
biosynthesis as suggested by our bioinformatic analysis, 5-histidyl-cysteine sulfoxide 4-16 
was synthesized using the OvoA enzyme following reported procedures (Figure 4-9). 
Using the resulting sulfoxide, a reaction containing ETA_14770 and DTT as reductant was 
set up, which allowed for the production of 5-mercaptohistidine 4-17 (Figure 4-6 and 
Figure 4-10). Interestingly, during the aerobic product purification, compound 4-17 was 
isolated in its disulfide form (4-17a, Figure 4-6 and Figure 4-11), which is the stable form 
under aerobic conditions.9,21,57 The formation of mercaptohistidine disulfide is indicative 
of the high nucleophilicity of the thiol group of 5-mercaptohistidine. Using 4-16 as 
substrate, the kinetic parameters of ETA_14770 were: kcat of 56.4  2.6 s
-1 and Km of 0.34 





Figure 4-6 1H NMR analysis of OvoB reactions. (A) Reaction with hercynyl-cysteine sulfoxide. (B) 
Reaction with histidyl-cysteine sulfoxide. (C) Isolated mercaptohistidine disulfide from reaction in (B). 
(D) Sulfenic acid adduct from chemical trapping reaction. 
 
enzyme substrate kcat (s-1) Km (mM) kcat /Km (mM-1s-1) 
ETA_14770 (OvoB) sulfoxide 4-15 16.4  0.6 0.70 ± 0.06 23 
ETA_14770 (OvoB) sulfoxide 4-16 56.4  2.6 0.34 ± 0.01 167 
Egt235 sulfoxide 4-15 8.7  0.1 0.16 ± 0.01 56 
Egt2 sulfoxide 4-16 0.64  0.02 1.65 ± 0.13 0.4 














4.3.3 Identification of ETA_14770 as ovothiol C-S lyase 
To determine whether ETA_14770 is the C-S lyase for the biosyntheses of 
ergothioneine or ovothiol, we compared its kinetic parameters to that of ergothioneine C-
S lyase, Egt2.34,35 Using an LDH-coupled assay, Egt2 had a Km for sulfoxide 4-16 of 1.65 
± 0.13 mM and a kcat of 0.64 ± 0.02 s
-1 (Table 4-1 and Figure 4-7). This result suggests a 
147-fold higher catalytic efficiency of Egt2 for sulfoxide 4-15 than that of sulfoxide 4-16 
(Table 4-1). Using sulfoxide 4-16 as the substrate, ETA_14770 exhibited a catalytic 
efficiency of 167 mM-1s-1 (Table 4-1 and Figure 4-7), which is significantly higher than 
any other combinations listed in Table 4-1 (ETA_14770/sulfoxide 4-15, Egt2/sulfoxide 4-
15, and Egt2/sulfoxide 4-16). Results from this comparative kinetic characterization 
implied that ETA_14770 is most likely the ovothiol C-S lyase (catalyzing 4-16 → 4-17 






Figure 4-7 OvoB and Egt2 kinetic parameters determined by an LDH-coupled assay. The reaction rate 
was determined by measuring NADH consumption at 340 nm. A 1-mL assay mixture at 25°C contained 
0.13 mM NADH, 1 mM DTT, 22.5 U/mL LDH (~500× of OvoB activity in the assays) in a 50 mM KPi 
pH 8.0 buffer, and various amounts of substrate 4-15 or 4-16, and OvoB (10 nM for compound 4-15 
and 6 nM for compound 4-16). The rate was plotted against substrate concentrations and fitted using 
GraphPad Prism. (A) OvoB exhibited a Km for the sulfoxide substrate 4-15of 0.70 ± 0.06 mM and a kcat 
of 16.4 ± 0.6 s-1. (B) OvoB exhibited a Km for the sulfoxide substrate 4-16 of 0.34 ± 0.01 mM and a kcat 
of 56.4 ± 2.6 s-1. (C) Egt2-LDH couple assay was carried out similar to that of OvoB except that OvoB 
was replaced with 15 nM Egt2. Egt2 exhibited a Km for the sulfoxide substrate 4-16 of 1.65 ± 0.13 mM 
and a kcat of 0.64 ± 0.02 s-1. 
 





































































































Figure 4-8 Characterizations of ergothioneine isolated from OvoB reaction in the presence of DTT as 
the reductant. (A) 1H NMR spectrum of ergothioneine (500 MHz, D2O): δ 3.00 (dd, J = 11.8, 14.0 Hz, 
1H), δ 3.08 (dd, J = 2.5, 12.3 Hz, 1H), δ 3.11 (s, 9H), δ 3.75 (dd, J = 3.9, 11.8 Hz, 1H), δ 6.61 (s, 1 H). (B) 
Molecular ion region of the HRMS spectrum of ergothioneine. Calculated value for ergothioneine as 







































Figure 4-9 Characterizations of sulfoxide substrate 4-16  prepared through enzymatic reaction using 
OvoA from E. tasmaniensis. (A) 1H NMR spectrum of sulfoxide 4-16 (500 MHz, D2O): δ 3.27 (dd, J = 
6.3, 15.6 Hz, 1H), δ 3.32 (dd, J = 7.2, 15.6 Hz, 1H), δ 3.49 (dd, J = 7.4, 13.9 Hz, 1H), δ 3.78 (dd, J = 5., 
13.8 Hz, 1H), δ 3.86 (dd, J = 5.8, 7.5 Hz, 1H), δ 3.96 (dd, J = 5.3, 7.3 Hz, 1H), δ 7.84 (s, 1H). (B) Molecular 
ion region of the HRMS spectrum of sulfoxide. Calculated value for sulfoxide as [M-H]- form (negative 









































Figure 4-10 Characterizations of 5-mercaptohistidine isolated from OvoB reaction. (A) 1H NMR 
spectrum of 5-mercaptohistidine (500 MHz, D2O): δ 3.03 (dd, J = 7.4, 13.8 Hz, 1H), δ 3.17 (dd, J = 4.8, 
13.9 Hz, 1H), δ 3.91 (dd, J = 4.7, 6.8 Hz, 1H), δ 8.12 (s, 1H). (B) Molecular ion region of the HRMS 
spectrum of 5-mercaptohistidine. Calculated value for this compound as [M+H]+ form (positive mode) 
form was m/z 188.0488, and found m/z 188.0495. 
 































Figure 4-11 Characterizations of 5-mercaptohistidine disulfide isolated from the OvoB reaction. (A) 
1H NMR spectrum of 5-mercaptohistidine dimer 7a (500 MHz, D2O): δ 2.29 (dd, J = 7.1, 15.1 Hz, 2H), 
δ 2.41 (dd, J = 5.3, 15.1 Hz, 2H), δ 3.53 (dd, J = 5.2, 8.1 Hz, 2H), δ 7.71 (s, 2H). (B) 13C NMR spectrum 
of oxidized 5-mercaptohistidine purified from OvoB reaction. (125 MHz, D2O): δ 25.79 (3), δ 54.32 (2), 













4.3.4 Production of pyruvate and ammonia from OvoB-catalysis 
In addition to mercaptohistidine, pyruvate and ammonia production were also 
characterized in the OvoB reaction following the procedure presented in Chapter 3 for the 
Egt2 study. The solvent-exchangeable proton on the methyl group of pyruvate was 
converted to non-exchangeable protons using 4-fluorophenylhydrazine. The ratio between 
mercaptohistidine and the pyruvate adduct 4-18 was quantified with 1H NMR and ethyl 
viologen as an internal standard. The quantification indicated that the OvoB reaction 
produced mercaptohistidine and pyruvate in a 1: 1 ratio (Figure 4-12). Ammonia is also a 
byproduct of this reaction and was quantified using K2[HgI4] in Nessler’s reagent. As stated 
previously, ammonia turns brown in the presence of K2[HgI4]. The production of 
ammonium from the OvoB reaction was then monitored at 462 nm, an absorption peak of 
this solution. The resulting absorbance was determined to be 0.74 ± 0.08. Furthermore, the 
NH4
+ produced from the OvoB reaction was determined to be approximately 1:1 ratio with 
mercaptohistidine produced (Figure 4-13). Hence, the OvoB reaction affords 





Figure 4-12 1H-NMR quantification of the oxidized 5-mercaptohistidine and pyruvate ratio in the 
OvoB reaction. Ethyl viologen was an internal standard to quantify the ratio between the methyl group 
of pyruvate adduct 4-18 (1.87 ppm) and oxidized mercaptohistidine (7.72 ppm), which was ~1:1. Top: 
expanded regions between 1.0 ppm to 2.5 ppm. Bottom: expanded regions between 6.5 ppm to 9.5 ppm. 
 
Figure 4-13 NH4+ titration standard curve. (A) The standard solutions were prepared with (NH4)2SO4 
and the A462 of OvoB reaction sample was 0.74 ± 0.08 (shown in blue). The amount of NH4+ produced 
from OvoB reaction was determined to be ~ 1:1. (B) NH4+ standard curve. A462 of PLP reaction sample 






























y =  2.4986x - 0.0064
R2 = 0.9993






























4.3.5 Involvement of a sulfenic acid intermediate in the OvoB reaction 
Due to the similarity between the C-S lyase reactions in ergothioneine and ovothiol 
biosynthetic pathways, OvoB most likely follows a mechanistic model that resembles 
EgtE/Egt2-catalysis. In this reaction, DTT potentially functions as a reductant to reduce 
the sulfenic acid intermediate 4-19 to the thiol 4-17 as reported in the ergothioneine C-S 
lyase EgtE/Egt2 studies (Figure 4-14).33,35 The sulfoxide substrate and PLP binding results 
in the external aldimine intermediate 4-16a, which undergoes deprotonation at the Cys α-
carbon position to afford a quinonoid intermediate 4-16b. Subsequent C-S bond cleavage 
produces 5-mercaptohistidine sulfenic acid 4-19 and a PLP-based aminoacrylate 
intermediate 4-16c, which decomposes to produce pyruvate and ammonia. The reactive 
sulfenic acid is potentially released in the solution and then reduced by either small 






Figure 4-14 Proposed mechanism of OvoB shows the involvement of sulfenic acid intermediate.  
 
To verify the involvement of a sulfenic acid intermediate in OvoB-catalysis, a 
chemical trapping reaction was performed following the reported procedures in Chapter 
3.33,35 In this reaction, excess 1,3-dicyclonehexane was added to the OvoB reaction (Figure 
4-6D). 1H NMR analysis of the purified product indicated the formation of the sulfenic 
acid-1,3-cyclohexadione adduct 4-20 (Figure 4-15). This result suggested that a sulfenic 
acid intermediate is also a key species in OvoB-catalysis. Additionally, in Chapter 3, 
sulfenic acid from the Egt2 reaction can be reduced by the cysteine thiol on the protein or 




C-S lyses, it is possible that the sulfenic acid from OvoB-catalysis might share a similar 
catalytic strategy as that used in Egt2.  
 
Figure 4-15 Characterizations of sulfenic acid-1,3-cyclohexadione adduct 4-20 from the OvoB reaction. 
(A) 1H NMR spectrum of 1,3-cyclohexadione-mercaptohistidine adduct (500 MHz, D2O): δ 1.77 (p, 
J = 6.5, 12.9, 2H), δ 2.29 (t, J = 6.4, 4H), δ 2.92 (dd, J = 7.8, 14.6 Hz, 1H), δ 3.02 (dd, J = 5.5, 14.8 Hz, 
1H), δ 3.65 (dd, J = 5.7, 8.4 Hz, 1H), δ 7.48 (s, 1 H). (B) HRMS spectrum of the adduct. Calculated value 





































4.3.6 Overall structure of OvoB 
Recall the steady-state kinetic studies of OvoB in which both hercynyl-cysteine 
sulfoxide 4-15 and 5-histidyl-cysteine sulfoxide 4-16 can serve as the substrate for this C-
S lyase. However, these two sulfoxides are structurally distinct in several aspects. First, the 
sulfoxide functionality is at the ε-carbon and δ-carbon of the imidazole ring in compound 
4-15 and 4-16, respectively (Figure 4-2). Second, in compound 4-15, the amine group is 
tri-methylated, but unmethylated in compound 4-16. To understand the substrate selectivity 
of the OvoB reaction, the crystal structure of PLP-bound OvoB at a 2.7 Å resolution was 
obtained (Figure 4-16 and Table 4-2). The final model of OvoB is comprised of residues 
11 to 389, with the 10 residues of the N-terminal disordered. Similar to our recently 
reported ergothioneine C-S lyase Egt2,35 the OvoB central catalytic domain (residues 94-
256) has a classic seven stranded -sheets wrapped within six α-helices, which is a typical 
folding feature in type I PLP-dependent enzymes.58 The N-terminal (residues 11-93) and 
C-terminal domains (residues 257-389) form a lid that shelters the PLP-binding pocket and 
the active site from the solvent (Figure 4-16A). The active site is formed by the catalytic 
and C-terminal domains of one monomer along with the N-terminal and C-terminal 
domains of another monomer (Figure 4-16B). In the active site, an internal aldimine 
between the PLP cofactor and Lys240 was observed. The PLP pyridine ring and the 
aromatic ring of Tyr125 form a π-π stacking interaction (Figure 4-16C). The orientation of 
the PLP’s pyridine ring is anchored by the side chains of Asn176, Asp204, and His207. 
The phosphate group of PLP forms hydrogen bonds with side chain of Tyr66 and the main 
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Figure 4-16 OvoB structural analysis. (A) The overall structure of OvoB. Monomer 2 is shown in gray 
(B) Surface representation of OvoB monomer 1 active site. (C) The active site of OvoB shows the 
interaction network of residues around the PLP cofactor (yellow stick).  
 
4.3.7 Substrate recognition of OvoB 
The effort to obtain the structure of the OvoB•substrate 4-16 binary complex was 
unsuccessful, possibly due to the high turnover number of OvoB. To probe the substrate 
selectivity of OvoB, hercynyl-cysteine sulfoxide 4-15 or 5-histidyl-cysteine sulfoxide 4-16 
was modeled separately into the OvoB structure (Figure 4-17) and then compared with the 
reported structures of ergothioneine C-S lyase Egt2•compound 4-15 binary complex and 
Egt2•compound 4-16 docking model (Figure 4-17).35 In the OvoB•compound 4-16 
docking model, the histidine carboxyl group of the substrate forms a salt bridge with 
Arg364 and a hydrogen bond with Ser352, while the amino moiety forms a hydrogen bond 































is loosely defined through a hydrogen bond with Arg364. The sulfoxide of substrate 4-16 
forms a hydrogen bond with the side chain of Arg364 and this position is further 
strengthened through a hydrogen bond with the main-chain amide of Ala41. The amino 
group of cysteine moiety forms hydrogen bonds with the side chains of Tyr66 and Tyr125, 
and the PLP phosphate group (Figure 4-17A). 
 
 
Figure 4-17 Comparison of OvoB and Egt2 substrate binding. (A) Model of OvoB•substrate 4-16 (blue 
stick) complex. (B) Model of OvoB•sulfoxide 4-15 (blue stick) complex. (C) The reported structure of 
Egt2•substrate 4-15 binary complex (salmon). (D) Model of Egt2•substrate 4-16. 
 
To explain the substrate preference of OvoB for the histidyl-cysteine substrate, 
sulfoxide 4-15 was modelled into the OvoB structure (Figure 4-17B). In this model, the 
cysteine amino group maintains hydrogen bonds with the side chain of Tyr66 and Tyr125, 











































position in 4-15 vs. δ-position in 4-16), most of the interactions predicted for the histidine 
portion in OvoB•sulfoxide 4-16 complex are absent in the OvoB•sulfoxide 4-15 complex. 
The hercynyl-cysteine sulfoxide 4-15 forms only one hydrogen bond with the main-chain 
amide of Ala41 while the interactions between the Arg364 side chain to both the sulfoxide 
and histidine imidazole ring are not observed. In addition, the OvoB substrate modeling 
results were further compared to the structure of ergothioneine C-S lyase Egt2. In our 
reported Egt2•sulfoxide 4-15 binary complex,35 the N-trimethylamine of hercynyl-cysteine 
sulfoxide forms a cation-π interaction with Phe304 (Figure 4-17C) but this interaction is 
not observed in the structure of OvoB (Figure 4-17B). The model of the Egt2•substrate 4-
16 complex was also generated (Figure 4-17D) and similar to the OvoB case, the difference 
in C-S bond location in the substrate dictates its interaction with the enzyme. In this 
scenario, the histidine imidazole ring of sulfoxide 4-15 forms hydrogen bonds with Tyr134 
and His276 which were absent in the model of the Egt2•substrate 4-16 complex. These 
docking results are consistent with the selectivity of OvoB for histidyl-cysteine sulfoxide 
4-16 and Egt2 toward hercynyl-cysteine sulfoxide 4-15, respectively. Notably, OvoB 
exhibits a larger active site (~700 Å calculated by Dogsite)59 relative to that of Egt2 (~600 
Å).35 This might be a contributing factor to the substrate promiscuity of OvoB reaction. 
 
4.3.8 Investigation of the proposed cysteine recycling mechanism in OvoB  
In 2001, Vogt et al used C. fasciculate (an ovothiol-producing strain) cell lysate as 
the catalytic system in the presence of DTT as the reductant, and reported that in addition 




reaction. Notably, the sum of the two thiol species exceeded the amount of sulfoxide used 
in the reaction. A mechanistic model was offered to explain this unexpected result in which 
the sulfur from DTT was used for the formation of L-Cys (Figure 4-18).24 OvoB structural 
characterization indicated that the active site of OvoB is slightly larger than that of Egt2, 
which is consistent with the possibility of accommodating additional molecules in the 
active site for the proposed cysteine regeneration activity. With the establishment of the in 
vitro catalytic system, we repeated the OvoB reaction using [3’-13C]-labeled sulfoxide 4-
16a (structural information in Figure 4-19). 13C-NMR analysis revealed the production of 
only [3-13C]-pyruvate (Figure 4-19), without any detectable [3-13C]-cysteine. This result 
suggested that OvoB does not support cysteine regeneration, and the observed cysteine 
production in Vogt’s report is most likely a result from other enzymes in the cell lysate 
mixture. Intriguingly, PLP alone can also mediate the C-S lyase reaction in the presence of 
DTT to afford thiol 4-17, pyruvate, and ammonia in a 1:1:1 ratio (kcat = 0.31 ± 0.03 s
-1, 
Figure 4-20 and Figure 4-21). However, this activity is nearly two-orders of magnitude 






Figure 4-18 Proposed ovothiol A biosynthesis by Steenkamp et al.24  (A) Proposed cysteine recycling 
mechanism in ovothiol biosynthesis. (B) Proposed mechanism to explain the formation of cysteine when 






Figure 4-19 13C-NMR of the OvoB reaction in the presence of DTT as the reductant (A) 13C NMR 
(125 MHz, D2O) spectrum of [3’-13C]-labelled sulfoxide substrate 4-16a obtained from the OvoA 
reaction: δ 56.66. (B) 13C NMR spectrum (125 MHz, D2O) of the OvoB reaction using 4-16a as the 








Figure 4-20 The C-S lyase reaction using PLP as the catalyst and sulfoxide 4-16 as the substrate. (A) 
Kinetic analysis of PLP reaction using LDH coupled assay similar to that of OvoB kinetic analysis 
monitored at 340 nm. A 1-mL assay mixture at 25 °C contained 2.0 mM sulfoxide 4-16, 0.13 mM 
NADH, 1.0 mM DTT, 22.5 U/mL LDH (40000× of PLP activity in the assay) in 50 mM KPi pH 8.0 
buffer, and various amounts of PLP. The rate was plot against PLP concentrations and fitted using 
GraphPad Prism. PLP exhibited a kcat for the sulfoxide of 0.31 ± 0.03 s-1. (B) 1H-NMR spectrum of the 
PLP reaction shows a peak at δ8.10, which is the chemical shift of the imidazole hydrogen atom of 
purified mercaptohistidine in the presence of DTT. (C) HRMS analysis of PLP reaction mixture 
provided further evidence confirming the presence of mercaptohistidine as the product. Calculated 
value for compound 4-16 as [M-H]- form (negative mode) was m/z 186.0343 and found m/z 186.0349. 
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Figure 4-21 1H NMR spectrum of pyruvate and mercaptohistidine quantification from the PLP 
reaction. Using ethyl viologen as an internal standard, the ratio between 5-mercaptohistidine (7.72 
ppm) and the pyruvate adduct (1.87 ppm) was determined to be ~1:1. Top: expanded region between 
1.0 ppm to 2.5 ppm. Bottom: expanded region between 6.5 ppm to 9.5 ppm 
 
4.3.9 Identifying the N-MTase in ovothiol biosynthesis  
After successful reconstitution of the OvoB activity in vitro, the identity of the π-
N-MTase in ovothiol A biosynthesis remains to be identified. Our bioinformatic analysis 
of the E. tasmaniensis genome identified 52 MTases, however, none were functionally 
related to OvoA based on String database analysis. Interestingly, pfam analysis revealed 
that OvoA has three domains: the iron-binding DinB_2, formylglycine (FGE)-sulfatase 
domain for sulfoxidation activity, and the uncharacterized MTase domain.34 Recently, 
Seebeck and co-workers suggested the possibility that the OvoA MTase domain is 




ergothioneine biosynthesis, the fungal N. crassa Egt1 gene also encodes three domains, a 
DinB_2, FGE-sulfatase domains for C-S bond formation, and a MTase domain. Similarly, 
the Egt1 gene was proposed as a bi-functional enzyme, responsible for both sulfoxidation 
and methylation in ergothioneine biosynthesis.61 However, the proposed methyltransferase 
activity in Egt1 was not observed in the in vitro characterization of Egt1.34 To test whether 
OvoA functions as a bi-functional enzyme, OvoA methylation activity using thiol 4-17 and 
S-adenosylmethionine (SAM) as the substrates was examined. Interestingly, OvoA indeed 
methylates mercaptohistidine 4-17 to afford ovothiol A 4-2. The kinetic parameters of 
OvoA MTase activity were measured using a coupled assay commercially available from 
Promega (MTaseGlo, Promega). In this coupled assay, the side-product S-
adenosylhomocysteine (SAH) is converted to ATP through a series of enzymatic 
transformations (Figure 4-3).54 The amount of ATP is then quantified by luminescence 
intensity generated from the ATP-involved luciferase catalysis. Through this assay, OvoA 
kinetic parameters measured were: a kcat of 3.05 ± 0.17 min
-1 and a Km of 7.81 ± 1.18 M 
for SAM at a saturating concentration of compound 4-17 and a kcat of 3.37 ± 0.19 min
-1 
with a Km of 7.03 ± 1.15 M for compound 4-17  at a saturating SAM concentration (Figure 






Figure 4-22 Kinetic parameter measurements of the OvoA MTase activity under a saturated SAM 
concentration (50 µM) were determined using MTase-Glo. A 20-µL reaction mixture contained 10 nM 
OvoA, 30 µM SAM, 1 mM EDTA, 3 mM MgCl2, 1 mM DTT, 0.1 mg/mL BSA, 50 mM NaCl, and 
varying concentration of 5-mercaptohistidine (2.5-30 µM) in 20 mM Tris-HCl, pH 8.0 buffer, was set 
up using 96-well plates at 25°C in duplicates. The reaction was quenched with TFA at 5, 10, and 20 
min. Then, the MTase-Glo reagents were added to convert SAH to ATP. After adding the MTase-Glo 
solution, luminescence was measured. Standard curve was generated using known concentrations of 
SAH. (A) The amount of products produced at various time points were then plotted against time to 
derive the rate of OvoA MTase under different conditions. The rates at different substrate 
concentrations were then plotted to derive the Km and kcat. (B) Production rate was plotted against [5-
mercaptohistidine]. Under a saturated concentration of SAM (50 µM), OvoA exhibited kcat of 3.4 ± 0.2 
min-1 with Km of 7.0 ± 1.2 µM. 
  
 
Figure 4-23 Kinetic parameters of the OvoA MTase activity under a saturated 5-mercaptohistidine 
concentration (50 µM) were determined using the MTase-Glo assay. A 20-µL reaction containing 10 
nM OvoA, 30 µM 5-Mercaptohistidine, 1 mM EDTA, 3 mM MgCl2, 1 mM DTT, 0.1 mg/mL BSA, 50 
mM NaCl, and varying concentration of SAM (1.25-30 µM) in 20 mM Tris-HCl, pH 8.0, was set up 
using well-plate at 25°C in duplicates. The reaction was quenched with TFA at 5, 10, and 20 min. Then, 
the MTase-Glo reagents were added to convert SAH to ATP. After adding the MTase-Glo detection 
solution, luminescence was measured to calculate the corresponding ATP concentration. Standard 
curve was generated using known concentrations of SAH. (A) The product produced were then plotted 
against time to derive the rate of OvoA MTase under different conditions. The rates at different 
substrate concentrations were then re-plotted to derive the Km and kcat. (B) Production rate was plotted 
against [SAM]. Under saturating 5-mercaptohistidine concentration (50 µM), OvoA exhibited a kcat of 
3.1 ± 0.2 min-1 with a Km of 7.8 ± 1.2 µM.  














































































































To examine the regioselectivity of the methylation reaction, the product was 
isolated and characterized (Figure 4-24). Similar to mercaptohistidine 4-17, ovothiol A 4-
2 was isolated in the disulfide form. Upon the addition of DTT, the reduced form of 
ovothiol A was obtained (Figure 4-25). The methylation of ovothiol A at the π-N position 
instead of the τ-N position was confirmed by 2D COSY NMR spectroscopy (Figure 4-26). 
The identification of the methyltransferase activity in OvoA completes the in vitro 
reconstitution of ovothiol A biosynthesis (Figure 4-27). In this pathway, OvoA mediates 
the oxidative coupling of the C-S bond formation reaction between L-Cys and L-His to 
afford histidyl-cysteine sulfoxide. Subsequent C-S bond cleavage mediated by a PLP-
dependent enzyme OvoB results in mercaptohistidine 4-17 as a product. Then, OvoA 
MTase domain catalyzes the methylation of π-N imidazole ring resulting in ovothiol A as 
a final product. The reconstitution of ovothiol A allows further production of this 





Figure 4-24  Characterizations of ovothiol A disulfide isolated from OvoA methyltransferase reaction 
mixture. (A) 1H NMR spectrum of ovothiol A dimer 8a (500 MHz, D2O): δ 2.48 (dd, J = 7.2, 14.7 Hz, 
2H), δ 2.57 (dd, J = 5.7, 14.9 Hz, 2H), δ 3.48 (s, 6H), δ 3.63 (dd, J = 5.4, 8.9 Hz, 2H), δ 7.75 (s, 2H). (B) 
HRMS spectrum of ovothiol A dimer. Calculated value for compound 8a as [M+H]+ form (positive 
mode) was m/z 401.1060, and found m/z 401.1077. 
 





















































Figure 4-25 Characterizations of ovothiol A isolated from OvoA MTase reaction in the presence of 
DTT. (A) 1H NMR spectrum of ovothiol A (500 MHz, D2O): δ 2.49 (dd, J = 7.6, 13.7 Hz, 1H), δ 2.58 (dd, 
J = 4.7, 13.9 Hz, 1H), δ 3.33 (s, 3H), δ 3.92 (dd, J = 4.6, 8.9 Hz, 1H), δ 8.25 (s, 1H). (B) HRMS spectrum 
of ovothiol A. Calculated value for compound as [M+H]+ form (positive mode) was m/z 202.0645, and 
found m/z 202.0652. 
 






























Figure 4-26 COSY-NMR Spectrum of the ovothiol A dimer shows the correlation between H7 and H3 
plus H7 and H6 pairs. This spectrum supported the structural assignment with a methyl group at the 







Figure 4-27 The reconstituted ovothiol A biosynthesis. 
 
4.3.10 Biological relevance of N-methylation reactions 
This OvoA-catalyzed N-methylation reaction is among the very few reported cases 
of a histidine’s side-chain N-methylation. The methylation reaction can occur on either the 
τ-N or π-N position of histidine imidazole ring. An example of a τ-N reaction is the 
methylation of histamine 4-21 mediated by histamine N-methyltransferase (HNMT, Figure 
4-28). Histamine is a neurotransmitter for the brain, which is metabolized to N-π-methyl-
histamine 4-22 by HNMT. HNMT is expressed in the central nervous system and its 
enzymatic activity has been linked to pathological aspects of Parkinson’s disease. Recent 
studies indicated that Hnmt-deficient mice exhibit high levels of aggressive behavior and 
dysregulation of the sleep-wake cycle.62 This result demonstrated the critical role of HNMT 
in regulating histamine levels in the brain, which may in turn control the sleep cycle and 
aggression in the animal model. Despite the important physiological functions, much less 




In addition to OvoA, another reported case of the π-N-methylation reaction is 
carnosine N-methyltransferase 1 (CARNMT1). In this reaction, carnosine 4-23 is 
converted to -alanyl-N-π-methyl-L-histidine (anserine 4-24, Figure 4-28). Thus far, 
CARNMT1 is the only reported structure on such types of enzymes.63 Structural studies 
revealed the substrate recognition of carnosine, in which the π-N not the τ-N is solvent-
exposed and deprotonated for the methylation reaction. The lack of structural information 
on other N-MTases make the study on the molecular basis underlying the regio-specific 
catalysis and substrate recognition very challenging. Hence, the identification of OvoA’s 
N-methylation activity adds another example for this small class of methyltransferases, 
which might shed some light on this type of chemical transformation. 
 
 






4.4 Conclusions and Future Directions  
In this Chapter, using a bioinformatic analysis, OvoB was identified to be 
functionally related to the OvoA sulfoxide synthase in the biosynthesis of ovothiol A. 
Subsequent biochemical studies indicated that OvoB is the ovothiol C-S lyase, not the 
ergothioneine as previously proposed. The structural information provides insight into the 
substrate specificity of OvoB showing extensive interactions between histidyl-cysteine and 
the enzyme. These interactions are not present when the hercynyl-cysteine sulfoxide was 
modeled into the structure of OvoB. Mechanistic studies of OvoB were performed 
revealing the involvement of sulfenic acid intermediate in this reaction. Additionally, 
OvoA was identified as a bi-functional enzyme catalyzing the oxidative C-S bond 
formation resulting in sulfoxide and methylation of mercaptohistidine. The enzymes 
responsible for the remaining steps in ovothiol A biosynthesis were identified and 
biochemically characterized. These results complete the reconstitution of ovothiol A in 
vitro (Figure 4-27). Due to the potential therapeutic use of ovothiol, this work might serve 
as the basis for further metabolic engineering for large-scale production of ovothiol A. 
Although, the pathway of ovothiol A was reconstituted in vitro, the enzyme 
responsible for the methylation reaction to afford ovothiol B and C is not yet known. To 
search for the enzyme mediates the mono- and di-methylation at the amino group, 
bioinformatic analysis is an attractive approach. Similar to the identification of OvoB, the 
genome of ovothiol producer, E. tasmaniensis, can be analyzed to identify 
methyltransferases with conserved motif for amino group methylation. Thus far, many 




known about histidine methylations. To narrow down the candidate, the String database 
can be used to analyze the  gene co-occurrence and functional association information of 
the methyltransferase candidates.44 Additionally, the methyltransferase candidates from 
genome of E. tasmaniensis can be compared with methyltransferases in other ovothiol-
producing organisms such as sea urchin, asteroid, octopus, and marine diatoms. This 
comparison might reveal the gene encoding amino group methyltransferases.  The 
bioinformatic prediction can then be verified using genetic studies such as gene knockout 
and the cluster upregulation. Through this approach, the biosynthetic intermediate can be 
identified, which may provide information regarding the gene function. In addition to 
genetic studies, biochemical characterization of the methyltransferase candidates can be 
performed to verify its activity in vitro. This will allow the structural characterization of 
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5.1 Introduction 
5.1.1 Oxidative C-S bond formation reactions in the ergothioneine and ovothiol 
pathways 
Ergothioneine 5-1 and ovothiols (5-9 to 5-11) are thiolhistidines with a sulfur 
substitution at the - or -carbon of the histidine imidazole ring, respectively. The  sulfur 
incorporation strategy in the pathways of ergothioneine and ovothiol differ from other 
reported pathways discussed in Chapter 1.1-8 Two aerobic ergothioneine biosyntheses in 
mycobacteria and the fungi have been reported (Figure 5-1A). In these pathways, the trans-
sulfuration is mediated by non-heme iron enzyme-catalyzed oxidative C-S bond formation 
(EgtB/Egt1)9,10 and PLP-lyase catalyzed C-S cleavage (EgtE/Egt2).11 These two reactions 
were examined in Chapter 2 and Chapter 3. In Chapter 2, biochemical characterization 
revealed the broad substrate specificity of EgtBCth, exhibiting both the EgtB- and Egt1-type 
of activity. Using Rosetta Enzyme Design in combination with structural analysis, the 
activity of EgtBCth was engineered toward the Egt1-type of activity for further development 
of ergothioneine production. In Chapter 3, the biochemical and structural studies on the 
fungal C-S lyase Egt2 illuminated the involvement of sulfenic acid in this reaction. The 




Similar to ergothioneine biosynthesis, the ovothiol pathway also involves two 
critical steps: the oxidative coupling C-S bond formation mediated by a non-heme iron 
enzyme, OvoA, and a reductive C-S bond cleavage mediated by a PLP-dependent enzyme, 
OvoB (Figure 5-1B).12  In Chapter 4, the ovothiol A biosynthetic pathway was 
reconstituted in vitro revealing OvoA as a bi-functional enzyme, which catalyzes both the 
C-S bond formation and the methylation reactions. The methylation activity is not observed 
in ergothioneine sulfoxide synthases, Egt1, which also contains methyltransferase domain. 
Additionally, the OvoA enzyme also differs from Egt1- and EgtB-catalysis in terms of the 
substrate selectivity and the regioselectivity of C-S bond formation (Figure 5-1).13,14 
Specifically, EgtB mediates the oxidative coupling between hercynine 5-2 and -Glu-Cys, 
while Egt1 uses hercynine 5-2 and L-Cys as the substrates.  For these two reactions, the C-
S bond is formed at the -carbon of histidine imidazole ring. On the contrary, OvoA 
catalyzes the oxidative coupling between L-His 5-1 and L-Cys while the resulting C-S bond 





Figure 5-1 Biosyntheses of ergothioneine and ovothiol. (A) The anaerobic ergothioneine biosynthetic 
pathways in bacteria and fungai. (B) The proposed ovothiol biosynthetic pathway. 
 
5.1.2 Cysteine dioxygenase activity in OvoA-catalysis 
In addition to the differences in substrate selectivity and regioselectivity, in vitro 
characterization of wild-type OvoA also revealed a cysteine oxidation activity, which 
affords cysteine sulfinic acid 5-7 as a side-product in this reaction ( 10% of the product 
mixture, Figure 5-1). This was the first discovery of such activity in enzymes other than 
cysteine dioxygenase (CDO).14 Notably, the production of cysteine sulfinic acid is 




oxidative coupling product 5-6 and cysteine sulfinic acid 5-7 might be two pathways 
branching out from a common intermediate in the OvoA reaction.  
A similar mechanistic model has also been proposed for EgtB-catalysis in 
ergothioneine biosynthesis.10,15 In the reported structure, Mycobacterium thermoresistible 
EgtB (EgtBMth) processes an N-terminal DinB-like four-helix bundle (residues 7 – 150) and 
a C-terminal C-type lectin fold (Figure 5-2A).10 The enzyme’s active site is buried in a 15-
Å deep tunnel, and the catalytic iron is located at the bottom of the tunnel. The iron center 
is coordinated by three histidine residues (His51, His134 and His138) and three water 
ligands. By replacing the FeII center with MnII, the structure of EgtB•dimethylhistidine•γ-
Glu-Cys tertiary complex was obtained (Figure 5-2B). In this structure, the 
dimethylhistidine (DMH) substrate analog coordinates to the MnII center using its 
imidazole sidechain while γ-Glu-Cys coordinates to the metallocenter using its side-chain 
sulfur.  The sixth ligand is a water molecule, which occupies a site most likely for oxygen 
binding and activation. Additionally, the water ligand is hydrogen-bonded to the hydroxyl 
group of an active site Tyr377. Mutation of EgtB Y377 to F377 suppressed the oxidative 
coupling reaction, but increased cysteine dioxygenase activity (kcat of 1.2 s
-1, comparable 
to that of the native CDO activity, kcat of 1.8 s
-1).6,15 This result suggested that the second 





Figure 5-2 M. thermoresistible EgtB structure. (A) Overall EgtB topology shows the N-terminal with 
the DinB-like helix bundle (in blue) with the C-terminal containing the lectin fold (in salmon/orange). 
EgtB contains two-stranded β-sheet region (shown in cyan). (B) The EgtB tertiary complex with DMH 
(shown in green stick) and γ-Glu-Cys (γGC, shown in magenta stick) as the ligands of the Mn2+ center 
(shown in purple sphere). Notably, the water ligand (shown in red sphere) hydrogen bonds with an 
active site Tyr377. 
 
5.1.3 Kinetic isotope effect on the C-S bond formation reaction in EgtB-catalysis 
Subsequent steady-state kinetic characterization revealed that EgtBY377F exhibits a 
kcat and Km for hercynine and γ-Glu-Cys comparable to those of the wild-type enzyme. 
Similar to the case of wild-type OvoA-catalysis, the γ-Glu-Cys dioxygenase activity in 
EgtBY377F depends on the presence of hercynine 5-2. Without hercynine, γ-Glu-Cys is 
oxidized to γ-Glu-cystine at a rate orders of magnitude lower than the γ-Glu-Cys sulfinic 
acid or sulfoxide formation rates. This result suggests that the cysteine sulfinic acid and 
sulfoxide formation are possibly two pathways branching out from a common intermediate 
in both EgtB and OvoA catalysis.14,15 Additionally, the kinetic isotope effects (KIE) was 
measured for wild-type EgtB and the EgtBY377F variant.
15 Using [2-2H]-hercynine 5-2 as 





unity. This result suggested that the C2-H bond cleavage is not the rate-limiting step in 
EgtB-catalysis. Subsequently, the solvent KIE of wild-type EgtB and EgtBY377F were 
measured. The sulfoxide synthase activity of wild-type EgtB and the γ-Glu-Cys 
dioxygenase activity of EgtBY377F resulted in a similar solvent KIE (1.2 ± 0.2 and 0.9 ± 0.1, 
respectively). For the sulfoxide synthase activity of EgtBY377F, the solvent KIE was 
reported as 1.9 ± 0.1 with catalytic efficiency four orders of magnitude lower than that of 
the wild-type.15 The increased solvent KIE suggested that the substitution of Tyr377 solely 
alters the sulfoxide synthase activity, and not the γ-Glu-Cys dioxygenase activity. Due to 
this reason, one or multiple hydrogens or protons could be transferred in the rate-limiting 
step of the EgtB-catalysis. The detailed mechanistic implication of this result will be 
discussed in this Chapter.  
The chemistries involved in the ergothioneine and ovothiol biosynthetic pathways 
are very similar (Figure 5-1) despite their differences in substrate selectivity and product 
regioselectivity between EgtB/Egt1 and OvoA.9,13,14,16,17 In OvoA-catalysis, the cysteine 
dioxygenase activity has been reported in addition to the sulfoxide synthase activity.14 
Although wild-type EgtB does not exhibit γ-Glu-Cys dioxygenase activity, the dominant 
reaction in the EgtBY377F mutant is γ-Glu-Cys oxidation. The discovery of sulfur oxidation 
in EgtB and OvoA adds another level of complexity into their mechanistic investigations. 
Both EgtB and OvoA-catalysis are four-electron oxidations, in which molecular oxygen is 
fully reduced to water. In this process, the oxidative C-S bond formation and the sulfur 
oxidation each provides two electrons. However, it has yet to be determined whether C-S 





Figure 5-3 Tyrosine-cysteine cross-linking in cysteine dioxygenase and two unnatural tyrosines used 
in this study (MtTyr and MeOTyr). 
 
Based on the biochemical and structural characterization of EgtB, the active site 
Tyr377 was proposed to be critical for the sulfoxide synthase activity.10,15 However, owing 
to the lack of an OvoA crystal structure, the OvoA homology model was generated, 
suggesting that OvoA Tyr417 is the counterpart of EgtB. In this chapter, the mechanistic 
studies of OvoA-catalysis were performed by replacing Tyr417 with 2-amino-3-(4-
hydroxy-3-(methylthio) phenyl) propanoic acid (MtTyr, 5-12, Figure 5-3) through an 
amber-suppressor mediated unnatural amino acid incorporation method. The incorporation 
of MtTyr at Tyr417 is a mimicry of the Cys-Tyr crosslink observed in CDO’s active site 
(Figure 5-3). Through this unnatural tyrosine incorporation, the two OvoA activities can 
be modulated: the oxidative coupling and the cysteine sulfinic acid formation. However, 
since natural tyrosine and MtTyr 5-12 differ in both their pKa values and reduction 
potentials,18-21 the role of Tyr417 as a Lewis acid/base16,22 or as part of redox chemistries 
remains obscure.23 To address this issue, another tyrosine analog, 3-methoxytyrosine 
(MeOTyr, 5-13) was used (Figure 5-3). MeOTyr has almost the same pKa with much lower 
reduction potential (by almost 200 mV) compared to that of tyrosine.24 In addition, the 
presence of two competing pathways in OvoA-catalysis (Figure 5-1) enabled the use of 




the isotope effect at one of the branching steps25-27 and substrate deuterium KIE on V/K 
(DV/K) using intermolecular competition.28-30 When  MeOTyr-OvoA is used as the enzyme, 
we altered the rate-limiting step of the OvoA reaction, which allows us to successfully 
detect an inverse deuterium KIE when deuterium-labeled histidine was used as the 
substrate. The analysis of this result in conjunction with mechanistic models proposed from 
computational studies suggested that Tyr417 plays a redox role in OvoA-catalysis, and the 





5.2 Material and Methods  
5.2.1 General materials and equipment 
All reagents and equipment used are similar to those indicated in Chapter 2 unless 
otherwise specified. L-Cysteine (3-13C, 99% purity) and [U-2H5]-His (ring-2,4-D2; α, β, β-
D3, 98% purity) were purchased from Cambridge Isotope Laboratories, Inc. The OvoA 
protein sequencing was conducted on a QExactive Plus Hybrid Quadrupole-Orbitrap mass 
spectrometer (Thermo Scientific).   
5.2.2 OvoA structural modeling   
Protein sequence alignment of E. tasmaniensis OvoA (OvoA_erwinia, GenBank 
accession number WP_012439783) with EgtB from Mycobacterium smegmatis 
(EgtB_smegmatis, GenBank accession number WP_011731158) and Mycobacterium 
thermoresistible (EgtB_thermo GenBank accession number WP_050811957.1) were 
performed using T-Coffee.31 The sequence alignment results show high sequencing 
similarity and the conserved active site tyrosine. OvoA structure prediction was carried out 
using I-TASSER32 and the predicted OvoA structure was aligned with the EgtB structure 
(PDB: 4X8B). The structural alignment results show an overall similarity between the 
OvoA and EgtB active sites with the conserved tyrosine in the active site in close proximity 




5.2.3 OvoA wild-type and OvoAY417F overexpression and purification 
OvoA (WP_012439783) was codon-optimized for Escherichia coli overexpression 
by Genscript. The gene was then subcloned into pASK-IBA-5plus expression vector using 
the XbaI and XhoI restriction site. The plasmid was then transformed into BL21(DE3) 
competent cell and one colony was inoculated in LB media supplemented with 100 µg/mL 
of ampicillin at 37 C overnight. Then, 10 mL of this overnight culture was inoculated to 
1 L LB medium supplemented with 100 µg/mL of ampicillin and 0.1 mM ferrous 
ammonium sulfate. The cells were culture at 37 C until OD600 reached 0.8, and protein 
overexpression was induced with the addition of anhydrotetracycline (AHT) to 250 ng/L 
final concentration. Cells were cultured for 14 hr at 25 C before harvesting by 
centrifugation. A typical yield for 1 L of cell culture is approximately 4 g of wet cells.  
The protein was purified as reported previously.14 In brief, 5 g of cell were 
resuspended in 80 mL of anaerobic buffer (100 mM Tris-HCl, 500 mM NaCl, pH 8.0) in 
an anaerobic Coy chamber. Lysozyme was then added into the cell suspension to 1 mg/mL 
final concentration. The cell mixture was incubated on ice for 30 min. The cells were 
disrupted by sonication and the cell debris was removed by centrifugation at 20,000 g for 
30 mins. Then the supernatant was mixed with the Strep-Tactin resin (20 mL) and incubate 
on ice for 40 min with gentle agitation. After incubation, the column was washed with 80 
mL lysis buffer. The protein was eluted with 100 mM Tris-HCl, 100 mM NaCl and 2.5 
mM desthiobiotin, pH 8.0. The protein was then concentrated anaerobically by 




A Q5 site-directed mutagenesis kit was purchased from New England Biolabs. Site-
directed mutagenesis based on the OvoA wild-type was carried out to generate OvoAY417F. 
The OvoAY417F protein was overexpressed and prepared with a same protocol as OvoA 
wild-type. 
5.2.4 Preparation of 2-amino-3-(4-hydroxy-3-(methylthio) phenyl) propanoic acid 
(MtTyr) 
This experiment was carried out in collaboration with a former graduate student, 
Dr. Li Chen, in Prof. Pinghua Liu’s lab. One liter of the tyrosine phenol lyase (TPL) F36L 
enzymatic reaction mixture contained 10 mM 2-(methylthio) phenol, 30 mM ammonium 
acetate, 60 mM sodium pyruvate, 5 mM β-mercaptoethanol, 40 μM PLP, 50 mM KPi buffer 
pH 8.0 and the TPLF36L mutant enzyme (30 μM final concentration). The reaction was 
incubated in the dark with stirring at 25℃ for 24 hr. The reaction mixture was acidified to 
pH 3.0 with TFA and the precipitated protein was removed by filtering the mixture through 
a 3-cm thick celite pad. The filtrate was extracted by 500 mL of ethyl acetate. The aqueous 
layer was loaded onto a 100 mL Dowex 50WX8-100 cation exchange column (Sigma-
Aldrich). After loading, the column was washed by 500 mL of 30% ACN. The 2-amino-3-
(4-hydroxy-3-(methylthio) phenyl) propanoic acid was then eluted by 10 % NH4OH. 
Fractions with positive ninhydrin tests were combined. The target compound MtTyr was 
crystallized when the elution was neutralized. The crystals were filtered and lyophilized to 






Figure 5-4 Biosynthesis of MtTyr, catalyzed by TPLF36L.4 
MtTyr: 1H NMR spectrum (500 MHz, D2O) δ 2.17 (s, 3H), 2.51 (dd, J = 13.8, 7.3 
Hz, 1H), 2.68 (dd, J = 13.8, 5.3 Hz, 1H), 3.23 (dd, J = 7.3, 5.3 Hz, 1H), 6.33 (d, J = 8.1 Hz, 
1H), 6.65 (dd, J = 8.1, 2.2 Hz, 1H), 6.72 (d, J = 2.3 Hz, 1H).  
MtTyr: 13C NMR spectrum (500 MHz, D2O) 13C NMR (500 MHz, D2O) δ 13.72, 
39.93, 57.44, 117.12, 124.05, 126.10, 126.30, 127.33, 162.03, 182.74. 
5.2.5 Enzymatic synthesis and purification of 2-amino-3-(4-hydroxy-3-(methoxy) phenyl) 
propanoic acid (MeOTyr)  
This experiment was performed by a visiting scholar, Dr. Changming Zhao, at Prof. 
Pinghua Liu’s lab. The MeOTyr compound was synthesized by TPLF36L.
18,24 One liter of 
the reaction system contained 10.0 mM guaiacol, 30 mM ammonium acetate, 60 mM 
sodium pyruvate, 5 mM -mercaptoethanol, 25.0 M PLP, 3 M TPLF36L in 50 mM KPi 
buffer pH 8.0. The reaction was incubated while stirring under the dark at 25 C for 12 hr. 
Then, additional portion of guaiacol and TPLF36L were added to 10 mM and 3 M, 
respectively. The reaction was then incubated for an additional 12 hr. The reaction was 
monitored by 1H NMR until completion. Hydrochloric acid was used to quench the reaction 
by acidifying the mixture to pH 3.0 and the precipitates were eliminated by filtering the 




acetate as that of the aqueous layer, which was collected. Then, the aqueous layer was 
loaded onto a column containing 100 mL of Dowex 50WX8-100 cation exchange resin (H+ 
form). The column was washed by 500 mL of 30% ACN followed by 2.0 L of water. Then, 
MeOTyr was eluted by 6.0 % NH4OH. The fractions were tested by ninhydrin thin-layer 
chromatography and the targeted elutions were combined. Then, the solvent was removed 
by lyophilization and the final products were stored at -20 C. 
MeOTyr: 1H NMR spectrum (500 MHz, D2O) δ 2.60 (dd, J = 14.19, 7.11 Hz, 1 H), 
δ 2.77 (dd, J = 13.89, 7.18 Hz, 1 H), δ 3.37 (t, J = 7.01 Hz, 1 H), δ 3.61 (s, 3 H), δ 6.52 (dd, 
J = 18.81, 10.01 Hz, 2 H), δ 6.63 (s, 1 H).  
MeOTyr: 13C NMR spectrum (500 MHz, D2O) δ 39.11, 55.84, 57.08, 113.55, 
116.73, 122.43, 126.29, 148.85, 148.90, 180.42. HRMS (ESI) calculated value for MeOTyr 
as [M-H]- was m/z 210.0772 and found m/z 210.0771. 
5.2.6 Production of the OvoAY417MtTyr and OvoAY417MeOTyr variants using the amber codon 
suppression method  
This experiment was conducted in collaboration with a former graduate student Dr. 
Li Chen and visiting scholar Dr. Changming Zhao in Prof. Pinghua Liu’s lab. Site-directed 
mutagenesis based on the wild-type OvoA construct was carried out to create 
OvoAY417MtTyr following the suggested protocol (New England Biolabs). For the 
OvoAY417MtTyr construct, the Tyr417 codon was mutated to TAG (OvoAY417TAG). pBK-
MtTyrRS was reported recently.18 To overexpress OvoAY417MtTyr, a plasmid containing 
OvoAY417TAG was co-transformed with pBK-MtTyrRS into E. coli BL21(DE3). A single 




and 12.5 μg/mL chloramphenicol and incubated overnight at 37℃. 10 mL of the seed cells 
were transferred into 1 L of LB media supplemented with 0.1 mM ferrous ammonium 
sulfate, 100 μg/mL ampicillin and 12.5 μg/mL chloramphenicol. When the OD600 reached 
1.2, MtTyr was added into the culture medium at a final concentration of 1 mM. At the 
same time, 0.5 μg/mL anhydrotetracycline (AHT) and 0.02% L-arabinose were added to 
induce OvoAY417MtTyr and pBK-MtTyrRS, respectively. The cells were incubated at 25℃ 
for an additional 14 hr before harvesting by centrifugation.  
The OvoAY417MtTyr variant protein was then purified anaerobically using the same 
protocols as for wild-type OvoA with slight modifications.14 Cells (8 g) were resuspended 
in 80 mL of anaerobic buffer (100 mM Tris-HCl, 500 mM NaCl and 10% glycerol, pH 8.0) 
in an anaerobic coy chamber. Lysozyme (0.2 mg/mL) was then added into the cell 
suspension. The cell mixture was incubated at 2 5℃ for 20 min and on ice for 10 min with 
gentle agitation. The cells were disrupted by sonication and the cell debris was removed 
by centrifugation at 20,000 g for 30 mins. Then the supernatant was mixed with the Strep-
Tactin resin (20 mL) and incubate on ice for 40 min with gentle agitation. After incubation, 
the supernatant was drained out and the column was washed with 80 mL anaerobic buffer. 
The OvoAY417MtTyr protein was eluted with the elution buffer (100 mM Tris-HCl, 100 mM 
NaCl and 2.5 mM desthiobiotin, pH 8.0).  
For the OvoA protein using for reaction in D2O, the elution buffer was prepared in 
D2O (100 mM Tris-HCl, 100 mM NaCl and 2.5 mM desthiobiotin, pH 7.6). The protein 
was then concentrated anaerobically by ultrafiltration to approximately 40 μM. After that, 




The OvoAY417MeoTyr mutant was overexpressed and purified following the same 
protocol as OvoAY417MtTyr. A Methanococcus jannaschii tyrosyl amber suppressor tRNA 
(MjtRNATyrCUA)/tyrosyl-tRNA synthetase (MjTyrRS) pair that specifically recognizes 
MeOTyr was developed.33 To overexpress OvoAY417MeoTyr, a plasmid harboring 
OvoAY417TAG was co-transformed into BL21(DE3) with pEVOL-MeOTyr, which harbors 
the MjtRNATyrCUA/MjTyrRS pair. OvoAY417MeoTyr was over-expressed following the same 
method as OvoAY417MtTyr. 
5.2.7 OvoAY417MtTyr and OvoAY417MeOTyr tandem mass spectrometry analysis 
This experiment was conducted in collaboration with a visiting scholar Dr. 
Changming Zhao at Prof. Pinghua Liu’s lab. To confirm the incorporation of MtTyr at 
Tyr417 in the OvoA mutant protein, 30 μg of the OvoAY417MtTyr protein was collected from 
the desired band from the SDS-PAGE analysis. Then, the protein was digested by Trypsin 
Gold® (Promega) following the recommended protocol. The tryptic digested peptides were 
then sequenced using the QExactive Plus Hybrid Quadrupole-Orbitrap mass spectrometer 
(Thermo Scientific). The exact mass of the peptide containing the unnatural amino acid 
MtTyr was extracted from the total ion current with a mass tolerance of 2.0 ppm. The 
MS/MS data was analyzed by the XcaliburTM software. A similar approach was performed 
to characterize the incorporation of MeOTyr at Tyr417 in the OvoA mutant protein. 
5.2.8 Iron content determination of OvoA variants using atomic emission spectroscopy  
The iron content of OvoAY417F, OvoAY417MtTyr and OvoAY417MeoTyr was determined 




OvoAY417MeoTyr were diluted using 1% HNO3 to a 1.5 mg/mL final concentration to release 
the iron into solution. The precipitated protein was removed via centrifugation at 10,000 
rpm for 10 min. The samples were prepared in duplicates. The iron standard solutions were 
prepared using Iron, Reference Standard Solution (Fisher scientific). These solutions were 
then used to generate a standard curve by measuring the intensity at 259.940 nm. The 
average intensity for OvoAY417F was 9634 ± 283 and the iron concentration of the sample 
derived from the standard curve was 0.93 ± 0.05 ppm. The iron content of the purified 
OvoAY417F was determined to be 0.95 ± 0.03 equivalent. The average intensity for 
OvoAY417MtTyr was 9720 ± 102 and the iron concentration of the sample derived from the 
standard curve was 0.96 ± 0.05 ppm. The iron content of the purified OvoAY417MtTyr was 
determined to be 0.94 ± 0.04 equivalent. Similarly, the average intensity of OvoAY417MeoTyr 
was 11745 ± 745 and the iron concentration of the sample derived from the standard curve 
was 1.16 ± 0.06 ppm. The purified OvoAY417MeoTyr protein had 1.14 ± 0.06 equivalent. 
5.2.9 Steady-state kinetic analysis of OvoA variants  
This study was performed in collaboration with a former graduate student Dr. Li 
Chen and visiting scholar Dr. Changming Zhao in Prof. Pinghua Liu’s lab. The kinetic 
parameters of OvoAY417F, OvoAY417MtTyr and OvoAY417MeoTyr were determined following 
the reported procedure by measuring the oxygen consumed with the NeoFox oxygen 
electrode (Ocean Optics).14 For OvoAY417F, the reaction contained 0.75 µM enzyme, 2 mM 
L-His (or 2 mM L-Cys),1 mM DTT, 0.2 mM sodium ascorbate in 50 mM air-saturated KPi 




reaction was repeated in triplicates. The data was fitted to a Michaelis-Menten equation 
using GraphPad Prism.  
Similar assays were performed for the L-Cys concentration dependence kinetic 
analysis of OvoAY417MtTyr. A 1-mL assay mixtures contained 1 μM OvoAY417MtTyr, 2.0 mM 
L-His, 1 mM DTT, 0.2 mM sodium ascorbate in 50 mM air-saturated KPi buffer, pH 8.0 
and various amounts of L-Cys (0.1 – 6.0 mM). For the L-His concentration dependence, 
the reaction mixture was the same as that of L-Cys concentration dependence, but L-Cys 
concentration was kept constant at 2.0 mM and L-His concentration was varied (0.1 – 6.0 
mM).  
For characterization of OvoAY417MeoTyr, a 1-mL reaction containing 2 mM L-His, 1 
mM sodium ascorbate, 1 mM DTT, varying L-Cys concentration (0.05 – 6 mM), and 0.85 
μM of OvoAY417MeoTyr in 50 mM KPi pH 8.0 buffer was set up 25 C. For L-His 
concentration dependence, a similar reaction set up was performed, except that the L-Cys 
concentration was kept constant at 2 mM and the L-His concentration was varied between 
0.05 – 6 mM.   
5.2.10 Measurement of the substrate’s deuterium KIE using wild-type OvoA 
In collaboration with a former graduate student Dr. Li Chen in Prof. Pinghua Liu’s 
lab, the KIE measurements was performed, in which three conditions were set up: 
Reaction 1: The OvoA reaction using unlabeled L-His and unlabeled L-Cys. The 
reaction mixture contained 20 mM air-saturated KPi buffer in H2O at pH 8.0, 10 mM L-




OvoA. The reaction was run aerobically at 25 ℃ for 2 hr. After the reaction was completed, 
the protein was removed by ultrafiltration. 
Reaction 2: The OvoA reaction using unlabeled L-His and [β-13C]-Cys. The 
reaction mixture contained 20 mM air-saturated KPi buffer in H2O at pH 8.0, 10 mM L-
His, 10 mM [β-13C]-Cys, 3.0 mM DTT, 1.0 mM sodium ascorbate, and 8 μM iron-
reconstituted OvoA. The reaction was run aerobically at 25 ℃ for 2 hr. After the reaction 
was completed, the protein was removed by ultrafiltration. 
Reaction 3: The OvoA reaction using [U-2H5]-His and [β-
13C]-Cys. The reaction 
mixture contained 20 mM air saturated KPi H2O buffer at pH 8.0, 10 mM [U-
2H5]-His, 10 
mM [β-13C]-Cys, 3.0 mM DTT, 1.0 mM sodium ascorbate, and 8 μM iron-reconstituted 
OvoA. The reaction was run aerobically at 25 ℃ for 2 hr. After the reaction was completed, 
the protein was removed by ultrafiltration. 
The reaction mixtures of reaction 1 and reaction 3 were combined and then 
analyzed by LC-MS (negative ion mode). A HYPERCARB column (Thermo scientific) 
was employed and the gradient was: 0-3 min, 95% B; 3-12 min, 95% B - 30% B; 12-14 
min, 30% B; 14-17 min, 30% B - 95% B; 17-20 min, 95% B at a flow rate of 0.2 mL/min. 
Solvent A: H2O, adjusted to pH 9.2 by ammonia; Solvent B: Acetonitrile, adjusted to pH 
9.2 by ammonia. High resolution mass spectra of the coupling product and cysteine sulfinic 
acid were recorded. The ion intensity of each compound was an average of twenty mass 
spectrometry scans. The ratios of 5-6: 5-6b, 5-6: 5-6c and 5-7: 5-7b were calculated based 




Then, it was used to calculate the isotope effect with the equations showed in Figure 5-5. 
This set of experiments was repeated four times. 
Reaction 2 and reaction 3 were also analyzed by 13C-NMR spectroscopy by mixing 
400 μL reaction mixture with 200 μL D2O to prepare the NMR samples. 
5.2.11 Measurement of the solvent deuterium KIE using wild-type OvoA  
In addition to the substrate deuterium KIE measurement (Reaction 1-3), we also 
measured the solvent deuterium KIE of wild-type OvoA. This experiment was performed 
in collaboration with a former graduate student Dr. Li Chen in Prof. Pinghua Liu’s lab. For 
the OvoA solvent deuterium KIE, three OvoA enzymatic reactions were performed: 
Reaction 4: The OvoA reaction in H2O using unlabeled L-His and unlabeled L-Cys. 
The reaction mixture contained 20 mM air-saturated KPi H2O buffer at pH 8.0, 10 mM L-
His, 10 mM L-Cys, 3.0 mM DTT, 1.0 mM sodium ascorbate, and 8 μM iron-reconstituted 
OvoA. The reaction was run aerobically at 25 ℃ for 2 hr. After the reaction was completed, 
the protein was removed by ultrafiltration. 
Reaction 5: The OvoA reaction in H2O using unlabeled L-His and [β-
13C]-Cys. The 
reaction mixture contained 20 mM air-saturated KPi H2O buffer at pH 8.0, 10 mM L-His, 
10 mM [β-13C]-Cys, 3.0 mM DTT, 1.0 mM sodium ascorbate, and 8 μM iron-reconstituted 
OvoA. The reaction was run aerobically at 25 ℃ for 2 hr. After the reaction was completed, 
the protein was removed by ultrafiltration. 
Reaction 6: The OvoA reaction in D2O using unlabeled L-His and [β-
13C]-Cys. The 
reaction mixture contained 20 mM air-saturated KPi D2O buffer at pH 8.0, 10 mM L-His, 




reconstituted OvoA. The reagents were dissolved in KPi D2O buffer and the enzyme was 
also prepared in D2O buffer. The reaction was run aerobically at 25 ℃ for 2 hr. After the 
reaction was completed, the protein was removed by ultrafiltration. 
The Reaction 4 and Reaction 6 mixtures were combined and the ratios (5-6: 5-6c 
and 5-7: 5-7b) were measured directly using LC-MS as described in the previous section 
to calculate the solvent KIE using the equations showed in Figure 5-5. This set of 
experiments were repeated four times as well. Reaction 5 and reaction 6 were also analyzed 
by 13C-NMR spectroscopy by mixing a 400 μL reaction mixture with 200 μL D2O to 
prepare the NMR samples. 
5.2.12 Measurement of OvoAY417MeOTyr substrate KIE  
This study was performed in collaboration with a visiting scholar Dr. Changming 
Zhao at Prof. Pinghua Liu’s lab. For the OvoAY417MeOTyr substrate isotope effect assay, 
three enzymatic reactions were carried out as describe below. 
Reaction 1: 20 mM air-saturated KPi buffer (pH 8.0), 10 mM L-His, 10 mM L-Cys, 
3 mM DTT, 1 mM sodium ascorbate, and 8 μM iron-reconstituted OvoAY417MeOTyr. The 
500-μL reaction system was incubated at 25 C with stirring for 2 hr. Protein was removed 
by ultrafiltration after the reaction was complete. 
Reaction 2: 20 mM air-saturated KPi buffer (pH 8.0), 10 mM L-His, 10 mM [β-
13C]-Cys, 3 mM DTT, 1 mM sodium ascorbate, and 8 μM iron-reconstituted 
OvoAY417MeOTyr. The 500-μL reaction system was incubated at 25 C with stirring for 2 hr. 




Reaction 3: 20.0 mM air saturated KPi buffer (pH 8.0), 10 mM [U-2H5]-His, 10 
mM [β-13C]-Cys, 3 mM DTT, 1 mM sodium ascorbate, and 8 μM iron-reconstituted 
OvoAY417MeOTyr. The 500-μL reaction system was incubated at 25 C with stirring for 2 hr. 
Protein was removed by ultrafiltration after the reaction was complete. 
The reaction mixtures of reaction 1 and reaction 3 were combined with equal 
volume and analyzed by LC-MS with the method described previously.34 400 μL reaction 
mixture of reaction 2 was mixed with 200 μL D2O and analyzed by 
1H and 13C-NMR 
spectroscopy. 400 μL reaction mixture of reaction 3 was mixed with 200 μL D2O and 
analyzed by 13C-NMR spectroscopy. 
5.2.13  Internal competition KIE measurement of OvoAY417MeOTyr reactions 
This study was conducted by a visiting scholar Dr. Changming Zhao at Prof. 
Pinghua Liu’s lab. To measure the internal competition KIE of the OvoAY417MeOTyr 
catalyzed reaction, a 600-μL reaction containing 0.5 mM L-His, 0.5 mM [U-2H5]-His, 3 
mM L-Cys, 0.5 mM DTT, 0.5 mM sodium ascorbate, and 4 μM of OvoAY417MeOTyr, was 
set up at 25 C with stirring. A 150-μL aliquot was taken from the reaction mixture at time 
0, 5, 10, and 20 mins. The reaction was quenched immediately with the addition of HCl to 
1.5% final concentration. Precipitate proteins were removed by centrifugation. The internal 
standard, U-15N3-His, was added into the individual supernatant of the reactions quenched 
at different time points with a final concentration of 0.5 mM. The samples were adjusted 




5.2.14 Mass spectrometric analysis of KIE measurement of OvoAY417MeOTyr reactions 
This experiment was performed in collaboration with a visiting scholar Dr. 
Changming Zhao at Prof. Pinghua Liu’s lab. The sulfoxide 5-6, cysteine sulfinic acid 5-7 
and L-His 5-1 from the OvoAY417MeOTyr reactions were analyzed by an LTQ-FT-ICR mass 
spectrometer (Thermo Scientific) coupled with an Agilent 1200 Series system. A 
HYPERCARB column (Thermo scientific) was employed for the chromatography with a 
gradient of: 0-5 min, 95% B; 6-15 min, 95% B - 30% B; 16-20min, 30% B; 21-25 min, 
30% B - 95% B; 26-30 min, 95% B at a flow rate of 0.2 mL/min. Solvent A: H2O with 
0.5% ammonia; Solvent B: Acetonitrile with 0.5% ammonia. The intact mass was scanned 
from mass-to-charge ratio 100 to 400 with a selected ion monitoring method in negative 
mode. The tandem mass spectroscopy was carried out with a collision induced dissociation 





5.3 Results and Discussion 
5.3.1 Measurement of the substrate deuterium KIE using the wild-type OvoA   
Isotope labeling experiments are valuable tools for the investigation of the chemical 
reaction mechanisms. Some enzymes are subject to KIEs which modulate reaction rates 
depending on the isotopic substitution of their substrates. Due to this reason, KIE studies 
have been widely used to dissect the mechanisms of a wide range of enzymes. In this study, 
we employed the KIE studies to unravel the underlying chemical basis of OvoA-catalysis. 
In cases where two competing pathways branch out from common intermediate, such as 
some P-450 oxygenase/oxidase-catalyzed reactions, if the step immediately after the 
common intermediate in one pathway has the KIE, then, the KIE can be measured using 
the isotopically sensitive branching method.26,27 Previous studies in both OvoA and EgtB-
catalysis led to the proposal that the oxidative coupling product 5-6 and cysteine sulfinic 
acid 5-7 are produced by two pathways branched out from a common intermediate.10,14,15 
As represented by a simple kinetic model shown in Figure 5-5, from common intermediate 
(ES*) along the OvoA catalytic pathway, P1 is the sulfoxide synthase product 5-6  resulting 
from the oxidative C-S bond formation branch, and P2 is cysteine sulfinic acid 5-7  
produced from the cysteine oxidation branch. The relative amounts of P1 and P2 are directly 
proportional to the rate constants of the two steps at the branching point (k3 and k5 in 
Equation 1, Figure 5-5). This allows the isotope effect on k3 (k3H/k3D) to be measured by 




with unlabeled substrates and a reaction with isotopically labeled substrates (Equation 2, 
Figure 5-5).  
 
 
Figure 5-5 Use of the isotopically sensitive branching method in OvoA-mechanistic studies. P1 
represents compound 5-6 and P2 represents cysteine sulfinic acid 5-7 in this study. 
  
To measure the KIE of the k3 step in the branch producing the oxidative coupling 
product 5-6, two approaches were taken: using isotopically labeled histidine (Figure 5-6A) 
and/or conducting the reaction in D2O buffer (Figure 5-8). In the first approach, two sets 
of parallel reactions were run under identical conditions (Figure 5-6A). In the first reaction, 
unlabeled L-Cys and L-His were used as the substrates, while in the second reaction, [β-
13C]-Cys and [U-2H5]-His were used instead. In both reactions, wild-type OvoA was used. 
After completion, the two reactions were combined. Then, mass spectrometry was used to 
quantify the relative amounts of the products (cysteine sulfinic acid 5-7 vs. 5-7b and 
sulfoxide 5-6 vs. 5-6b). The KIE was calculated using Equation 2 in Figure 5-5. For the 




independent KIE measurements were performed. Therefore, the KIE values reported in this 
work are the average of four independent experiments.  
5.3.2 Substrate deuterium KIE close to unity in wild-type OvoA-catalysis 
Figure 5-6B shows representative spectra from one set of experiments. The m/z of 
289.0612 (left panel of Figure 5-6) corresponds to the coupling product 5-6 in [M-H]- form 
produced from the first reaction in which unlabeled substrates were used. In a parallel 
reaction using labeled substrates, a m/z of 294.0896 was observed suggesting the formation 
in [M-H]- form of the coupling product 5-6b (left panel of Figure 5-6). The ratio of 5-6 and 
5-6b ([P1H]/[P1D] = 0.88, Figure 5-6) reflects the relative amounts of coupling products 
produced from these two reactions. Using a similar approach, the ratio of the cysteine 
sulfinic acids (5-7 and 5-7b) produced from these two reactions was accurately measured 
([P2H]/[P2D] = 0.87, Figure 5-6 right panel). Based on the [P1H]/[P1D] and [P2H]/[P2D] 
obtained from the reactions in Figure 5-6, the KIE on k3 was then calculated using Equation 
2 in Figure 5-5. The average KIE of the four repeats was reported as: kH/kD 1.01  0.02. In 
addition to mass spectrometric studies, the same set of reactions were also characterized 
by 13C-NMR, which revealed the production of histidyl-cysteine sulfoxide 5-6b and 
cysteine sulfinic acid 5-7b (Figure 5-7). This observation was consistent with the results 
obtained from the mass spectrometry analysis. There are at least two possible explanations 
for the close to unity KIE obtained in this study. This result implies the lack of a substrate 
primary deuterium KIE on the k3 step, suggesting that the C-H bond cleavage at the δ-
position of L-His is not the rate-determining step (RDS). This observation resembles to that 




isotope labeling affects both pathways (k3 and k5) at a comparable level, thus, resulting in 
a KIE close to unity.  
 
 
Figure 5-6 Measurements of the substrate KIE using the isotopically sensitive branching method. Using 
[U-2H5]-His as the substrate. (A) The reaction conditions of the two reactions. (B) Mass spectra of 





Figure 5-7 13C-NMR spectra of wild-type OvoA catalyzed reactions. (A) 13C-NMR spectrum of the 
reaction mixture using [β-13C]-cysteine and unlabeled histidine as the substrates; (B) 13C-NMR 
spectrum of the reaction mixture using [β-13C]-cysteine and [U-2H5]-histidine as the substrates. 
 
5.3.3 Small solvent deuterium KIE in the wild-type OvoA reaction 
In addition to the substrate KIE, the solvent KIE on the k3 step was examined. Two 
sets of reactions were run in parallel (Figure 5-8). In the first reaction, unlabeled L-Cys and 
L-His were used as the substrates, and the reaction was run in H2O buffer, while in the 
second reaction, [β-13C]-Cys and unlabeled L-His were used and the reaction was run in 
D2O buffer. After the two reactions were completed, the products were analyzed as 
described in Figure 5-6. Based on the ratios of sulfoxides 5-6 and 5-6c, and  cysteine 






using Equation 2 (Figure 5-5), to be 1.29  0.01. Subsequent 13C-NMR analysis also 
revealed the production of the histidyl-cysteine sulfoxide 5-6b and cysteine sulfinic acid 
5-7c, which is consistent with the mass spectrometry analysis (Figure 5-9). Recently, OvoA 
solvent KIE studies have been conducted using steady state kinetics and a small solvent 
KIE (1.2  0.1) was reported.35 Despite the different approaches, these results are in 
agreement with the small solvent KIE of OvoA-catalysis. 
  
 
Figure 5-8 Measurements of solvent KIE using wild-type OvoA. (A) The reaction conditions in H2O 






Figure 5-9 13C-NMR spectra of wild-type OvoA catalyzed reactions. (A) 13C-NMR spectrum of the 
reaction mixture using [β-13C]-cysteine and unlabeled histidine as the substrates in H2O buffer. (B) 
13C-NMR spectrum of the reaction mixture using [β-13C]-cysteine and unlabeled histidine as the 
substrates in D2O buffer.  
 
5.3.4 Investigating the role of Tyr417 in OvoA-catalysis  
The detected solvent KIE, albeit small, is consistent with the supposition that the 
sulfoxidation and the cysteine oxidation are two branches of a common intermediate, with 
solvent exchangeable protons being part of the k3 step of the branching point. Alternatively, 
the solvent may affect the two pathways to slightly different degrees, leading to the small 
KIE observed in this measurement. This observation immediately raises the question as to 
what could be the factors that govern the partitioning between the two pathways. Thus far, 
the structure of OvoA has not been reported, however,  the structure of M. thermoresistibile 






biochemical characterization of EgtBMth, in which the cysteine dioxygenase activity was 
not observed. However, EgtBY377F efficiently oxidizes γ-Glu-Cys to γ-Glu-Cysteine 
sulfinic acid while maintaining as low as 0.1% level of the oxidative C-S bond formation 
activity. 10,15 These results implied that the active site Tyr might play a key role in 
modulating the partitioning between these two activities: oxidative coupling and cysteine 
dioxygenase activities. Given the similar reactions between EgtB and OvoA, it is possible 
that an active site Tyr might have the same function in OvoA-catalysis. 
Owing to the lack of crystal structure, the OvoA model was generated using the I-
TASSER program (Figure 5-10C).32 The sequence analysis and structural comparison 
suggested that Tyr417 in OvoA might be the counterpart of Tyr377 in EgtB. To test this 
prediction, the OvoAY417F mutant was purified following the reported procedures
14. The 
recombinant OvoAY417F was purified to near homogeneity as observed in the SDS-PAGE 
analysis and the iron content of this enzyme was determined to be 0.95 ± 0.03 per monomer 
(Figure 5-11). The 1H-NMR spectrum of OvoAY417F reaction revealed the formation of 
cysteine sulfinic acid 5-7b as the dominant product (Figure 5-12). The same reaction was 
analyzed by 13C-NMR, which further supported the sulfinic acid 5-7b formation from the 






Figure 5-10 Sequence alignments of OvoA with EgtB and the OvoA structure model. (A) Protein 
sequence alignment of OvoA with EgtB from M. smegmatis and M. thermoresistible shows the 
conserved active site tyrosine (red box). (B) Active site of EgtB (PDB: 4X8B) compared to the predicted 
OvoA structure (C) using I-TASSER, showing the conserved 3-histidines binding motif for the iron 
center and the active site tyrosine. EgtB is in salmon and OvoA is shown in blue. The iron center is the 
yellow sphere and the water ligand is the red sphere. 
 
Figure 5-11 Characterization of OvoAY417F. (A) SDS-PAGE analysis of purified OvoAY417F. (B) Iron 
standard curve generated from AES. The average intensity for the sample was 9634 ± 283 (blue circle) 
and the iron concentration of the sample derived from the standard curve was 0.93 ± 0.05 ppm. The 




































Figure 5-13 13C-NMR spectra of the OvoA reactions. (A) The wild-type OvoA reaction. (B) The 














5.3.5 Steady-state kinetic characterization of the OvoAY417F mutant   
NMR analysis revealed that the mutation of Tyr417 did not alter the regio-
selectivity of the OvoA-catalysis. Instead, the primary catalytic activity of the OvoAY417F 
variant was changed to cysteine dioxygenase activity. This observation is in line with that 
obtained from the study of the EgtBY733F variant. The kinetic parameters of OvoAY417F was 
further characterized using oxygen consumption assay following the procedure reported 
for the wild-type13 (Figure 5-14). OvoAY417F exhibited a Km of 82.5 ± 7.1 μM for L-His 
and of 279 ± 36 μM for L-Cys with turnover of 3.01± 0.05 s-1. The turnover of the 
OvoAY417F variant is 3-fold lower than that of the wild-type (kcat of 9.53 ± 0.33 s
-1)13 
suggesting the significance of Tyr417 in OvoA-catalysis. Despite being catalytically 
competent, the oxidative coupling activity of OvoAY417F is extremely low and more than 
99% of the product is cysteine sulfinic acid. Therefore, it would be challenging to obtain 
an accurate measurement of the KIE of the oxidative-coupling branch depicted in Figure 
5-5 by the isotopically sensitive branching method if OvoAY417F is used as the enzyme. 
 
Figure 5-14 OvoAY417F steady-state kinetic analysis. (A) L-His concentration dependence kinetic 
analysis. (B) L-Cys concentration dependence kinetic analysis. A 1-mL assay contained 0.75 μM 
enzyme, 2 mM L-His (or 2 mM L-Cys), 1 mM DTT, 0.2 mM ascorbate in 50 mM air-saturated KPi 
buffer, pH 8.0 and various amounts of L-His or L-Cys at 25℃. The data was fitted to a Michaelis-
Menten equation using GraphPad Prism. OvoAY417F exhibited a Km of 82.5 ± 7.1 μM for L-His and of 




5.3.6 Biochemical characterization of the OvoAY417MtTyr variant 
To resolve the above issue, Tyr417 was replaced with a tyrosine analog using an 
amber-codon mediated unnatural amino acid incorporation. In the cysteine dioxygenase 
structure, one of the important features is the presence of a Cys-Tyr crosslink (Figure 
5-3).36-38 Such cross-link is not essential for CDO activity since the mutation of Cys93 to 
Ala or Ser significantly reduces its activity, but does not abolish it.39-44 Since wild-type 
OvoA exhibits some level of cysteine dioxygenase activity, the Tyr417 was replaced with 
MtTyr (5-12, Figure 5-3), a mimicry of the Tyr-Cys cross-link in the CDO’s active site. 
MtTyr was enzymatically synthesized using a tyrosine phenol lyase (TPL) F36L variant 
following reported procedures.18 The resulting MtTyr was further characterized by 1H-






Figure 5-15 Characterization of MtTyr. (A) 1H-NMR Spectrum of 2-amino-3-(4-hydroxy-3-
(methylthio) phenyl) propanoic acid. (500 MHz, D2O) δ 2.17 (s, 3H), 2.51 (dd, J = 13.8, 7.3 Hz, 1H), 
2.68 (dd, J = 13.8, 5.3 Hz, 1H), 3.23 (dd, J = 7.3, 5.3 Hz, 1H), 6.33 (d, J = 8.1 Hz, 1H), 6.65 (dd, J = 8.1, 
2.2 Hz, 1H), 6.72 (d, J = 2.3 Hz, 1H). (B) 13C-NMR spectrum (500 MHz, D2O) δ 13.72, 39.93, 57.44, 
117.12, 124.05, 126.10, 126.30, 127.33, 162.03, 182.74. 
 
To incorporate MtTyr, a Methanococcus jannaschii tyrosyl amber suppressor 
tRNA (MjtRNATyrCUA)/tyrosyl-tRNA synthetase (MjTyrRS) pair  was developed by Prof. 
Jiangyun Wang from the Chinese Academy of Science in Beijing.18 The OvoAY417MtTyr 
































confirmed using tandem mass spectrometry (Figure 5-16). The iron content of the 
OvoAY417MtTyr variant was determined following the same procedures as the OvoAY417F. 
The purified OvoAY417MtTyr protein contained 0.94  0.04 equivalents of iron, which is 
close to that of the wild-type OvoA, suggesting that the incorporation of MtTyr does not 
significantly perturb the metallocenter binding. 
 
 
Figure 5-16 Electrospray ionization MS/MS spectrum of a tryptic peptide of the OvoAY417MtTyr. This 
peptide contains residues 413-428, which shows the incorporation of MtTyr at Tyr417. The parent ion 
has the signal with m/z 628.9539 (3 charges). 
 
The OvoAY417MtTyr variant was then characterized by the three assays discussed 
earlier: oxygen consumption, 1H-NMR, and 13C-NMR analysis.14 The kinetic parameters 
determined for the OvoAY417MtTyr variant were: kcat 1.14  0.02 s
-1, Km of 253  25 M for 
L-Cys, and Km of 506  35 M for L-His. Compared with wild-type OvoA,




OvoAY417MtTyr variant is 10-fold lower (Figure 5-17). In the 
1H-NMR assay, the peak at 
7.75 correlates to the formation of the sulfoxide product 5-6 (Figure 5-18B). This result 
suggested that replacing Tyr417 with MtTyr does not affect the regioselectivity of this 
enzyme. Interestingly, 13C-NMR results clearly indicated that the OvoAY417MtTyr variant 
behaves differently from wild-type OvoA (Figure 5-18C and Figure 5-18D). In wild-type 
OvoA-catalysis, cysteine sulfinic acid 5-7 was approximately 10% of the total products 
(Figure 5-18C). However, in OvoAY417MtTyr-catalysis, up to 30% of the products is cysteine 
sulfinic acid (Figure 5-18D). Mutating Tyr417 to MtTyr, indeed, alters the partitioning 
between the sulfoxide synthase and cysteine dioxygenase activities of OvoA-catalysis. 
 
 
Figure 5-17 The OvoAMtTyr steady-state kinetic analysis. (A) L-His concentration dependence kinetic 
analysis. (B) L-Cys concentration dependence kinetic analysis. A 1-mL assay contained 1 μM enzyme, 
2 mM L-His (or 2 mM L-Cys), 1 mM DTT, 0.2 mM ascorbate in 50 mM air-saturated KPi buffer, pH 
8.0 and various amounts of L-His or L-Cys at 25℃. The data was fitted to a Michaelis-Menten equation 
using GraphPad Prism. OvoAMtTyr exhibited a Km of 506 ± 35 μM for L-His and of 253 ± 25 μM for L-





Figure 5-18 NMR analysis of the OvoAY417MtTyr reactions. 1H-NMR of the OvoA wild-type (A) and 
OvoAY417MtTyr (B) reaction mixtures. 13C-NMR spectra of the OvoA wild-type (C) and OvoAY417MtTyr 

















OvoA exhibits broad substrate selectivity and regioselectivity of the C-S bond of 
the product. The latter biochemical characteristic is dependent on the methylation state of 
the amine group of His or the stereochemistry of the His stereocenter.35 When hercynine 
5-2 or D-His replaced L-His 5-1 as the substrate, the C-S bond formation regioselectivity 
changes from the δ- to -position of the L-His side-chain. However, the lack of OvoA’s 
crystal structure hindered structure-function studies to understand this effect. Similarly, 
how the methylthiol group from MtTyr affects the active site environment of OvoA is not 
fully understood (e.g., hydrogen bonding network, active site waters, or even positions of 
active site residues). Despite this issue, the disturbance is possibly minimal since the 
OvoAY417MtTyr reaction produces sulfoxide 5-6 and cysteine sulfinic acid 5-7 as the 
products, and the C-S bond formation regioselectivity remains unchanged.13,35 
Nevertheless, the ratio between 5-6 and 5-7 changes from 9:1 in the wild-type OvoA to 7:3 
in the OvoAY417MtTyr variant. Due to the comparable amount of the products from sulfoxide 
synthase and cysteine dioxygenase activity in the OvoAY417MtTyr-catalysis, this variant was 
further characterized through the isotopically sensitive branching method to understand the 
mechanism of OvoA.  
5.3.7 OvoAY417MtTyr variant exhibits substrate deuterium KIE close to unity  
Similarly to the wild-type, the KIE studies of the OvoAY417MtTyr were performed 
using unlabeled L-His and L-Cys in one reaction, and [U-2H5]-His and [β-
13C]-Cys in 
another reaction (Figure 5-19). A set of results from one run of the experiment is shown in 
Figure 5-19. The ratio of 5-7 and 5-7b ([P1H]/[P1D] Figure 5-19) was 0.68, which reflects 




and 5-6b ([P1H]/[P1D], Figure 5-19) was 0.63, which reflects the amounts of the coupling 
products formed in these two reactions. From this ratio, the KIE for k3 on the oxidative C-
S bond formation branch was calculated using Equation 2 (Figure 5-6). The average KIE 
of four repeats was 1.08  0.01. The reaction mixtures were also analyzed by a 13C-NMR 
assay in which the results were also consistent with the mass spectrometry analysis (Figure 
5-20). 
 
Figure 5-19 Substrate KIE measurements using OvoAY417MtTyr. (A) The reaction conditions of the two 
reactions. (B) Mass spectra of the coupling product (left) and cysteine sulfinic acid (right) from the 





Figure 5-20 13C-NMR spectra of OvoAY417MtTyr catalyzed reactions. (A) 13C-NMR spectrum of the 
reaction mixture using [β-13C]-Cys and unlabeled L-His as substrates. (B) 13C-NMR spectrum of the 
reaction mixture using [β-13C]-Cys and [U-2H5]-His as substrates.  
 
5.3.8 Measurement of the solvent deuterium KIE using OvoA Y417MtTyr variant  
In addition to substrate KIE studies, we also conducted solvent deuterium KIE 
experiments using OvoAY417MtTyr variant by following the protocol outlined in Figure 
5-21A. Based on the ratio of compounds 5-6 and 5-6c (1.95), and 5-7 and 5-7b (0.93), the 
solvent deuterium KIE on k3 was calculated using Equation 2 (Figure 5-5), to be 2.09  
0.02. The results presented in Figure 5-21B is one of the four sets of data used to calculate 
KIE. This solvent KIE provides another set of evidence supporting the hypothesis that 






pathways branched out from a common intermediate and that their ratio can be modulated. 
In the reaction catalyzed by the OvoAY417MtTyr variant, the ratio of 5-7 to 5-6 increases from 




Figure 5-21 Measurements of solvent KIE using OvoAY417MtTyr. (A) The reaction conditions in H2O 





5.3.9 Proposed Mechanistic models of OvoA-catalysis  
The discovery of the sulfoxide synthase and cysteine dioxygenase activities in the 
OvoA reaction raises a question about which one is the first-half reaction14: pathway A or 
pathway B (Figure 5-22). In pathway A, the oxidation of thiolate to sulfenic acid precedes 
the C-S bond formation to afford the sulfoxide product 5-6. On the other hand, pathway B 
suggests that the oxidative C-S bond formation is the first-half reaction. Thus far, there is 
no reported mechanistic or structural work on OvoA. However, structural information10 
and mechanistic investigations using density function theory and quantum 
mechanics/molecular mechanics (QM/MM) methods of EgtB has become available.22,23 
Notably, OvoA and EgtB/Egt1 differ in both substrate selectivity and the product C-S bond 
regioselectivity.9,13,14,16,17 However, the chemistries involved in these two biosynthetic 
pathways are similar (Figure 5-1). For this reason, information from the EgtB mechanistic 
studies serves as a guide for the discussion of the OvoA mechanistic model. 
In pathway A, two exchangeable ligands (H2O) are replaced upon substrate binding, 
resulting in a vacant site for oxygen binding and activation. After oxygen is activated, the 
FeIII-superoxo intermediate then reacts with the thiolate to form a cysteine sulfenic acid 
and an FeIV=O species (A-1, Figure 5-22). A few possible pathways are available for 
subsequent oxidative C-S bond formation (two electron chemistry vs. one-electron 
chemistry, pathways I, II and III in Figure 5-22).17  These models were formulated based 
on Seebeck’s initially mechanistic proposal and EgtB structural information.45-47 In 
pathway I, the FeIV=O species abstracts a hydrogen atom from the -carbon of the 




recombination between this radical and a thiol radical leads to the formation of the 
oxidative coupling product 5-6. Alternatively, in pathway II, the FeIV=O species oxidizes 
the imidazole ring to produce an imidazole cation radical A-3, which undergoes radical 
recombination to form a C-S bond. Recent computational work based on density function 
theory by Wei et al. suggests that Tyr377 participates in EgtB-catalysis by deprotonating 
the hercynine -position, and this step is the rate-limiting step in EgtB-catalysis.22 
Therefore, in pathway II mechanistic model, Tyr417 of OvoA may function as a Lewis 
acid/base (A-4→ sulfoxide product 5-6, Figure 5-22).  In pathway III, on the contrary, the 
reaction follows a two-electron chemistry in which nucleophilic attack by the imidazole 
ring on the sulfenic acid functional group leads to C-S bond formation (A-1→ A-4, Figure 
5-22). Subsequent deprotonation of the imidazole ring A-4 by a base, potentially Tyr417, 







Figure 5-22 Proposed OvoA mechanistic models. (A) The oxidation of thiolate to sulfenic acid precedes 
the C-S bond formation. (B) The oxidative C-S bond formation is the first-half reaction. 
 
In addition to pathway A in Figure 5-22, Faponle et al. reported their EgtB 
mechanistic studies using a combination of quantum mechanics/molecular mechanics 
(QM/MM) approach.23 Results from this study led to a model very similar to the one in 
pathway B (Figure 5-22), in which the formation of a thioether is the first half of the 
reaction. In this model, after substrate binding, oxygen binding and activation leads to the 
first intermediate, an FeIII-superoxo species B-1. Then, a proton-coupled electron transfer 
process from Tyr417 and through the active site water network reduces the superoxo 
species B-1 to the FeIII-hydroperoxo species B-2 and at the same time, produces a Tyr417-




Cys on the imidazole sidechain of L-His links the two substrates through a thioether bond. 
Simultaneously, the hydrogen atom of the hydroperoxo species relays back to the Tyr417-
based radical to regenerate Tyr, producing an FeII-superoxo species B-3. In the next step, 
the FeII-superoxo B-3 abstracts a hydrogen atom from the imidazole ring to re-generate the 
aromaticity and produces an FeII-hydroperoxo intermediate B-4 (Figure 5-22). In this 
pathway, the C-S bond formation step, specifically, the formation of the B-3  intermediate, 
is the rate-limiting step with an energy barrier of 14.2 kcal/mol23 (Figure 5-22). The results 
from the QM/MM based mechanistic studies suggested that Tyr377 is involved in EgtB 
catalysis through a proton-coupled electron transfer process to reduce the superoxo 
intermediate B-1 to a hydroperoxo intermediate B-2. Similar function might be applicable 
to Tyr417 of OvoA. Notably, this model differs from the model proposed by Seebeck 
originally, in which the Tyr377 serves as a Lewis acid to provide a proton to the peroxo 
species to produce the hydroperoxo intermediate.15  
5.3.10 Examining the mechanism of OvoA from substrate and solvent deuterium KIE 
results 
The current results from the KIE studies suggest that OvoA most likely follow 
pathway B in Figure 5-22. In this mechanistic model, no primary KIE is expected when 
[U-2H5]-His is used as the substrate. This corresponds to the results obtained in this work, 
in which no primary KIE was observed and similar conclusions were reached from the 
previous steady-state kinetic analysis.35 In pathway II, the oxidation of imidazole goes 
through a step-wise process (Figure 5-22). Recently, OvoA recognized fluoro-histidine as 




a fluoro-substitute affects the L-His reduction potential, the lack of an obvious effects on 
the OvoA activity suggests that either OvoA does not follow this mechanistic model or that 
this step is not the rate-limiting step if this mechanistic model is operational.35 Tyr417 
might function as an acid to provide the proton in the A-1 → A-4 reaction, while it serves 
as a base in the A-4 → 5-6 conversion. Notably, recent density function theory calculation 
studies from Wei et al. led to a proposal close to the pathway II model, in which the 
deprotonation step (A-4 → 5-6) is the rate-limiting step and a substrate deuterium KIE as 
high as 5.7 was predicted (Figure 5-22).22 The deprotonation step is also part of pathway 
III in Figure 5-22. However, such a high substrate deuterium KIE predicted from Wei et 
al.22 was not observed in this OvoA studies. Despite this result, it cannot be ruled out that 
mechanistically, OvoA and EgtB might undergo distinct mechanisms.22 Obtaining the 
OvoA structural information in the future will be important. Theoretical calculations and 
experimental characterizations could then be conducted on the same system for 
comparative studies. For the fluoro-histidine analog, there are no KIE studies yet, hence, it 
will be worthwhile to re-examine this substrate analog quantitatively by these KIE studies. 
In the cysteine dioxygenase studies, it was suggested that the creation of a partial 
cysteine sulfur radical might be a key factor in directing the formation of the first S−O 
bond in the CDO catalytic cycle. It has also been suggested that this is the rate-limiting 
step along the cysteine oxidation pathway.45-49 If the mechanistic model proposed by 
Faponle et al. on EgtB-catalysis is followed by OvoA-catalysis (pathway B, Figure 5-22), 
the proton-coupled electron transfer from Tyr417 to the FeIII-superoxo species B-2 serves 




oxidation pathway to the oxidative C-S bond formation. Therefore, the B-1 → B-2 
conversion will be the critical step in controlling the partitioning between the cysteine 
dioxygenase and the oxidative C-S bond formation pathways. Indeed, in our OvoA studies 
reported here, the dominant activity of the OvoAY417F mutant is the cysteine dioxygenase 
activity. Our current results are partially consistent with the pathway B (Figure 5-22).  
For the EgtBY377F mutant, a small solvent deuterium KIE was observed for the 
oxidative C-S bonding formation activity.15 Steady-state kinetic studies of wild-type OvoA 
indicated that there is a small solvent deuterium KIE (1.2  0.1).35 This value is very close 
to our solvent deuterium KIE (1.29  0.01) measured using the isotopically sensitive 
branching method. Although, there is a close match between the two KIEs, the link between 
these two measurements should be drawn with precaution as, in this work, the KIE studies 
measure the partitioning between the two pathways; and solvent may affect both pathways. 
The solvent KIE studies for cysteine dioxygenase have been reported. However, the 
cysteine oxidation branch of OvoA-catalysis is different from the cysteine dioxygenase-
catalysis characterized previously.45-49 In cysteine dioxygenase, cysteine serves as a 
bidendate ligand. In OvoA and EgtB, L-Cys is monodendate and the imidazole sidechain 
of L-His is the other ligand. In the absence of L -His, OvoA does not have any cysteine 
dioxygenase activity,14 which suggests that L-His coordination to the iron-center plays a 
crucial role in the cysteine oxidation branch of the OvoA-catalysis. Therefore, literature 
information related to cysteine dioxygenase-catalysis may not be directly applicable to the 




 If the conclusions reached by Faponle et al. in their QM/MM EgtB study holds 
true for OvoA-catalysis, then, the B-2 → B-3 reaction in Pathway B is the rate-determining 
step (Figure 5-22).23 However, we did not observe a substrate deuterium KIE (Figure 5-6). 
There might be at least three possible reasons. First, as Wei et al. suggested, OvoA may 
indeed undergo a mechanism which is slightly different from that of EgtB-catalysis.22 
Second, there may be a similar level of deuterium KIE for the proposed rate-limiting steps 
of the two branches. Third, it may also be possible that, in OvoA-catalysis, some key 
species (B-1 and B-5) exist in equilibrium and what is observed in our kinetic isotopically 
sensitive branching studies reflects the change of their relative distribution upon isotope 
labeling.  
Mutating Tyr417 to MtTyr changes both the pKa and reduction potential.
18,50,51 In 
a small molecular model system that mimics the Tyr-Cys crosslink, the pKa of 2-
(methylthio)-p-cresol was lowered by  0.8 units relative to p-cresol, and the reduction 
potential of 2-(methylthio)-p-cresol  was lower than that of p-cresol by  370 mV.52 In the 
OvoAY417MtTyr variant, both the pKa and reduction potential of the MtTyr are less than that 
of tyrosine. If the model B in Figure 5-22 is followed, it predicts an outcome favoring more 
oxidative-coupling product formation. Surprisingly, the oxidative coupling product 
decreases from 90% with wild-type OvoA to roughly 70% with the OvoAY417MtTyr variant. 
Thus, if OvoA-catalysis follows the mechanistic model showed in Figure 5-22, a likely 
explanation to account for the above results is that MtTyr substitution also affects the 
cysteine dioxygenase activity. This is possible because in cysteine dioxygenase, although 




Cys does improve cysteine dioxygenase activity by nearly 10-fold.45 In the OvoAY417MtTyr 
variant reaction, the amount of oxidative coupling product further decreases from 70% in 
H2O buffer to 50% in D2O buffer. If MtTyr does affect both pathways, the observed 
solvent KIE suggests that MtTyr modulates these two pathways to different degrees at the 
critical steps of the two branches (k3 vs. k5, Figure 5-5). 
5.3.11 Further studies of OvoA-catalysis via kinetic isotope sensitive branching method 
Our studies clearly indicate that MtTyr incorporation can be used to modulate 
OvoA-catalysis. However, both pKa and reduction potential of MtTyr are different from 
that of natural Tyr.18,50,51 Thus, it is challenging to differentiate between the contributions 
of these two factors from the current sets of studies. To address this issue, a Tyr analog, 3-
methoxytyrosine (MeOTyr, 5-13) was chosen. MeOTyr shares almost the same pKa with 
much lower reduction potential (by almost 200 mV) relative to that of natural Tyr (Figure 
5-3).24 In addition, the presence of two competing pathways in OvoA-catalysis (Equation 
1, Figure 5-5) enables the use of KIE studies via two different approaches: kinetic isotope 
sensitive branching (Equation 2) to measure isotope effect at one of the branching 
steps26,27,53 and substrate deuterium KIE on V/K (DV/K) of P1 using intermolecular 
competition (Equation 3, Figure 5-5).54-56  
5.3.12 Replacing Tyr417 with MeOTyr via an amber-codon suppression system 
The Methanococcus jannaschii tyrosyl amber suppressor tRNA 
(MjtRNATyrCUA)/tyrosyl-tRNA synthetase (MjTyrRS) pair has been developed to 




13C-NMR analysis (Figure 5-23). The resulting MeOTyr was then incorporated into OvoA 
to produce OvoAY417MeOTyr following the same procedure as that of MtTyr.
34 
OvoAY417MeOTyr was purified anaerobically to near homogeneity (Figure 5-24A). The iron 
content of the purified OvoAY417MeOTyr was determined to be 1.14±0.06 equivalents of 
iron using atomic emission spectroscopy (Figure 5-24B).57,58 The identity of MeOTyr-
OvoA was further verified by tandem mass spectrometry (Figure 5-24C), which confirmed 





Figure 5-23 Characterization of MeOTyr using NMR spectroscopy. (A) 1H-NMR spectrum of 
MeOTyr. (500 MHz, D2O) δ 2.60 (dd, J = 14.19, 7.11 Hz, 1 H), δ 2.77 (dd, J = 13.89, 7.18 Hz, 1 H), δ 
3.37 (t, J = 7.01 Hz, 1 H), δ 3.61 (s, 3 H), δ 6.52 (dd, J = 18.81, 10.01 Hz, 2 H), δ 6.63 (s, 1 H). (B) 13C-
NMR spectrum of MeOTyr. (500 MHz, D2O) δ 39.11, 55.84, 57.08, 113.55, 116.73, 122.43, 126.29, 







Figure 5-24 OvoAY417MeOTyr characterizations. (A) SDS-PAGE analysis of OvoAY417MeOTyr affinity 
chromatography. Lane 1: Molecular weight marker. Lane 2: purified OvoAY417MeOTyr. (B) Iron 
standard curve generated from AES. The average intensity for the sample was 11745 ± 745 (blue circle) 
and the iron concentration of the sample derived from the standard curve was 1.16 ± 0.06 ppm. The 
iron content of the purified OvoAY417MeOTyr was determined to be 1.14 ± 0.06 equivalent. (C) Tandem 
mass spectrometric analysis of tryptic digested OvoAY417MeOTyr (residue 413-428). The parent ion has a 
signal with m/z 623.6282 (3 charges). 
 
OvoAY417MeOTyr was then characterized by oxygen consumption, 
1H-NMR, and 13C-
NMR assays.14,16 Based on the oxygen consumption assay, the kinetic parameters for 
OvoAY417MeOTyr were: kcat of 1.5 ± 0.1 s-1 and Km of 399 ± 36 M for L-His, Km of 175 







of the OvoAY417MeOTyr variant are close to that of wild type OvoA (Km of 420 ± 31 M for 
L-His, and Km of 300 ± 34 M for L-Cys) reported previously,
13 while the kcat is 6.6-fold 
lower than that of wild-type OvoA (kcat of 9.53 ± 0.33 s
-1). The 1H-NMR assay also 
confirmed the production of sulfoxide 5-6 (Figure 5-25D). 
 
Figure 5-25 Activity analysis of OvoAY417MeOTyr. (A) Cysteine-dependent kinetic assay of 
OvoAY417MeOTyr. A 1-mL reaction contained 2 mM L-His, 1 mM ascorbate, 1 mM DTT, varying L-Cys 
concentration (0.05 – 6 mM), and 0.85 M of OvoAY417MeOTyr in 50 mM KPi pH 8.0. The reaction was 
setup 25 C. OvoAY417MeOTyr exhibited a Km for L-Cys of 175 ± 19 µM with a kcat of 1.5 ± 0.1 s-1. (B) 
Histidine-dependence kinetic studies of OvoAY417MeOTyr was performed using similar protocol as that 
of cysteine-dependence, except L-Cys was kept at 2 mM and L-His was varied (0.05 – 6 mM). 














When [β-13C]-Cys was used as the substrate for OvoAY417MeOTyr, 
1H- and 13C-NMR 
spectra indicated that cysteine sulfinic acid 5-7 comprises up to 26% of the product 
mixture (Figure 5-26 and Figure 5-27). In wild-type OvoA, cysteine sulfinic acid 5-7 is 
less than 10% of the product mixture.14 These results indicated that substitution of Tyr417 
by MeOTyr in OvoA does not affect the identities of the products from OvoA catalysis; 
rather, this mutation alters the partitioning between the oxidative coupling and the cysteine 
sulfinic acid formation pathways (Equation 1, Figure 5-5). This result is quite different 
from when hercynine was used as the substrate, replacing L-His, where the C-S bond 
formation regioselectivity changed from the δ- to -position of L-His’s imidazole ring.13 
 
Figure 5-26 Sulfoxidation and cysteine oxidation quantification of the OvoAY417MeOTyr reaction using 
1H NMR analysis. Ethyl viologen was used as an internal standard. The ratio between sulfoxide and 
cysteine sulfinic acid was quantified to be ~2.8: 1. Top: Expanded region (0.5 - 4.5 ppm) of the 

















Figure 5-27 13C-NMR analysis of the OvoAY417MeOTyr reactions. (A) [β-13C]-cystine and unlabeled L-His 
were used as substrates. (B) [β-13C]-cystine and [U-2H5]-His were used as substrate. 
 
5.3.13 Inverse substrate deuterium KIE in the reaction of OvoAY417MeOTyr  
With active OvoAY417MeOTyr, the deuterium KIE using the kinetic isotope sensitive 
branching method was measured. In the first reaction, unlabeled L-His and L-Cys were 
used as substrates, while [U-2H5]-His and [β-
13C]-Cys were the substrates for the second 
reaction (Figure 5-28A). These two reactions were quenched and mixed, and the ratios 
between the two products (5-6 vs. 5-6b and 5-7 vs. 5-7b) were quantified by mass 
spectrometry; the analytical results from one set of experiments are presented in Figure 
5-28B. The ratio of 5-6 and 5-6b ([P1]H/[P1]D, Figure 5-28) is 0.68 while the ratio between 
5-7 and 5-7b ([P2]H/ [P2]D, Figure 5-28) is 0.81. Based on the kinetic model shown in 
Figure 5-5 the KIE obtained for [U-2H5]-His is 0.84 (Equation 2, Figure 5-5). This 







inverse KIE for [U-2H5]-His observed in OvoAY417MeOTyr (Figure 5-28) differs significantly 
from that of wild-type OvoA, in which the KIE for [U-2H5]-His was close to unity.
34 Such 
differences imply that substitution of Tyr417 by MeOTyr changes the rate-determining 
step in OvoA-catalysis. Typically, the inverse KIE implies a change in hybridization from 
sp2 to sp3 of a carbon atom substituted with the isotope. In this experiment, [U-2H5]-His 
was used as the substrate and its effect will be discussed along with the implications in 
OvoA mechanism. It is unlikely that α- and β-positions will have significant contributions 
to this inverse KIE. However, the measured KIE may be a combined effect from both the 
- and δ-positions of the imidazole sidechain, while the δ-position might be the major 
contributor to the observed inverse deuterium KIE. 










Figure 5-28 Measuring the kinetic isotope sensitive branching KIE of OvoAY417MeOTyr using [U-2H5]-
His as the substrate. (A) Conditions used for the two reactions. Mass spectrometry spectra of the 
coupling product (B) and Cysteine sulfinic acid (C). The ratios of these products in the two sets of 





5.3.14 Measuring substrate DV/K KIE using intermolecular competition experiment 
In oxygenases and oxidases, the O2 activation and the formation of the oxidative 
species is the first irreversible step.  Due to these reasons, it is not possible to measure the 
isotope effect on V/K. However, the presence of a branching pathway unmasks the isotope 
effect on V/K (DV/K, Equation 3, Figure 5-5) making the KIE measurement 
feasible.26,27,29,53,54,56 Therefore, in OvoA-studies, besides the use of the isotopically 
sensitive branching method to directly measure the isotope effect on one of the steps at the 
branching point, the deuterium isotope effect on V/K of P1 was also measured  to provide 
another line of evidence to support the inverse KIE observed in the isotopically sensitive 
branching studies. To measure DV/KP1, the competition experiments using a 1:1 mixture of 
unlabeled L-His and [U-2H5]-His as the substrates were performed (Figure 5-29). In this 
method, three parameters need to be measured (Equation 9, Figure 5-29): the percent 
conversion (f) of the reaction at the time point t and the ratio between the heavy and light 
forms of the substrate of interest (Rs and R0 are the ratios of [U-
2H5]-His 5-1b and unlabeled 
L-His 5-1 at time point t and at time point zero, respectively, Figure 5-29).  
To accurately measure the percent conversion f and the ratio between 5-1b and 5-1 
at the zero point and time t, another form of L-His, [U-15N3]-His 5-1c was introduced as an 
internal standard. A known concentration of 5-1c was mixed with the reaction mixture at 
the zero time point in a certain ratio and the mixture was analyzed by mass spectrometry. 
With the known concentration of 5-1c, and the measured ion intensities of 5-1, 5-1b, and 




point t, an aliquot of the reaction mixture was withdrawn and quenched by hydrochloric 
acid. The quenched reaction mixture was then mixed with a known amount of [U-15N3]-
His 5-1c standard and characterized by mass spectrometry to determine the ratio between 
5-1 and 5-1b at time point t (Figure 5-29). 










Figure 5-29 DV/KP1 KIE measurement in an intermolecular competition experiment. (A) Schematic 
representation of the experimental design and equations used for data analysis. L-His and [U-2H5]- His 
were mixed at a given ratio and L-Cys was then introduced to initiate the reaction. After the reaction 
was quenched at different time points (e.g., f = 0.6 – 0.8), [U-15N3]-His of known concentration was then 
added to the reaction and the amount of remaining 5-1 and 5-1b was calculated based on their ion 




initiation of the reaction was also measured (f = 0). For the equation (Equation 9 in part A) used to 
calculate the deuterium KIE on V/K, the meanings of these terms are: f (percent conversion), X1 (initial 
mole fraction of the unlabeled substrate 1), X1b (initial mole fraction of the labelled substrate 1b), R0 
(initial substrate ratio between 1b and 1), Rs (residual substrate ratio between 1b and 1 at time point 
t).  Representative mass spectrometry results for one set of experiment at f = 0 (B) and at f = 0.704 (C). 
 
The accurately measured parameters including  R0, Rs, and percent conversion f, 
(Equations 4 – 8, Figure 5-29),54 were used to calculate deuterium KIE DV/KP1 (equation 
9, Figure 5-29). The reaction was quenched at time points when the percent conversion f 
was in the range of 0.6 – 0.8 to minimize errors associated with KIE measurement.29,56 
Figure 5-29 has representative spectra of the zero time point and at the time point t (f = 
70.4%) for one set of experiments. The DV/K obtained was 0.94 ± 0.02, which is also an 





Figure 5-30 Internal competition KIE measurement of OvoAY417MeOTyr reactions. Mass spectra of 
reaction at time = 0 min (A) and at time = 10 min (B). Detailed calculations are shown in (C). 
 
5.3.15 Tyr417 is involved in proton-coupled electron transfer process in OvoA-catalysis 
If the kinetic model shown in Equation 1 of Figure 5-5 does represent OvoA-
catalysis, the KIE measured from kinetic isotope sensitive branching (Figure 5-28 studies) 
should be correlated with KIE in the competition experiment (Figure 5-29). Specifically, 
the value of DV/KP1 can be calculated using the experimental value of 
Dk3 obtained from 
the isotopically sensitive branching method.  In equation 3, k3H/k5 is the ratio (74:26) of 












incorporating Dk3 measured in Figure 5-28 studies into equation 3, the calculated deuterium 
KIE on V/K [D(V/K)] is 0.95 – 0.97. The experimentally measured D(V/K) from Figure 5-29 
studies is 0.94  0.02. Hence, there is a reasonably good agreement between these two sets 
of independent studies. 
Based on the above discussion of the two mechanistic models, in pathway A, the 
active site Tyr is most likely function as a Lewis base and primary deuterium isotope effect 
as high as 5.7 for [δ-2H]-His has been predicted by Wei et al (Figure 5-22).22 In pathway 
B, however, Tyr417 is involved in redox chemistry and an inverse secondary deuterium 
isotope effect is predicted for [δ-2H]-His by Faponle et al (Figure 5-22).23 In this study, 
when a OvoAY417MeOTyr variant was used, indeed, an inverse deuterium KIE was observed 
from studies using both kinetic isotope sensitive branching and intermolecular competition 
methods. This result differs from that of wild-type OvoA,34  which has a KIE close to unity. 
Therefore, the replacement of Y417 with MeOTyr has led to a change of the rate-limiting 
step in OvoA-catalysis. OvoAY417MeOTyr produces the same two products as that of wild-
type OvoA, which highly suggests that mechanistically, OvoAY417MeOTyr behaves the same 
as wild-type OvoA. However, the ratio of the two products 5-6 vs. 5-7 (Figure 5-22) 
changes when Tyr417 is replaced by an unnatural Tyr. MeOTyr has a pKa that is almost 
the same as that of Tyr, while their reduction potentials are different by 200 mV.24 
Therefore, it is tempting to assign the different reaction outcomes between OvoAY417MeOTyr 
and wild-type OvoA to the reduction potential differences between MeOTyr and Tyr. 
These two lines of evidences (an inverse deuterium isotope effect for [U-2H5]-His and the 




with the mechanistic model in pathway B suggested by one of these three computational 
studies.28-29, 45 Therefore, our studies highly suggest that Tyr417 is playing some redox 
roles in OvoA-catalysis and our results in this study favor the pathway B model in Figure 
5-22. Notably, both Wei, Tian, and their co-workers commented that the pathway is 
sensitive to active site structure and there is a chance that EgtB and OvoA follow different 
mechanisms.22,59 Therefore, additional studies of EgtB using our approaches in OvoA-





5.4 Conclusions and Future Directions 
In ovothiol biosynthesis, a non-heme iron enzyme (OvoA) catalyzes a four-electron 
oxidative coupling between L-His and L-Cys. In literature, whether oxidative C-S bond 
formation or sulfur oxidation is the first half of OvoA-catalysis, is a heated debate. In this 
work, using OvoAY417MtTyr variant provided new insights into this intriguing reaction. For 
OvoAY417MtTyr, the ratio between sulfoxide 5-6 and cysteine sulfinic acid 5-7 further 
changes from 7:3 in H2O buffer to approximately 1:1 in D2O buffer. These changes were 
also reflected by the solvent deuterium KIE value. The other intriguing result is the 
observation of a small, yet reproducible substrate deuterium KIE of 1.08  0.01 in 
OvoAY417MtTyr variant, suggesting that the C-H bond cleavage is not the rate-determining 
step in OvoA-catalysis. Additionally, these results suggest that the two OvoA activities 
(sulfoxidation vs. cysteine oxidation) might branch out from a common intermediate and 
that the active site tyrosine residue plays some key roles in controlling the partitioning 
between these two pathways. To further investigate its role, the Tyr417 of OvoA was 
replaced with MeOTyr via an amber-suppressor method to modulate its reduction potential. 
This variant exhibited an inverse deuterium KIE for [U-2H5]-His in both kinetic isotope 
sensitive branching and intermolecular competition methods. In conjunction with the 
reported quantum mechanics/molecular mechanics (QM/MM) studies, our results suggest 
that Tyr417 supports redox roles and imply that oxidative C-S bond formation is likely the 




This study provides valuable mechanistic insights into the OvoA-catalysis. 
However, the oxidative C-S bond formation reaction is sensitive to the active site structure. 
Thus, the computation mechanistic models proposed for EgtB catalysis might not be 
applicable to the OvoA reaction.22,59 Obtaining the structure of OvoA will allow the 
mechanistic studies of this reaction through QM/MM methods and this effort is ongoing in 
our laboratory. In addition to structural and computational studies, the mechanism of OvoA 
will be determined using pre-steady state kinetic studies. Several spectroscopic tools 
including stopped-flow, freeze-quench, EPR, and Mossbauer, can be employed to 
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